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Summary 
 
Human cytomegalovirus (HCMV) infection in newborns and immunocompromised 
individuals with immature or deficient immune systems can cause life-threatening 
diseases. The clinical and subsequent economical burden of HCMV infection led the US 
Institute of Medicine designating a vaccine for HCMV as the highest level of priority. 
Complex virus-host interactions have developed over millions of years of co-evolution, 
making the understanding of the pathogenesis of HCMV disease particularly challenging. 
Consequently, a crucial factor in aiding the development of effective vaccinations and 
therapies to significantly reduce morbidity and mortality associated with HCMV infection is 
elucidating what immune mechanisms contribute to/impede protection against infection. 
For example, is the induction of immunomodulatory agents such as cytokines beneficial or 
harmful to the host during infection? Given the known immunosuppressive properties of 
one such cytokine, interleukin-10 (IL-10), in conjunction with the evolutionary acquisition 
by HCMV of its own IL-10 homologue, I hypothesised that mammalian- and viral-IL-10 
suppress protective immunity during acute CMV infection. Utilising a mouse model of 
CMV infection, I revealed a surprising antiviral role for IL-10 during acute infection in vivo, 
which was achieved via limitation of activation-induced death of NK cells. The 
IL-10-related cytokine interleukin-22 (IL-22) provides critical protection against certain 
infectious agents and I therefore hypothesised that IL-22 provides protective immunity 
during acute CMV infection. Utilising the murine infection model once more, I discovered 
a tissue-specific antiviral role for IL-22 during acute infection in vivo and made the 
surprising finding that neutrophils play a protective role during infection. I also 
demonstrated that neutrophils can directly inhibit viral replication in vitro. Thus, novel 
insights into cytokine biology in the context of viral infections in vivo revealed by these 
studies highlighted important considerations for future research into herpesvirus 
infections, and has major implications for the treatment of this important infectious 
disease. 
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Chapter 1 – Introduction 
 
1.1. Introduction to Thesis 
Human cytomegalovirus (HCMV) is one of eight herpesviruses that commonly infects 
humans, and the public health impact of HCMV infection is arguably one of the most 
underappreciated of any infectious disease in the western world today (1). HCMV 
infections in healthy individuals are generally asymptomatic. However, in newborns and 
immunocompromised individuals with immature or deficient immune systems, infection 
can cause life-threatening disease affecting many organ systems. Due to millions of years 
of co-evolution, complex virus-host interactions have developed, making the 
understanding of the pathogenesis of HCMV disease particularly challenging (2). 
Therefore elucidating what immune mechanisms contribute to protection against infection 
will be crucial in aiding the development of effective vaccinations and therapies to 
significantly reduce morbidity and mortality associated with HCMV infection and disease, 
for example understanding if the induction of endogenous immunomodulatory agents 
such as cytokines is beneficial or harmful to the host during infection. In this thesis, I will 
describe the role that members of a particular family of cytokines known as the 
interleukin-10 family play in modulating the immune system during acute cytomegalovirus 
infection. 
 
1.2. Cells of the innate immune system  
The innate immune system represents the first line of host defence by providing an 
immediate response against invading pathogens. Cells of the innate immune system 
include natural killer (NK) cells, mast cells, granulocytes and phagocytic cells. Mast cells 
are found in the skin, at mucosal sites and in connective tissues. They play a central role 
in inflammatory responses and immediate allergic reaction. They release potent 
inflammatory mediators such as histamines (organic nitrogen compounds that increase 
the permeability of capillaries to allow greater influx of immune cells to infected tissues), 
 13 
 
chemotactic factors (soluble molecules which attract and guide the movement of cells 
during an inflammatory response), and cytokines (small cell-signalling protein molecules 
used extensively in intercellular communications). Histamine is also released when mast 
cells detect injury, and these cells are therefore also important in wound healing (3).  
 
Macrophages are large professional phagocytes capable of engulfing substantial numbers 
of microbes, including bacteria, as well as other cells. They are capable of moving across 
the capillary membrane into the area between cells in pursuit of pathogens. They act as 
immune sentinels within tissues and organs, regulating immune activation and 
inflammation as well as metabolism (4, 5). Organ-specific macrophages are differentiated 
from monocytes. Monocytes are also innate immune cells which move quickly to sites of 
infection in response to inflammatory signals and once in the tissue, divide and 
differentiate into macrophages and dendritic cells (DCs). DCs are also phagocytic cells 
and are found predominantly in the skin and mucosal linings of the respiratory and gastro-
intestinal tracts. They are potent antigen-presenting cells (APCs) that capture antigens in 
the periphery, process them into peptides and present them to lymphocytes in the lymph 
nodes, thus are a key link between the innate and adaptive immune systems (6). There 
are several DC-subsets including myeloid-DCs which are most similar to monocytes and 
pick up antigen in the periphery before migrating to T cell areas to present antigen, 
plasmacytoid-DCs which are found in lymphoid organs and produce large amounts of the 
antiviral cytokines interferon-alpha (IFNα) and interferon-beta (IFNβ), and Langerhans 
cells which are DCs predominantly found in the skin and the mucosa. DCs are also 
involved in the induction of immunological tolerance in peripheral tissues under steady-
state conditions (7) which is critical in preventing the immune system from mounting an 
immune response to self antigens or to harmless exogenous antigens. 
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Neutrophils are the most abundant type of phagocyte and are usually the first cells to 
arrive at the site of infection. They are known as granulocytes due to the presence of 
granules in their cytoplasm which release lytic enzymes and produce reactive oxygen 
intermediates with antimicrobial potential (8). These lytic enzymes include cathelicidin, 
defensins and cathepsins, all of which provide critical protection against bacteria, fungi 
and many enveloped and non-enveloped viruses. As well as providing defence against 
invading pathogens through phagocytosis and the release of soluble anti-microbial 
granules, neutrophils also generate neutrophil extracellular traps which bind, trap and kill 
microbes extracellularly (9). Other granulocytes of the innate immune system are 
basophils and eosinophils. Basophils release predominantly histamine from their granules 
and are important in defence against parasites but also have a role in allergic reactions 
such as asthma (10). Eosinophils on the other hand secrete a range of toxic proteins and 
free radicals which are highly effective in killing pathogens (10). NK cells are cytotoxic 
lymphocytes which survey host tissue for signs of infection, transformation and stress, 
and kill target cells that are detrimental or of no further use to the host (11). NK cells will 
be discussed in depth later in section 1.6. 
 
1.3. Activation of the innate immune system 
Inflammation is the first response of the immune system to harmful stimuli such as 
invading pathogens, damaged cells or irritants. Acute inflammation is initiated by cells 
already present in the injured or damaged tissue, including resident macrophages, DCs 
and mast cells. On the surface of these cells are receptors known as pattern recognition 
receptors (PRRs). These receptors are capable of identifying pathogen-associated 
molecular patterns (PAMPs) which are conserved molecules broadly expressed by 
microbial pathogens, but are clearly distinct from host proteins. A major subset of PRRs is 
the Toll-like receptors (TLRs). Extracellular infections are detected by a series of cell 
surface TLRs which become activated by microbial elements. Intracellular pathogens are 
recognised by endosomal TLRs. The engagement of TLRs with their cognate microbial 
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PAMPs stimulates intracellular reaction sequences, which leads to activation of 
transcription factors, primarily nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFKB), which is a protein complex that controls the transcription of DNA. These 
intracellular reactions not only trigger phagocytosis, but also the release of 
pro-inflammatory cytokines and chemokines (cytokines that induce directed chemotaxis in 
nearby responsive cells) to recruit and prime APCs for the initiation of the adaptive 
immune response.  
 
1.4. Cells of the adaptive immune system  
The adaptive immune system acts as a second line of host defence by providing an 
antigen-specific response which is retained after the elimination of the pathogen in the 
form of immunological memory, allowing for a faster and more efficient response during a 
subsequent encounter with the same pathogen or a slight variant of that pathogen. The 
adaptive immune system is predominantly mediated by two types of lymphocyte; B cells 
and T cells. T cells are primarily responsible for cell-mediated immunity and B cells are 
responsible for humoral immunity via production of antibodies, but they work together and 
in conjunction with cells of the innate immune system to mediate effective adaptive 
immunity (12).  
 
B cell development begins in the fetal liver and continues in the fetal/adult bone marrow of 
most mammals. Subsequent functional maturation then occurs in the secondary lymphoid 
tissues (e.g. the lymph nodes and spleen), and their functional endpoint as mature B cells 
is antibody production by terminally differentiated plasma cells. B cells are characterised 
by the presence of a B cell receptor on their surface which is able to bind a specific 
antigen. Functions of B cells other than their principal role of making specific antibodies 
against these antigens include performing the role of APCs and eventually developing into 
long-lived memory B cells (13).  
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T cells originate from haematopoietic stem cells (HSCs) in the bone marrow which 
migrate to and populate the thymus by rapidly expanding to produce a large population of 
immature thymocytes. These early thymocytes lack both CD4 and CD8 co-receptors and 
are therefore referred to as double negative cells. As they develop, they become double 
positive thymocytes before segregating into separate immunocompetent populations of 
single positive CD4+ and CD8+ T cell precursors (14). CD8+ T cells, or cytotoxic T cells, 
are a sub-group of T cells which induce the death of infected or damaged cells, or tumour 
cells. These cells recognise their target by binding to antigen associated with major 
histocompatibility complex (MHC) class I molecules. CD4+ T cells, or T helper cells (TH 
cells), assist other cells in various immunological processes, including the maturation of B 
cells and the activation of cytotoxic T cells and macrophages. CD4+ T cells can also 
acquire cytotoxic activity and directly kill infected or transformed cells and are particularly 
associated with chronic viral infections including HCMV, hepatitis viruses and human 
immunodeficiency virus (HIV)-1 (reviewed in (15)). These cells only recognise antigen 
coupled to MHC class II molecules.  
 
Naïve CD4+ T cells can be differentiated into distinct effector and regulatory lineages. This 
differentiation is antigen-driven and is controlled by cytokine cues from innate and 
possibly adaptive immune cells upon sensing invading microbes (16). The first two major 
groups of distinct CD4+ T cells to be discovered were designated as TH1 and TH2, and 
could be distinguished by the cytokines they produced as well as through the expression 
of cell surface molecules. TH1 cells predominantly produce interferon-gamma (IFNγ) and 
also produce lymphotoxin (LT) and high amounts of interleukin (IL)-2. The signature 
cytokines of TH2 cells are IL-4, lL-5 and IL-13 (reviewed in (17)). A third major effector 
population of CD4+ T cells are the TH17 cells and are characterised by the production of 
IL-17A, IL-17F and IL-22. As well as effector cells, a regulatory population of T cells 
(Tregs) can be induced to differentiate in vitro from naïve CD4+ T cells, and are 
designated inducible Tregs (iTregs) in order to distinguish them from the naturally 
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occurring Tregs (nTregs) (reviewed in (17)). Additional subsets including TH9 and 
T-follicular helper (Tfh) cells have also been described but remain less well characterised. 
The developmental pathways of distinct CD4+ T cell subsets are summarised in Fig. 1.1 
(adapted from (16)). 
 
 
 
 
 
Figure 1.1. Developmental pathways of CD4+ T cell subsets from naïve precursors 
Following exposure to foreign antigen, naïve CD4+ T cells are directed towards distinct 
developmental programs by cytokines (shown in bold text) that differentially induce 
lineage specific transcription factors (shown in grey text). The broken line associated with 
the Tfh pathway represents the possibility that these cells may not develop directly from 
naïve precursors. 
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1.5. Activation of T cell mediated immunity  
Efficient priming of adaptive immune responses requires not only the presentation of 
antigen in the context of MHC, but also the induction of accessory signals in the form of 
co-stimulation and cytokines from APCs (18). T cells are activated by the binding of the T 
cell receptor (TCR) to a short peptide presented by the MHC (MHC class I for CD8+ T 
cells and MHC class II for CD4+ T cells) on an APC (usually a DC in the case of a naïve 
response, but also B cells and macrophages). After this first antigen-specific signal, a 
second co-stimulatory signal is required for the T cell to become fully activated. The best 
characterised co-stimulatory molecule that T cells express is CD28, which interacts with 
CD80 and CD86 on the surface of APCs. This second signal licenses the T cell to 
respond to an antigen, as without it the T cell can become anergic (anergy is a state of 
immune unresponsiveness). Once activated, T cells undergo rapid clonal expansion. As 
described above, the TH1 response is characterised by the release of IFNγ which 
activates macrophages and induces B cells to make opsonising antibodies that mediate 
phagocytosis, and in general is most effective against intracellular viruses and bacteria. 
The TH2 response is characterised by the release of IL-4 which induces B cells to make 
neutralising antibodies; a response most effective against extracellular bacteria and 
parasites. CD8+ T cells release perforin and granzymes which cause infected, damaged 
or dysfunctional target cells to lyse or undergo apoptosis. Upon the resolution of infection 
most effector cells will die. However a few cells will become long-lived memory cells that 
can rapidly expand to large numbers of effector cells upon re-exposure to their cognate 
antigen, thus providing immunological memory against re-infection. 
 
1.6. NK cells: development and function 
NK cells were discovered more than 30 years ago and were originally defined as effector 
lymphocytes of the innate immune system capable of cytolytic functions. However, a more 
advanced view of NK cells has emerged over the years due to the recognition that they 
express a repertoire of activating and inhibitory receptors which allow them to mount an 
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efficient assault against viral and bacterial infections, tumour development and invading 
pathogens, whilst ensuring self-tolerance. Recent studies have also revealed that NK 
cells can display a form of immunological memory, thus NK cells exhibit attributes of both 
innate and adaptive immunity (19).  
 
NK cells have been shown to provide critical protection against a wide range of viral 
infections including arenaviruses (e.g. lymphocytic choriomeningitis virus (LCMV)), 
herpesviruses (e.g. CMV and herpes simplex virus (HSV)), orthomyxoviruses (e.g. 
influenza virus) and picornaviruses (e.g. coxsackie virus) (reviewed in (20)). The 
importance of NK cells in early defence can clearly be seen in studies using mice with NK 
cell deficiencies or using NK cell depletion techniques (21-27). Defects in NK cells in 
humans are rare, signifying the essential role for NK cells in host defence, but 
interestingly, patients with NK cell defects are usually extremely susceptible to 
herpesvirus infections (28). NK cells have also been shown to have a role in tumour-
surveillance as numerous studies in mice support the notion that NK cells are associated 
with the eradication of tumour cells, where as in humans, most evidence is derived from 
correlative studies (reviewed in (29)). 
 
NK cells develop primarily in the bone marrow and do not require the thymus for their 
development (11). Production of NK cells from bone marrow precursor cells requires the 
stromal cell-derived cytokine IL-15. Furthermore, a study with IL-15-/- mice showed that 
not only is IL-15 required for development, but is also essential for mature NK cell survival 
in vivo (30). NK cells possess an elaborate array of receptors that regulate their functions 
upon interaction with MHC class I proteins on target cells. In humans, these receptors are 
known as killer cell immunoglobulin-like receptors (KIRs), and in the mouse, they are 
known as Ly49 receptors (31). These receptor families include both inhibitory and 
activating receptors. Immature human and mouse NK cells express inhibitory KIRs and 
Ly49 receptors respectively during their development which is essential for establishing 
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efficient ‘missing self’ recognition. The missing self hypothesis was based on the 
observation that upon encounter with a normal autologous cell expressing MHC class I, 
NK inhibitory receptors are engaged. Loss of MHC class I expression (‘missing self’), in 
combination with the expression of one or more ligands for activating NK receptors, leads 
to the activation of the NK cell which then provokes NK cell-mediated attack on the target 
cell. Engagement of these inhibitory receptors during development results in the 
generation of functional NK cells in the periphery. In addition, the number of inhibitory 
receptors for autologous MHC class I molecules that NK cells express leads to varying 
responsiveness; with each additional self-MHC-specific inhibitory receptor, 
responsiveness increases quantitatively (reviewed in (11)).  
 
Two of the major effector functions of NK cells are 1) to mediate significant levels of 
cytotoxic activity and 2) to produce high amounts of certain cytokines and chemokines. 
Virus-induced IFNα and IFNβ are potent inducers of NK cell-mediated killing but in 
addition to these type I interferons, many other innate cytokines are also important in 
regulating NK cell cytotoxicity, proliferation and IFNγ production. These include IL-12, 
tumour necrosis factor (TNF)-α, IL-1α/β, IL-6, IL-10, transforming growth factor (TGF)-β, 
IL-15 and IL-18 (reviewed in (20)). There are two major mechanisms by which NK cells kill 
target cells, both of which require direct effector/target cell contact. The first involves the 
secretion of cytoplasmic granule toxins, predominately perforin, which disrupts the 
membranes of target cells, and granzymes, which are a family of structurally related 
serine proteases. Together, these induce apoptosis of the target cell. NK cell-derived 
perforin is not only important for the killing of virally infected cells but has also been 
shown to be the predominant NK cell antifungal mechanism against cryptococcal infection 
(32). The second mechanism involves the engagement of death receptors on the target 
cells (e.g. Fas) by their cognate ligands (e.g. FasL) on NK cells which results in classical 
caspase-dependent apoptosis (review in (33)). Caspases are highly conserved proteins 
that play a central role in the transduction of death-receptor apoptotic signals. Initiator 
 21 
 
caspases first become activated which in turn activate effector caspases, leading to 
programmed cell death initiated by degradation of a host of intracellular proteins.  
 
As well as eradicating infected cells or tumour cells via their ability to mediate 
spontaneous cytotoxicity, NK cells also play an important role in restricting infections and 
stimulating the adaptive immune response via their production of cytokines. It is now well 
established that cytokines such IFNγ and TNFα produced by NK cells contribute to the 
control of multiple murine and human viral (34) and bacterial infections (35, 36).  As well 
as having direct antiviral activity, IFNγ has multiple effects in the activation of innate and 
adaptive immunity (reviewed in (37)) and include stimulation of bactericidal activity of 
phagocytes, stimulation of antigen presentation through MHC class I and class II 
molecules, orchestration of leukocyte-endothelium interactions, effects on cellular 
proliferation and apoptosis, as well as being involved in the regulation of over 200 known 
IFN-stimulated genes. Therefore, cytokines secreted by NK cells, in particular IFNγ, are 
important effector molecules that contribute to direct pathogen control (34). 
 
Finally, immunological memory was until recently thought to be a property strictly limited 
to adaptive immunity. However, recent studies have suggested that NK cells have the 
capacity to alter their behaviour based on prior activation (reviewed in (38)). NK cells have 
been shown to mediate antigen-specific recall responses in several different model 
systems. In the absence of T and B cells, NK cells can mediate a hapten-specific contact 
hypersensitivity response to haptens which the mice were previously sensitised to (39). In 
addition, cytokine-activated NK cells transferred into naïve hosts produce significantly 
more IFNγ when restimulated as compared to naïve NK cells (40). Furthermore, NK cells 
have been shown to exhibit immunological memory against viral infections, as virus-
sensitised NK cells adoptively transferred into naïve recipients results in a robust 
secondary expansion, protective immunity and enhanced survival when rechallenged with 
mouse cytomegalovirus (MCMV) (41), influenza or vesicular stomatitis virus (VSV) (42). 
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Although NK cells do not rearrange the genes encoding their activating receptors, NK 
cells can generate long-lived memory cells which mediate a more efficient secondary 
response against previously encountered pathogens (43). Thus NK cells can be 
described as exhibiting attributes of both innate and adaptive immunity. The multiple roles 
of NK cells are summarised in Fig. 1.2. 
 
 
 
Figure 1.2. The multiple roles of NK cells 
NK cells express a repertoire of activating and inhibitory receptors which allow them to 
mount an efficient assault against viral and bacterial infections as well as tumour 
development. This is achieved via the production of cytokines such as IFNγ and TNFα 
and through cytotoxic mechanisms. NK cells can also display a form of immunological 
memory where-in long-lived memory NK cells develop.  
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1.7. Human cytomegalovirus (HCMV) 
1.7.1. Clinical implications of HCMV infection 
HCMV is a member of the Herpesviridae family of viruses. It is a β-herpesvirus, and like 
all viruses in this subfamily, exhibits species specificity and infects only particular types of 
differentiated cells within that species. During natural infection, HCMV is thought to 
replicate productively in fibroblasts; epithelial, endothelial, smooth muscle and neuronal 
cells; hepatocytes; granulocytes; and monocyte-derived macrophages; and is capable of 
infecting CD34+ haematopoietic cells in the bone marrow (44). The entry of herpesviruses 
into cells is a complex process initiated by adsorption and receptor binding followed by 
fusion of the virus envelope with a cell membrane (45). The method of HCMV entry is cell-
dependent. It is known that HCMV fuses with the membranes of fibroblasts, but enters 
endothelial and epithelial cells via endocytosis (45). HCMV can be transmitted via saliva, 
sexual contact, placental transfer, breastfeeding, blood transfusions and solid-organ or 
haematopoietic stem cell transplantation. Seroprevalence of HCMV in the worldwide 
population ranges between 45-100%. The highest prevalence is in South America, Africa 
and Asia and the lowest is in Western Europe and the United States (46).  
 
One of the most important clinical manifestations of primary HCMV infection is seen in 
newborn babies infected during pregnancy. The majority of congenitally infected babies 
are asymptomatic at birth, however 10-17% of these subsequently develop hearing 
defects or neurodevelopmental sequelae (47, 48). Approximately 10-15% of congenitally 
infected babies are symptomatic at birth, exhibiting irreversible central nervous system 
damage including microcephaly, encephalitis, seizures and deafness, as well as jaundice, 
hepatitis, pneumonitis, hepatosplenomegaly and thrombocytopenia (47, 48).  
 
Primary infection in an immunocompetent host is usually asymptomatic and rarely causes 
illness. In a few cases, infection can result in mononucleosis syndrome which manifests 
symptoms almost indistinguishable from those of Epstein-Barr virus (EBV)-induced 
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mononucleosis, including fever, sore throat and fatigue. After primary infection, HCMV 
establishes lifelong latency infection within the host. Therefore, in immunocompromised 
individuals, HCMV primary infection as well as reactivation from latency can lead to 
severe complications. HCMV is still regarded as being the most significant infectious 
pathogen in recipients of solid-organ transplants as, despite improved surveillance and 
treatment, it continues to cause morbidity and mortality after transplantation. For example, 
in the absence of preventative measures, 40-100% of all kidney transplantation recipients 
develop HCMV infection and up to 67% develop HCMV disease (49). Cytomegalovirus-
associated disease initially localises in the transplanted organ, but can subsequently 
spread systemically causing pneumonitis, hepatitis, nephritis, pancreatitis, myocarditis 
and retinitis among others (48). Reactivation of latent virus causes a significant risk for 
HSC transplantation recipients due to prolonged periods of immunodeficiency. In 
approximately 80% of cases, reactivation occurs in patients that were seropositive before 
transplantation, and again can lead to HCMV disease such as pneumonitis, entercolitis 
and gastritis (47).  
 
Prior to the introduction of highly active antiretroviral therapy (HAART), HCMV disease 
caused a significant problem for HIV-infected patients due to an impaired adaptive 
immune response, with approximately 40% of patients suffering from HCMV disease (47). 
Despite the decline in HCMV incidence in patients with acquired immune deficiency 
syndrome (AIDS) since the availability of HAART, HCMV infection can still be problematic 
for HIV patients. The most common manifestation of HCMV disease in HIV patients is 
retinitis, which leads to progressive loss of vision and blindness, and incidence of retinitis 
is between 10-40% in AIDS patients with low CD4+ cell counts (<100/µl) (50).  
 
Finally, it is interesting to note that the total HCMV-specific T cell response in HCMV 
seropositive subjects has been measured and is extremely large, with on average ~10% 
of the CD4+ and CD8+ T cell population being specific for HCMV peptides (51). This 
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‘memory inflation’ may have consequences for elderly individuals as the expansion of 
HCMV-specific memory cells may result in loss of naïve and non-HCMV-specific memory 
cells which could potentially lead to dysregulated immune responses to other pathogens 
(51). HCMV-associated changes in the immune system are highly predictive of early 
mortality among older persons (52) whilst HCMV reactivation in critically ill older patients 
also predicts early mortality (53). 
 
Due to the heavy burden that HCMV exacts when it infects children and 
immunocompromised individuals, a vaccine for HCMV was assigned the highest priority 
by the US Institute of Medicine in 1999. This was based on the financial cost and human 
suffering that would be alleviated by reducing the disease burden of congenital HCMV 
infections (54). 
 
1.7.2. HCMV genome structure and viral strains 
HCMV has the largest genome of any human virus (~235kb) and is estimated to encode a 
minimum of 166 protein-coding genes. HCMV has a linear DNA genome with a unique 
long (UL) region and a unique short (US) region, flanked by two sets of inverted repeats. 
HCMV research has historically relied on laboratory strains that have been heavily 
passaged on human foreskin fibroblasts (HFFs) in vitro; in particular strains AD169 and 
Towne (55). Propagation for even limited passages, such as the low-passage Toledo 
strain, introduces mutations in the genome (55). The broad tissue tropism exhibited by 
HCMV in vivo is lost in cell culture due to the adaptation of the virus to fibroblasts, which 
is strongly associated with mutations in the genes UL128, UL130 and UL131A (56). 
These genes are known to be essential for growth of HCMV in endothelial cells, epithelial 
cells and DCs (57). Mutations in these genes along with mutations in other regions of the 
genome that occur when HCMV is passaged in vitro consequently results in the 
laboratory virus strains used for research fundamentally differing from wild-type (wt) 
HCMV. The HCMV strain Merlin was originally isolated from the urine of a congenitally 
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infected infant and was sequenced after only 3 passages in HFFs. Of the lab strains 
sequenced to date, Merlin is considered to most accurately reflect the wt complement of 
genes as it contains no obvious mutations other than a frameshift in the RL13 gene and a 
single nucleotide substitution that truncates the UL128 gene (55, 58). 
 
1.7.3. HCMV and immune evasion 
Binding and entry of HCMV into target cells initiates a number of pathways that ultimately 
leads to the production of type I IFNs and other inflammatory cytokines that activate APCs 
and recruit NK cells which subsequently drives the development of adaptive immunity. 
Over millions of years of co-evolution of virus and host, HCMV has evolved multiple 
mechanisms to modulate and evade the host immune response. HCMV contains many 
genes that for example, regulate expression of MHC class I molecules, intracellular and 
extracellular receptors, cytokines and chemokines, some of which are homologues 
acquired from host genes  (59). A viral homologue of the anti-inflammatory cytokine IL-10 
is encoded by the UL111A gene and has some of the immunosuppressive properties of 
cellular IL-10 (discussed in depth in section 4.1.1), and a viral homologue of CXCL1 
encoded by the UL146 gene acts as an agonist for CXCR2 and induces neutrophil 
chemotaxis, which has been hypothesised to aid viral dissemination (60). The US28 gene 
encodes a viral chemokine receptor which can sequester CC-chemokines and deplete 
them from the medium, thus altering the chemokine environment of infected cells (60). A 
viral homologue of the TNF-receptor encoded by the UL144 gene has also been identified 
and is a potent activator of NFkB and CCL22 which attracts TH2 cells and Treg cells (61). 
The glycoprotein (gp) UL144 also binds to the inhibitory receptor B and T lymphocyte 
attenuator (BTLA) and inhibits T cell proliferation. BTLA expression is induced during 
activation of T cells and remains expressed on TH1 cells, and binding of UL144 to this 
inhibitory receptor consequently inhibits T cell proliferation (62).  
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Another major evasion mechanism relies on the inhibition of MHC class I-restricted 
antigen presentation and consequently impedes cytotoxic CD8+ T cell 
immunosurveillance. HCMV achieves this by several methods; US3 encodes a protein 
that binds MHC class I molecules and retains them in the endoplasmic reticulum (ER), 
gpUS2 and gpUS11 rapidly degrade MHC class I molecules, US6 encodes another 
glycoprotein that down-regulates MHC class I expression and finally, gpUS10 slows MHC 
class I maturation and egress from the ER (59, 63). HCMV also interferes with the 
presentation of MHC class II on professional APCs and subsequently impedes signalling 
to CD4+ T cells. Genes involved in impeding this signalling are US2 and US3 which 
encode proteins that bind and downregulate MHC class II expression (63). 
 
Cell death by apoptosis is a primitive mechanism of protection against viral infections. 
Four HCMV gene products, encoded by the immediate early (IE)1, IE2, UL36 and UL37 
genes, have been implicated in blocking apoptosis (reviewed in (64)) which may aid in 
viral propagation as well as avoiding immune clearance by cytotoxic T cells or NK cells. 
Furthermore, protection from mitochondria-induced cell death is mediated by a virally 
encoded RNA, β2.7, which interacts with complex I (the first enzyme in the mitochondrial 
respiratory pathway) which stabilises the mitochondrial membrane, thus aiding successful 
completion of the HCMV life cycle (65).  
 
Two HCMV Fcγ receptor homologues have also been identified, gp34 and gp68 (66). It 
was initially assumed that they would function like the viral Fcγ receptor from HSV-1, 
which protects against antibody-dependent cell-mediated cytotoxicity and complement 
activation, but the proteins have different pH requirements for binding which probably 
relates to different mechanisms following IgG engagement and therefore their function is 
still to be properly determined (63).  
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Other immune evasion genes include those for the production of proteins encoded by IE1 
and IE2 that interfere with IFN signalling (63), and a vast array of mechanisms to evade 
NK cell killing, discussed in detail below. 
 
1.7.4. HCMV and NK cells 
There is limited but compelling clinical evidence for the role of NK cells in immunity to 
HCMV infection. Individuals with rare NK cell defects often exhibit enhanced susceptibility 
to herpesvirus infections and can have serious recurrent episodes of HCMV disease (67, 
68). In renal transplant patients, enhanced NK cell activity was implicated in recovery from 
HCMV infection (69). Recovery of NK cell cytotoxicity following bone marrow 
transplantation also correlated with survival from HCMV related disease (70).  
 
Indirect evidence for the importance of NK cells in response to HCMV infection is 
suggested by the extensive mechanisms HCMV employs to evade or modulate NK cell 
function (71). As described in section 1.7.3, the HCMV genome encodes several proteins 
which contribute to the downregulation of MHC molecules on the cell surface. In theory, 
this should make HCMV-infected cells with downregulated expression of MHC molecules 
vulnerable to NK-mediated lysis. However, the UL18 gene encodes an MHC class I 
homologue (72) that acts as a decoy protein and is expressed on the cell surface and 
binds to the NK cell inhibitory receptor LIR1 (reviewed in (73)). Furthermore, a 
glycoprotein encoded by UL40 contains a sequence homology to a human leukocyte 
antigen (HLA)-E binding peptide which can substitute and up-regulate cell-surface 
expression of HLA-E on infected cells (74). HLA-E is a non-classical MHC class I 
molecule which binds to the NK inhibitory receptor complex CD94/NKG2A and therefore 
suppresses NK cell recognition of infected cells. NKG2D is a potent NK activating 
receptor and can recognise an array of ligands. Expression of these ligands is activated in 
response to viral infections. Glycoproteins encoded by UL16 and UL142 prevent cell 
surface expression of these NKG2D ligands, as does the non-coding microRNA 
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miRUL112 (reviewed in (73)) thus impeding NK recognition of infected cells. Other 
mechanisms to evade NK cell killing include production of a tegument phosphoprotein, 
pp65, which inhibits signalling mediated through the activating receptor NKp30 (75), and 
production of gpUL141 which prevents surface expression of CD155, a ligand for the 
activating receptor CD226 (76). The multiple evasion mechanism employed by HCMV, 
including those for NK cell evasion, are depicted in Fig1.3. 
 
 
Figure 1.3. Immune evasion mechanisms of HCMV 
Millions of years of co-evolution of virus and host has led to HCMV evolving multiple 
mechanisms to modulate and evade the host immune response. HCMV contains many 
genes for this immune evasion and are shown in bold text. 
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Despite the multiple evasion strategies evolved by the virus, NK cells have evolved further 
mechanisms to aid in their control of HCMV infection. To date the vast majority of in vitro 
studies examining the effector mechanisms used by NK cells to control HCMV infection 
have focused on their ability to recognise target cells and subsequently eliminate them via 
perforin-dependent cytolysis. However, NK cells have also been shown to inhibit HCMV 
replication through a non-cytolytic mechanism. Activated NK cells express LTαβ, and also 
secrete LTα and TNFα, which contributes to the release of IFNβ from the infected cell. 
The potent combination of IFNβ along with NK cell derived-IFNγ, inhibits virus replication 
(77). Finally, a recent study showed preferential expansion of a unique NK cell subset that 
co-express the activating receptor CD94/NKG2C and CD57 in HCMV+ donors. These 
cells preferentially lack expression of inhibitory receptors NKG2A and KIR3DL1 and the 
percentage of these cells rapidly increases in solid-organ transplant recipients with active 
HCMV infection (78). The authors of this study propose that this subset of NK cells may 
even act as ‘memory’ NK cells that have expanded in response to HCMV infection (78).  
 
1.8. Murine cytomegalovirus (MCMV) 
1.8.1. MCMV as a model for HCMV infection 
MCMV is a β-herpesvirus and like other cytomegaloviruses, is a member of the 
Herpesviridae family of viruses. It has a double stranded DNA genome encoding 170 
open reading frames (ORFs) (79). Like HCMV, MCMV demonstrates species specificity 
and establishes life-long persistence after the resolution of acute infection. It has a 
prevalence of between 60-90% in the wild mouse population. The route(s) of horizontal 
transmission are not yet clearly determined. However, infectious virus can be detected in 
saliva of chronically infected mice and productive infection is confined to glandular 
epithelial cells of the salivary glands for prolonged periods of time, even in an 
immunocompetent host, thus, saliva is likely to be a major source of virus for horizontal 
distribution (80). Sexual transmission may also be an important means of horizontal 
spread. The main entry route for MCMV is the epithelium of the gastrointestinal, upper 
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respiratory and genitourinary tracts (80). After entry into the host, the virus then spreads 
to various organs and infects many cell types including endothelial and epithelial cells, 
myocytes, fibrocytes, macrophages and bone marrow stromal cells (80). The entry route 
of MCMV and the earliest events of its transport into the nucleus are still poorly 
understood, but do include attachment of the virion to the cell surface, penetration through 
the cell membrane and transport of viral genes to a site where viral DNA replication can 
occur (81). MCMV infection is characterised by 3 stages: 1) the acute-phase wherein the 
visceral organs such as the liver, lungs and spleen are the main sites of infection with 
titres peaking between days 3 and 5 post-infection (p.i) and the CD8+ T cell response 
peaking at day 7 p.i; 2) the persistent phase where by infection in the visceral organs is 
under control but virus titres now peak in the salivary glands and CD4+ T cells are the 
main cell subset responsible for controlling infection; 3) latent infection when infectious 
virus can only be sporadically detected (82). The time course of MCMV infection is 
depicted in Fig. 1.4. 
 
 
Figure 1.4. Time course of MCMV infection 
MCMV infection is characterised by 3 distinct stages known as the acute phase, the 
persistent phase and the latent phase. Once latency is established, low levels of 
replicating virus can only be detected sporadically whilst the host remains immune 
competent. If the host becomes immune compromised, the virus can reactivate and high 
levels of replicating virus can once again be detected. 
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The experimental mouse models of MCMV infection have been extensively used for over 
40 years to study the individual components of the host response that mediate resistance 
to acute, chronic and recurrent infections. The Smith and the K181 laboratory strains of 
MCMV are the most widely used in MCMV infection models. The Smith strain was derived 
from the original isolate of MCMV and is the most commonly used. MCMV infection of 
experimental mice mimics virus-induced disease in humans, for example, high viral titres 
in target organs are associated with pneumonitis, hepatitis and retinitis, and there are 
even models of congenital viral infection by MCMV (83). Importantly, different strains of 
inbred mice exhibit striking differences in their levels of susceptibility to MCMV infection 
due to genetic differences and is explained in detail in section 1.8.3. These differences 
make the mouse an excellent model to examine the heterogeneous response seen in 
humans and the identification of these genetic determinants may aid the identification of 
key components of the host immune response that are required for effective control of 
viral infections in humans (83).  
 
1.8.2. MCMV and immune evasion 
Similarly to HCMV, MCMV encodes a number of proteins that function to evade the host 
immune system. For example, MCMV encodes 3 products that alter MHC class I function 
– encoded by m152, m4 and m6 - consequently interfering with the ability of infected cells 
to present antigen to CD8+ T cells (79, 82). MCMV also encodes three proteins that 
downregulate ligands of the activating receptor NKG2D – encoded by m145, m155 and 
m152 – thus inhibiting NK cell-mediated clearance (63). In conjunction with this, the 
MCMV gene m144 encodes a homologue for MHC class I. It has been suggested that this 
acts as a decoy for NK cells by engaging inhibitory NK receptors and protecting infected 
cells from cytolytic activity (80). MCMV also encodes a CC-chemokine homologue, 
MCK-2 which recruits leukocytes and aids dissemination of the virus to the salivary glands 
(84, 85). Furthermore, the protein encoded by m45 has been shown to protect infected 
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endothelial cells from premature cell death, thus allowing the completion of viral 
replication to occur within these cells (86).    
 
1.8.3. MCMV and NK cells 
The importance of NK cells in the defence against MCMV infection has been well 
characterised. The NK cell response does not develop to maturity in suckling mice until 
the third week of life, and until this stage, mice are extremely susceptible to MCMV 
infection. Adoptive transfer experiments using purified culture-derived NK cells from adult 
splenocytes showed that NK cells protected suckling mice (and also irradiated adult mice) 
from MCMV (87). Mice with genetic deficiencies in NK cell function are also highly 
sensitive to MCMV infection (88). Furthermore, in vivo depletion of NK cells results in 
substantially elevated titres of MCMV during early infection (89-91). During acute MCMV 
infection, NK cells execute their antiviral functions through the secretion of IFNγ and 
cytotoxic action, which are promoted by the production of pro-inflammatory cytokines 
IL-12 and IFNαβ respectively (20, 92).  
 
Certain mouse strains are more resistant to MCMV infection than others. The mechanism 
that controls resistance was identified through genetic mapping which indicated a non-
MHC linked resistance gene, designated Cmv-1, which encodes an NK activation 
receptor Ly49H. The Ly49 family of receptors, which are analogous to the human KIRs, 
are cell surface receptors expressed primarily on NK cells. They interact either with host 
classical MHC class I molecules or virus-encoded ligands (93). Their ectodomain is 
responsible for their specificity but it is the intracellular portion of the receptor which 
defines them as inhibitory (such as Ly49A and Ly49C) or activating (such as Ly49H and 
Ly49P) (94). In MCMV-resistant C57BL/6 mice, approximately 50% of NK cells express 
the Ly49H receptor under normal homeostatic conditions. Susceptible strains such as 
BALB/c, do not express this receptor. The Ly49H receptor in resistant mice binds directly 
to m157, a MCMV-encoded glycoprotein with structural homology to murine MHC class I. 
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Ly49H-m157 interactions during acute MCMV infection initiate an activating signalling 
cascade which results in rapid clonal proliferation of Ly49H+ NK cells, killing of infected 
cells and secretion of pro-inflammatory cytokines, consequently reducing virus load (95). 
In resistant mice, infection with an m157-deleted virus renders them susceptible to MCMV 
as does the deletion of the host Ly49H gene. Conversely, transgenesis of Ly49H into 
susceptible strains was found to afford resistance to MCMV (reviewed in (95)), 
demonstrating the importance of this receptor-ligand pairing in the control of MCMV.  
 
The retention of a viral protein that specifically activates an immune response appears 
paradoxical to survival of the virus. A possible explanation for this is that m157 is an MHC 
class I homologue and may have evolved to engage inhibitory NK cell receptors. In 
certain strains of mice, m157 binds the inhibitory receptor Ly49I. The Ly49I gene is 
evolutionary older than the Ly49H gene and since the Ly49 locus evolves rapidly, the 
inhibitory receptor could have been converted to an activating one whilst retaining the 
ability to bind m157 (96). 
 
1.9. Interleukin-10 and the Interleukin-10 receptor 
Activated haematopoietic cells secrete cytokines that play important roles in the regulation 
of immune responses by controlling cellular proliferation, differentiation and effector 
functions. IL-10 was first described as cytokine synthesis inhibitory factor and was 
identified as a product of TH2 cells (97). It is an α-helical cytokine that belongs to the same 
family as type I IFNs and IFNγ. Mouse IL-10 and human IL-10 cDNAs encode very similar 
ORFs of 178 amino acids, sharing 73% amino acid homology (98). Human IL-10 is 
produced predominantly by macrophages, DCs, B cells and Tregs (99), although it can be 
produced by virtually all T cell subsets (100). Expression of IL-10 is regulated by several 
different mechanisms including the enhancing or silencing of IL10 transcription which is 
under the control of specific transcription factors, as well as regulation at the 
post-transcriptional level (101). The control of IL-10 mRNA stability at a 
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post-transcriptional level may facilitate more rapid control of IL-10 expression under 
certain circumstances than could be achieved by activation of transcription alone (98).  
 
The IL-10 receptor (IL-10R), like all receptors of α-helical cytokines, is composed of an 
extracellular binding module and an intracellular domain, and two subunits are required to 
generate a functional receptor complex (99). The IL-10R1 (IL-10Rα) is the ligand-binding 
subunit and is expressed by most haematopoietic cells, although generally at levels of 
only a few hundred molecules per cell. The IL-10R2 (IL-10Rβ) is the accessory subunit for 
signalling and is constitutively expressed in most cells and tissues. As there is no 
evidence for significant up-regulation of IL-10R2 in response to activation, any stimulus 
capable of activating IL-10R1 should therefore render most cells responsive to IL-10 (98). 
The interaction of IL-10 with its receptor engages the Jak family of tyrosine kinases Jak1 
and Tyk2, which are constitutively associated with IL-10R1 and IL-10R2 respectively. This 
leads to tyrosine phosphorylation and activation of STAT (signal transducer and activator 
of transcription) proteins, predominantly STAT3 and to a lesser extent STAT1 and STAT5. 
STAT3 is the common transcription factor downstream of IL-10-IL-10R that mediates 
most inhibitory actions of IL-10 upon innate and adaptive responses (98, 99). 
 
1.9.1. IL-10 modulation of immune cell function 
The majority of the literature to date demonstrates that IL-10 is a suppressive cytokine. It 
potently inhibits the production of a number of cytokines by activated monocytes and 
macrophages, including TNFα and IL-1αβ which often have synergistic activities on 
pro-inflammatory pathways. IL-10 also inhibits monocyte production of chemokines that 
are involved in inflammation by recruiting monocytes, DCs, neutrophils and T cells (102). 
In addition to reducing pro-inflammatory mediators, IL-10 also enhances expression of 
their natural antagonists and anti-inflammatory molecules, for example IL-1R antagonist, 
whilst also inhibiting expression of IL-1R1 and IL-1R2 on monocytes (102).  
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Another important function of IL-10 is the inhibition of expression of MHC class II and 
co-stimulatory molecules, such as CD80 and CD86, on monocytes which consequently 
affects the ability of these cells to present antigen to and activate T cells. Interestingly, it is 
not the transcription or synthesis of MHC class II which is inhibited by IL-10, rather the 
prevention of the newly synthesised molecules reaching the plasma membrane, resulting 
in the accumulation of internalised MHC class II complexes in intracellular vesicles (103). 
Inhibited expression of co-stimulatory molecules by IL-10 is also observed on DCs, again 
impeding T cell responses. IL-10 also inhibits the generation and maturation of monocyte-
derived-DCs (MD-DCs) with reduced levels of co-stimulatory and MHC class II molecules 
(102). IL-10 not only modulates cytokine production by monocytes, macrophages and 
DCs, but also by neutrophils. Furthermore, local and systemic inflammation driven by 
early influx of neutrophils is also reduced by IL-10, either indirectly through inhibition of 
neutrophil chemo-attractant production by macrophages, or directly via increased 
neutrophil apoptosis (reviewed in (104)). 
  
In addition to the indirect inhibition of T cell activation and proliferation due to the 
downregulation of MHC molecules, co-stimulatory molecules and pro-inflammatory 
mediators by APCs, IL-10 also has direct effects on T cells by inhibiting cytokine 
production and chemokine receptor expression by CD4+ T cells. Interestingly, activation of 
T cells in the presence of IL-10 can induce anergy, which can be associated with the 
induction of a population of Tregs that produce high levels of IL-10, consequently 
suppressing antigen-specific responses (102). IL-10 has differential effects on CD8+ T 
cells depending on their activation state. As discussed above, in the presence of 
professional APCs, IL-10 indirectly suppresses proliferative responses and induces 
anergy, however if CD8+ T cells are activated via their TCR in the absence of APCs, IL-10 
in combination with low-dose IL-2 directly initiates growth-promoting activity of CD8+ T 
cells (105). 
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Paradoxically, IL-10 has been shown to enhance survival of normal human B cells, 
although this does depend on activation state as discussed in (106), is a potent cofactor 
for B cell proliferation, and induces Ig production, isotype class switching and the 
differentiation of plasma cells into memory B cells (102). IL-10 also affects NK cell 
function in terms of cytotoxicity and IFNγ production which will be discussed in depth in 
section 3.1.1. The pleiotropic effects of IL-10 are summarised below in Fig. 1.5. 
 
 
Figure 1.5. The pleiotropic effects of IL-10 
IL-10 has direct immune suppressive effects on antigen presenting cells and both direct 
and indirect suppressive effects on T cells. Conversely, IL-10 has immune stimulatory 
effects on B cells. The effects of IL-10 on NK cell cytotoxicity and IFNγ production are 
variable between in vitro and in vivo experiments and are to be discussed in depth in 
section 3.1.1. Blue solid lines = direct inhibition by IL-10, blue dashed line = indirect 
inhibition by IL-10, purple solid arrows = functions enhanced by IL-10 and red dashed 
arrows = unknown effects (still to be discussed in section 3.1.1). 
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1.9.2. The role of IL-10 in infections 
IL-10 has emerged as a key regulator of immune responses induced by viral, bacterial, 
fungal and protozoal infections. Typically, IL-10 functions to dampen over-exuberant 
responses elicited by the pathogens and subsequently, the absence of endogenous IL-10 
or blocking of the IL-10 signalling pathway during these infections results in the onset of 
severe or often fatal infection-induced immune pathologies (107). For example, IL-10 
deficient mice succumb to Toxoplasma gondii infection within 2 weeks of infection where 
as wt littermates exhibit 100% survival (108). Enhanced mortality is associated with 
increased levels of the TH1 cytokines INFγ and IL-12 (108). In addition, IL-10 deficient 
mice also suffer from more severe disease and exhibit higher mortality rates than wt 
controls when infected with Plasmodium chabaudi, and enhanced pathology is associated 
with elevated levels of the TH1 cytokine TNFα (109). TH2 responses that lead to 
overproduction of IL-4, IL-5 and IL-13 can cause severe fibrosis in certain infections and 
are also regulated by IL-10 (107). Mice treated with IL-10 developed less liver, lung and 
pancreatic fibrosis when challenged with carbon tetrachloride, bleomycin and cerulean 
respectively (110-112). IL-10 treatment also reduced the severity of liver fibrosis in 
patients with chronic hepatitis C (HCV) infection (113).  
 
During acute viral infections, IL-10 appears to have contrasting functions. For example, 
IL-10 can limit infection-induced immunopathology induced by respiratory syncytical virus 
(RSV) (114), and influenza (115). However, following high dose influenza infection, IL-10-
deficient mice exhibit accelerated clearance of virus which is associated with the induction 
of antiviral TH17 cells (116), suggesting that the biological outcome of IL-10R signalling 
during acute infection may vary depending on the virus pathogen and the infectious dose. 
Conversely, during chronic virus infection, there is no evidence to suggest IL-10R 
signalling affords benefit to the host, as demonstrated in the LCMV model where IL-10 
actually antagonizes antiviral immunity and promotes virus chronicity (117, 118).  
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Interestingly, in certain persistent human viral infections including HCV, HIV and EBV, an 
increase in systemic IL-10 production can be observed, supporting the hypothesis that 
IL-10 may play a role in maintaining chronicity and pathogenicity in chronic infections; 
however, absolute proof of concept in humans is yet to be achieved (119).  
The role that IL-10 plays in regulating anti-herpesvirus immunity in vivo has been 
elucidated in murine systems, particularly the MCMV model of infection, and will be 
discussed in detail in section 3.1.2. 
 
1.9.3. Viral homologues of IL-10 
Multiple members of the Herpesviridae and Poxviridae family of viruses have IL-10-like 
ORFs which have been identified by sequence homology. The Poxviridae viruses that 
encode an IL-10 homologue all infect ruminants and include orfpox virus, sheeppox virus, 
goatpox virus and lumpy skin disease virus, although the biological properties of most of 
these remain to be determined (120-122). All of the herpesviruses determined to date as 
encoding IL-10 homologues are found in the beta- and gamma-herpesvirinae subfamilies 
and include rhesus CMV, African green monkey CMV, baboon CMV, rhesus LCV, equine 
HV 2, ovine HV 2 and the human herpesviruses HCMV and EBV (summarised in (120)). 
These viral IL-10 homologues range in size from 139-191 amino acids, comparable in 
size to mammalian IL-10 proteins (176-180 amino acids) (120). 
 
The EBV-encoded protein BCRF1 was the first herpesvirus-encoded protein identified to 
contain sequence homology (90% at amino acid level) with human IL-10 (123). BCRF1 is 
expressed during lytic infection (124) and inhibits monocyte stimulation of T cells and 
antagonizes expression of MHC class II (125) as well as co-stimulatory ligands (126) on 
the surface of macrophages and monocytes, suggesting BCRF1 functions to inhibit the 
activation of virus-specific CD4+ T cells. Furthermore, during active replication in B cells, 
BCRF1 may contribute to evasion of direct recognition by CD8+ T cells by interfering with 
B cell translocation of antigenic peptides to the ER for loading onto MHC class I (127). 
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BCRF1 may also exert more broad suppressive effects on the antiviral immune response 
via inhibition of cytokine production by T cells  (123) and monocytes (125). Conversely, 
BCRF1 also promotes B cell survival (128) and proliferation (129) in a comparable 
manner to cellular IL-10, thus implying that BCRF1 may promote carriage of latent virus in 
B cells.  
 
The IL-10 homologue encoded by HCMV is termed cmvIL-10. Unlike the high sequence 
homology of BCRF1, cmvIL-10 only exhibits 27% homology to human IL-10, but despite 
this, it can bind to IL-10R1 with essentially the same affinity as IL-10 and initiate IL-10R 
signalling (130). A latency-associated cmvIL-10 transcript (LAcmvIL-10) was also 
identified from the alternate splicing of the cmvIL-10 transcript (131). The functions of both 
cmvIL-10 and LAcmvIL-10 will be discussed in depth in section 4.1.1. 
 
1.10. Interleukin-22 and the Interleukin-22 receptor 
The IL-10 family of cytokines consist of 9 members which are divided into three 
subgroups. The first subgroup contains only IL-10 itself. The second subgroup is the IL-20 
subfamily of cytokines composed of IL-19, IL-20, IL-22, IL-24 and IL-26. Broadly, their 
major functions are to protect against extracellular pathogens as well as to drive tissue 
remodelling and wound healing. Type III IFNs made up of the closely related cytokines 
IL-28A, IL-28B and IL-29 make up the third subgroup (100). This section will focus on one 
member of the IL-20 subgroup, IL-22.  
 
IL-22 was initially known as IL-10 related T cell-derived inducible factor when it was first 
characterised by Dumoutier et al as it was a cytokine induced in mouse CD4+ T cells after 
stimulation with IL-9, and was found to share 22.8% homology with IL-10 (132). It was 
renamed IL-22 after the human protein was discovered along with other structurally 
related cytokines mentioned above (133). Murine IL-22 has 80.8% homology to human 
IL-22, and like all other IL-10 family members has an α-helical structure (134).  
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The IL-22 receptor (IL-22R) is a heterodimer composed of IL-22R1 (IL-22Rα) and 
IL-10R2. As discussed in section 1.9, IL-10R2 is constitutively expressed on most cell 
types, whereas IL-22R1 expression is limited to non-haematopoietic cells of the skin, 
lung, small intestine, liver, colon, kidney and pancreas (133). IL-22 binds first to IL-22R1 
and then the IL-22-IL-22R1 complex binds to IL-10R2, which propagates downstream 
signalling similar to that of the other IL-10 family members (135), primarily resulting in 
activation of STAT3 (136).  
 
Unlike IL-22R1 expression which is restricted to non-hematopoietic cells, IL-22 can be 
expressed by a number of innate and adaptive immune cells. TH17 cells are a major 
source of IL-22 production, along with activated NKT cells and γδ T cells, and CD8+ T 
cells can express IL-22 in vitro when cultured with the same cytokines that induce IL-22 in 
CD4+ T cells (136). Activated NK cells also express high levels of IL-22 (136), as do a 
heterogeneous population of innate lymphoid cells (ILCs) which largely lack expression of 
most lineage markers; the best characterised populations of ILCs being the NKp46+ILCs 
and the CD4+ILCs (135). A soluble secreted receptor of IL-22 also exists and is known as 
IL-22-binding protein (IL-22BP) (137). IL-22BP has been shown to counteract 
IL-22-IL-22R binding in vitro and may in fact have a higher binding affinity to IL-22 than 
that of IL-22 to IL-22R. However the pathways that regulate the expression of this 
receptor and its functions in vivo are yet to be characterised (135). 
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1.10.1. Functions of IL-22 
To date, IL-22 has been shown to have multiple functions in tissue inflammation, 
immunosurveillance and homeostasis, particularly at barrier sites such as the skin and 
mucosal surfaces. Initial studies characterising the functions of this cytokine showed that 
keratinocytes stimulated with IL-22 caused marked induction of genes involved in 
antimicrobial defence (138). Subsequent studies showed that production of antimicrobial 
proteins by epithelial cells in the lung and the gut were also induced by IL-22 (reviewed in 
(139)). Antimicrobial proteins constitute an ancient form of innate immunity against 
extracellular microbial infection that encompasses pathogen recognition, inflammation, 
pathogen-clearance and resolution of inflammation, and therefore provide excellent 
protection at skin and mucosal surfaces. Thus, the induction of these proteins by IL-22 is 
important for the maintenance of mucosal immunity (140, 141). IL-22 can also up-regulate 
expression of acute-phase proteins such as serum amyloid A, which recruits immune cells 
to the sites of inflammation, especially in the liver, and sustained IL-22 exposure induces 
a systemic acute-phase response (142). The acute-phase proteins serve a range of 
physiological functions such as inhibiting the growth of microbes, trapping pathogens via 
increased coagulation, and increasing vascular permeability to enhance cellular 
recruitment to the sites of inflammation. These studies suggested that IL-22 is an 
important immune mediator acting on mucosal tissues to regulate host responses (143). 
The multiple functions of IL-22 at different sites are summarised in Fig. 1.6.  
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Figure 1.6. The multiple functions of IL-22 
IL-22 has important functions in tissue inflammation, immunosurveillance and 
homeostasis, particularly at barrier sites, mucosal surfaces and the liver. IL-22 regulates 
the expression of genes encoding molecules associated with inflammation, repair, 
chemotaxis and the expression of antimicrobial peptides. 
 
 
In addition to regulating the expression of antimicrobial peptides and acute-phase 
proteins, IL-22 has been shown to have other important functions which are somewhat 
context dependent, as IL-22 can both promote pathological inflammation and also prevent 
tissue destruction. For example, IL-22 is necessary for the induction of dermal 
inflammation in a mouse model of psoriasis-like skin inflammation by inducing IL-1, IL-6 
and TNFα gene expression, as well as inducing gene expression of the antimicrobial 
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peptides S100A8, S100A9, defensin β1 and cathelicidins, which recruit and activate CD4+ 
T cells, neutrophils, macrophages and DCs (144). In the intestine, up-regulation of IL-22 
during infection with Toxoplasma gondii was essential for the development of ileitis in 
mice, and was associated with the upregulation of matrix metalloprotease 2, which drives 
immunopathology (145). Furthermore, in a collagen-induced arthritis model (a mouse 
model for rheumatoid arthritis), IL-22 was found to promote arthritic inflammation in the 
joints (146). 
 
In contrast, IL-22 has also been shown to have protective roles in the lung. Not only was it 
demonstrated that IL-22 attenuated antigen-induced airway inflammation, possibly by the 
inhibition of eosinophil recruitment into the airways via expression of IL-25, (147), but also 
γδ T cell-derived IL-22 protects against lung fibrosis via inhibition of collagen deposition in 
a mouse model of hypersensitivity pneumonitis, possibly involving IL-22 diminished 
recruitment of αβ T cells (148).  
 
Several groups have shown that in the liver, IL-22 is tissue protective during inflammation 
in mouse models of hepatitis. During hepatitis, hepatocytes are damaged leading to 
reduced liver function. However, IL-22 is a survival factor for hepatocytes and thus plays a 
protective role in preventing tissue injury (149, 150). Furthermore, during inflammatory 
bowel disease (IBD) where the epithelium of the gastrointestinal tract is destroyed, IL-22 
actually protects mice from IBD, in particular CD4+ T cell-mediated colitis as well as colitis 
mediated by the innate immune system (151). Conversely, in a colitis model induced by 
memory/effector CD4+ T cells rather than naïve cells, T cell-derived IL-22 is actually 
pathogenic, highlighting the different ways IL-22 impacts IBD (152). 
 
IL-22 also has a role in the host response to infectious diseases. IL-22 is highly expressed 
during certain infections, especially in response to extracellular pathogens. In the lung, 
IL-22 is important for controlling Klebsiella pneumonia infection in mice (143). It plays an 
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equally important role in protection from Citrobacter rodentium infection, as IL-22-/- mice 
have increased intestinal epithelium damage, greater bacterial loads and increased 
mortality (153). The critical role IL-22 plays in limiting bacterial replication and 
dissemination in these models is probably in part due to IL-22 inducing the expression of 
antimicrobial peptides from epithelial cells at these barrier surfaces (135). Interestingly an 
in vitro study using human NK cells demonstrated that NK cell-derived IL-22 contributed 
to defences against Mycobacterium tuberculosis by inhibiting its growth in macrophages 
via enhancing phagolysosomal fusion (154). 
 
1.11. Thesis aims 
Understanding how antiviral immune responses are suppressed during HCMV infection 
and identifying what immune mechanisms contribute to protection will assist in the design 
of effective vaccination and immune therapeutic strategies. Given the immunosuppressive 
functions of IL-10 and the evolutionary acquisition by HCMV of its own IL-10 homologue, 
elucidating the in vivo role of mammalian- and viral-IL-10 during acute infection is likely to 
aid in vaccine/therapy design. Moreover, IL-22 has been shown to provide critical 
protection against certain infectious agents, particularly bacterial infections. However, the 
role that IL-22 plays in antiviral immunity is not clear. Therefore, understanding how IL-22 
acts during in vivo MCMV infection may also profoundly influence the development of 
novel therapies to counter HCMV.     
 
The overall aims of this thesis are: 
1) Utilise the MCMV model of infection to elucidate the in vivo role of mammalian 
IL-10 during acute cytomegalovirus infection 
2) Ascertain the in vitro role of viral-IL-10 during HCMV infection  
3) Determine the function of IL-22 during acute MCMV infection  
 
The specific hypotheses I will be testing experimentally will be discussed in finer detail in 
each individual results section (chapters 3-5). 
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Chapter 2 - Materials and Methods 
 
2.0. Treatment of animals 
Wild-type (wt) C57BL/6 experimental mice were obtained from the external suppliers 
Harlan UK (Blackthorn, UK). Animals were kept under a Home office licence issued to Dr 
Ian Humphreys (PPL 30/2442) and were treated according to home office regulations. All 
mice were kept in specified pathogen free Scantainer housing at the home office 
designated facility at Heath Park Cardiff University. Rag-/- mice and IL-10-/- mice (both on 
a C57BL/6 background) were obtained from breeding colonies within the facility and were 
kept in filter top cages. Health status of animals within the facility was determined by 
sentinel screening every three months. Mice were culled by an approved schedule one 
method of euthanasia. 
 
2.1. MCMV virus generation 
Three to four week old, female BALB/c mice were obtained from Harlan and were infected 
with 1 x 104 plaque forming units (PFU) of low passage Smith strain (American Type 
Culture Collection, Manassas, VA) MCMV by intra-peritoneal (IP) injection. At day 13 p.i, 
salivary glands were harvested, and homogenised using an IKA T10 basic electric tissue 
homogeniser (Thermo Fisher Scientific, East Sussex, UK). The resulting homogenate was 
centrifuged (2000rpm, 10 minutes, 4oC) to pellet cellular debris. The virus-containing 
supernatant was overlaid onto a sorbitol cushion (section 2.23) and centrifuged at high 
speed (18100rpm, 75 minutes, 4oC). The virus pellet was then resuspended in endotoxin 
low 1 x PBS and sonicated for 5 minutes on ice. The sample was centrifuged (2000rpm, 
10 minutes, 4oC) and the supernatant was taken and aliquoted and stored under -80oC 
freezing conditions. Virus stocks were titred by plaque assay (section 2.7) on two-three 
separate occasions and an average taken. 
 
 
 47 
 
2.2. Viral infections and treatments 
Mice were infected by IP injection with 5 x 104 PFU or 3 x 104 PFU MCMV. In some 
experiments, mice were also administered by IP injection on the day of infection 250µg of 
either rat IgG (Chemicon International, Temecula, CA) or anti-IL-10R (clone 1B1.3A, 
BioXCell, West Lebanon, NH). For the NK cell depletion experiments, mice were 
administered 200µg of anti-NK1.1 antibody (clone PK136, BioXCell) on days -2, 0 and +2 
of infection by IP injection. In other experiments, mice were administered 50µg of either 
goat IgG (Chemicon) or anti-IL-22 (R&D Systems, Minneapolis, MN) by intravenous (IV) 
injection on days 0 and +2 of infection. For the neutrophil depletion experiments, mice 
were injected by IP with 100µg anti-Ly6G (clone 1A8, BioXCell) on days 0 and +2 of 
infection. 
 
2.3. Leukocyte isolation 
To isolate pulmonary leukocytes, mice were perfused with 10ml sterile PBS and lungs 
surgically excised, cut into small pieces and incubated in collagenase-containing buffer 
(section 2.23) at 37oC with mild agitation for 45 minutes. Cells were then passed through 
a 70µm nylon cell strainer, washed in PBS and resuspended in red blood cell lysis buffer 
(section 2.23) for 5 minutes at room temperature (RT). Samples were then washed in 
PBS and resuspended in a specific volume of R10 media (section 2.23). Spleens were 
excised and cells isolated by passage through a 70µm nylon cell strainer prior to washing 
with PBS, red blood cell lysis and resuspension in R10. Livers were also excised and 
passed through a 70µm and washed in PBS. Cells were resuspended in 37.5% percoll 
(diluted in PBS) and centrifuged at 2000rpm for 6 minutes before red blood cell lysis and 
resuspension in R10. Viable lymphocytes were quantified using trypan blue exclusion. 
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2.4. FACS staining 
Leukocytes (1 x 105 cells/200µl well) were incubated with Fc receptor blocking reagent 
(eBioscience, San Diego, CA) in facs buffer (section 2.23) and stained with various 
antibody panels to identify surface markers (see Table 1 for antibodies used). All 
antibodies for surface staining were diluted in facs buffer and incubated in 25µl volumes 
unless otherwise stated. Cells were then fixed with 3% paraformaldehyde (Thermo Fisher 
Scientific). In some instances, cells were permeabilised with saponin buffer (section 2.23) 
and stained with intracellular antibodies (see Table 2 for antibodies used). 
 
2.4.1. FACS staining to assess proliferation 
Isolated leukocytes were surface stained with anti-NK1.1-APC and anti-CD3-PE-Cy5, 
cells were fixed and permeabilised and stained with anti-Ki67-FITC.  
 
2.4.2. FACS staining to assess early NK cell apoptosis 
Isolated leukocytes were incubated with Live/Dead Fixable Aqua (Invitrogen, Carlsbad, 
CA), then stained with anti-CD3-Percp-Cy5.5, anti-NK1.1-APC and either Annexin-V FITC 
(BD Pharmingen, Franklin Lakes, NJ), or anti-caspase-3-PE (active form), according to 
manufacturer’s instructions. Briefly, for caspase-3 staining, after surface staining, cells 
were resuspended in BD Cytofix/Cytoperm solution and incubated for 20 minutes on ice in 
the dark. Cells were washed with BD Perm/Wash buffer and resuspended in Perm/Wash 
buffer containing the anti-caspase-3 antibody and incubated for 30 minutes at RT in the 
dark. Cells were again washed and resuspended in Perm/Wash buffer. For Annexin-V 
staining, after surface staining, cells were resuspended in 1 x BD Binding Buffer 
containing the Annexin V-FITC probe (1:50 dilution) and incubated for 15 minutes at RT in 
the dark. Cells were washed and resuspended in BD binding buffer and analyzed by flow 
cytometry within 1 hour. 
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2.4.3. FACS staining to assess ex vivo cytokine production 
Leukocytes were incubated at 1 x 105 cells/ml for 4 hours at 37°C in the presence of 
2µg/ml brefeldin A (Sigma-Aldrich, UK). Cells were then washed and incubated with Fc 
block and surface stained with appropriate antibodies prior to fixation with 3% 
formaldehyde (Thermo Fisher Scientific). Cells were then permeabilised with saponin 
buffer and stained with anti-IFNγ-FITC or anti-IFNγ-PE-Cy7. To assess IL-10 expression, 
splenocytes and lung leukocytes were stimulated for 5 hours at 37°C with either 50ng/ml 
PMA and 500ng/ml ionomycin (for expression by T cells and NK cells), 10µg/ml LPS, 
50ng/ml PMA and 500ng/ml ionomycin (for expression by B cells) or 10µg/ml LPS (for 
expression by APCs) (all reagents from Sigma-Aldrich). Cells were then incubated with Fc 
block and surface stained with anti-CD4-PB, anti-CD8-APC-H7, anti-CD3-PerCP-Cy5.5, 
anti-NK1.1-APC, anti-gamma delta TCR-FITC, anti-CD11b-PE-Cy7, or anti-B220-PE-Cy7 
prior to fixation, permeabilisation and intracellular staining with anti-IL-10-APC. To assess 
IL-22 expression, splenocytes and lung and liver leukocytes were stimulated for 4 hours 
at 37°C with 50ng/ml PMA, 500ng/ml ionomycin and 50ng/ml IL-23 (R&D systems) in the 
presence of 2µg/ml brefeldin A. Cells were then incubated with Fc block and surface 
stained with anti-CD3-APC-Cy7, anti-NK1.1-APC, anti-gamma delta TCR-FITC, 
anti-CD4-PB and anti-CD8-PerCP prior to fixation, permeabilisation and intracellular 
staining with anti-IL-22-PE. 
 
2.4.4. FACS staining to assess NK cell cytotoxicity 
Leukocytes were incubated for 1 hour with anti-CD107a-FITC (2µl/well = 5µg/ml) and then 
0.7µg/ml monensin (BD Pharmingen) was added for a further 4 hours at 37°C. Cells were 
then surface stained with anti-CD3 and anti-NK1.1.  
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Table 1. Details of antibodies used for flow cytometric detection of cell surface-expressed 
proteins 
 
Antibody Conjugate Clone Company Dilution 
α-Gamma Delta-
TCR 
FITC GL3 BD Pharmingen 1:75 
α-CD107a FITC 1D4B BD Pharmingen 2µl/well = 
5µg/ml 
 α-CD122 FITC TM-b1 eBioscience 1:100 
α-CD19 FITC eBIO13D BD Pharmingen 1:100 
α-CD69 FITC H1.2F3 BD Pharmingen 1:100 
α-Gr-1 FITC RB6-8C5 Biolegend 1:100 
α-KLRG1 FITC 2F1 Southern Biotech 1:100 
α-Ly49H FITC 3D10 BD Pharmingen 1:200 
α-Ly6B FITC 7/4 AbD Serotech 1:100 
α-NKp46 FITC 29A1.4 eBioscience 1:100 
α-CD122 PE TM-b1 eBioscience 1:100 
α-CD210 (IL-10R) PE 1B1.39 BD Pharmingen 1:100 
α-CD25 PE PC61-5 eBioscience 1:100 
α-CD27 PE LG.7F9 eBioscience 1:100 
α-Ly6G PE 1A8 BD Pharmingen 1:100 
α-Ly6B PE 7/4 AbD Serotech 1:20 
α-NK1.1 PE PK136 eBioscience 1:100 
α-TCRβ PE-Cy5.5 H57-597 eBioscience 1:50 
α-CD8α PerCP 53-6.7 BD Pharmingen 1:100 
α-CD3 PerCP-Cy5.5 145-2C11 BD Pharmingen 1:50 
α-I-A/I-E (MHC II) PerCP-Cy5.5 M5/114.15.2 Biolegend 1:200 
α-B220 PE-Cy7 RA3-6B2 Biolegend 1:100 
α-CD11b PE-Cy7 M1/70 eBioscience 1:100 
α-CD11c PE-Cy7 N418 BD Pharmingen 1:100 
α-CD69 PE-Cy7 H1.2F3 eBioscience 1:50 
α-CD95 PE-Cy7 Jo2 BD Pharmingen 1:100 
α-KLRG1 PE-Cy7 2F1 eBioscience 1:50 
α-F4/80 APC BM8 eBioscience 1:100 
α-NK1.1 APC PK136 BD Pharmingen 1:100 
α-CD11b APC-Cy7 M1/70 BD Pharmingen 1:75 
α-CD3 APC-Cy7 145-2C11 Biolegend 1:75 
α-CD8α APC-H7 53-6.7 BD Pharmingen 1:100 
α-CD127 (IL-7Rα) PB A7R34 eBioscience 1:100 
α-CD4 PB RM4-5 BD Pharmingen 1:100 
 
 
 
 51 
 
Table 2. Details of antibodies used for flow cytometric detection of intracellular proteins 
 
Antibody Conjugate Clone Company Dilution 
α-Granzyme B FITC GB11 Biolegend 1:100 
α-IFNγ FITC XMG1.2 eBioscience 1:100 
α-Ki67 FITC B56 BD Pharmingen 1:25 
α-Caspase-3 
(active form) 
PE C92-605 BD Pharmingen 1:6 
α-IL-22 PE IC582P R&D systems 1:50 
α-IFNγ PE-Cy7 XMG1.2 BD Pharmingen 1:75 
α-IL-10 APC JES5-16E3 eBioscience 1:100 
 
 
FITC = Fluoresceine-isothiocyanate 
PE = Phycoerythin 
PE-Cy5.5 = Phycoerythin-Cyanine 5.5 
PE-Cy7 = Phycoerythin-Cyanine 7 
PerCP = Peridinin chlorophyll 
PerCP-Cy7 = Peridinin chlorophyll-Cyanine 7 
APC = Allophycocyanin 
APC-Cy7 = Allophycocyanin-Cyanine 7 
PB = Pacific Blue 
 
 
2.4.5. FACS staining to assess MCMV specific CD4+ T cells 
Examination of MCMV specific CD4+ T cell responses was carried out by peptide 
stimulation with MHC class II restricted peptides. Splenocytes and lung leukocytes were 
incubated for 5 hours at 37°C in the presence of 2µg/ml brefeldin A and 3µg/ml MCMV-
derived peptides (Genscript, Piscataway, NJ). A medium alone control without peptides 
was run alongside the stimulations. The sequences of the peptides used were: 
M25: NHLYETPISATAMVI  
m139: TRPYRYPRVCDASLS 
m142: RSRYLTAAAVTAVLQ 
 
Cells were then stained with anti-CD4-PB and anti-CD3-PE-Cy5 before fixation, 
permeabilisation and intracellular staining with anti-IFNγ-FITC. 
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2.4.6. Acquisition and analysis 
All data were acquired on a BD FACS Canto II. Electronic compensation was performed 
with antibody-capture beads (BD Pharmingen) stained with individual monoclonal 
antibodies used in the experimental panel. A minimum of 30,000 events were acquired in 
each case and data were analyzed using FlowJo software version 8.5.3 (TreeStar Inc, 
Ashland, OR). Total numbers of different cell populations were calculated by multiplying 
the total number of viable leukocytes (assessed by trypan blue exclusion) by percent 
positive cells, as detected by flow cytometry. 
 
2.5. Cytometric Bead Array 
Excised lungs, livers and spleens (~50mgs) were weighed and washed once in PBS and 
then homogenised in 1ml DMEM (Invitrogen) prior to centrifugation at 2000rpm for 10 
minutes. Undiluted supernatants were then assayed for cytokines by cytometric bead 
array (Bender MedSystems, Vienna, Austria) according to manufacturer’s instructions. 
Briefly, standard curves were generated in duplicate by serial dilution and samples were 
also measured in duplicate. Standards and samples were incubated with bead mix and 
biotin-conjugate mix for 2 hours at RT on a plate shaker at 500rpm. After two washes, 
standards and samples were then incubated with streptavidin-PE mix for 1 hour at RT on 
a plate shaker at 500rpm. After two washes, standards and samples were resuspended 
and acquired using a FACS canto II. Data was analysed using FlowCytomix Pro 2.3 
software. Results were then calculated as pg cytokine/g tissue. 
  
2.6. ELISAs  
Excised lungs, livers and spleens (~50mgs) were weighed and then homogenised in 1ml 
DMEM prior to centrifugation at 2000rpm for 10 minutes. Undiluted supernatants were 
then assayed for IL-12, IL-22 and CXCL1 by ELISA. 
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2.6.1. IL-12: IL-12 was detected using a Peprotech (Rocky Hills, NJ) ELISA kit as per 
manufacturer’s instructions. Briefly, capture antibody (diluted as instructed on Certificate 
of Analysis) was added to an ELISA plate (Nunc, Roskilde, Denmark) and incubated over 
night at RT (all further incubations were also carried out at RT). The next day, wells were 
washed 5 times with ELISA wash buffer (section 2.23) and incubated with block buffer 
(1% BSA (Sigma-Aldrich) in PBS) for 1 hour. Wells were washed again before standards 
and tissue homogenate samples were added in duplicate to the plate and incubated for 
two hours. After washing, detection antibody (diluted as instructed) was added and 
incubated for 2 hours. After the wells were washed again, streptavidin-HRP was added for 
30 minutes. After the final washes, ABTS substrate (Sigma-Aldrich) was added. Colour 
development was monitored with a FLUOstar OPTIMA plate reader at 450nm wavelength 
with values subtracted at 570nm and optical density readings taken every 5 minutes over 
a 35 minute period.  
 
2.6.2. IL-22: IL-22 was detected using an eBioscience ELISA kit as per manufacturer’s 
instructions. Briefly, capture antibody (diluted as instructed on Certificate of Analysis) was 
added to an ELISA plate provided and incubated overnight at 4°C. The next day, wells 
were washed 5 times with wash buffer and the plate was blocked with 1 x assay diluent 
provided and incubated for 1 hour at RT (all further incubations were carried out at RT). 
Wells were washed again before the standards and tissue homogenate samples were 
added in duplicate to the plate and incubated for 2 hours. After washing, detection 
antibody (diluted as instructed) was added and incubated for 1 hour. After washing, 
working dilution of streptavidin-HRP was added and incubated for 30 minutes. The wells 
were then washed 7 times and incubated with substrate solution provided. After 15 
minutes, 50µl of stop solution (1M H3PO4) was added. Absorption was measured with a 
FLUOstar OPTIMA plate reader at 450nm wavelength with values subtracted at 570nm. 
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2.6.3. CXCL1: CXCL1 was detected using an R&D systems ELISA kit as per 
manufacturer’s instructions. Briefly, capture antibody (diluted as instructed) was added to 
an ELISA plate and incubated overnight at RT (all further incubations were also carried 
out at RT). The next day, wells were washed 5 times with wash buffer and blocked with 
reagent diluent (1% BSA in PBS) and incubated for 1 hour. Wells were washed again 
before standards and tissue homogenate samples were added in duplicate to the plate 
and incubated for 2 hours. After washing, detection antibody (diluted as instructed) was 
added and incubated for 1 hour. After washing, streptavidin-HRP was added and 
incubated for 20 minutes. The wells were then washed again and incubated with 
substrate solution for 20 minutes before stop solution was added. Absorption was 
measured with a FLUOstar OPTIMA plate reader at 450nm wavelength with values 
subtracted at 570nm). 
 
Standard curves for each ELISA were generated in Graphpad Prism (version 5.0) by 
logarithmic transformation and unknown values generated for each sample. Values were 
then calculated as either pg/ml or as pg/g of tissue. 
 
2.7. Plaque assay 
Replicating virus in organs of MCMV-infected mice was detected by plaque assay. Tissue 
samples taken were snap-frozen in liquid nitrogen and then stored at -80°. Tissue 
samples were weighed prior to use. The embryonic fibroblast cell line NIH-3T3 was 
obtained from the internal Cardiff University cell bank and cultured in a humidified cell 
culture incubator (37oC, 5% carbon dioxide) in D10 media (section 2.23). These cells 
were seeded onto Corning flat bottom 24 well cellbind plates (Appleton Woods, 
Birmingham, UK) at a concentration of 1.5 x 105 cells per well in 1ml of D10 and 
incubated overnight. Cells were checked the next day to ensure they had formed a 
monolayer of approximately 80-90% confluency. The snap-frozen samples were 
mechanically broken down in DMEM using an IKA T10 electric tissue homogeniser in 
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polypropylene snap-cap tubes (BD Pharmingen). Samples were serially diluted in DMEM. 
The D10 media from the plates containing the confluent cells was then removed by gently 
pouring into bleach, and 200µl of each serial dilution from the homogenised samples was 
added to duplicate wells. For high sensitivity plaque assays, plates were centrifuged at 
1200g for 30 minutes at RT and for standard plaque assays, plates were incubated at 
37°C for 1 hour. The serially diluted samples were then aspirated off into bleach and 
warm CMC media (section 2.23) was added to each well. Cells were incubated for 6 days 
at 37°C to allow plaques to develop. After 6 days, the CMC media was removed by gently 
pouring into bleach and the cells were fixed with 10% paraformaldehyde in PBS for 2-3 
hours or overnight, and stained with crystal violet solution (section 2.23) for 10 minutes. 
Plates were then gently washed under running water and left to air-dry. Plaques were 
counted and replicating virus calculated using the formula: 
 
PFU MCMV/ml = average number of plaques x dilution factor x 5 (200µl of virus-
containing media was used/well) 
 
To calculate PFU/gram tissue, the following formula is used: 
PFU/gram tissue = 1/sample weight x PFU/ml (as calculated above). 
 
2.8. DNA extraction from tissues 
Genomic DNA was isolated from spleen, lung and liver tissue using a DNeasy tissue kit 
(Qiagen, Valencia, CA), using a modified protocol. Tissue samples taken for DNA 
extractions were snap-frozen in liquid nitrogen and stored at -80°C. All DNA extraction 
work was done in an area that had been cleaned thoroughly with ethanol. All plastic-ware 
used was certified DNase and RNase free. Samples were incubated with 360µl of buffer 
ATL and 40µl of proteinase K at 56°C overnight in a shaking incubator. Samples were 
then forced through a G27 gavage needle (0.4 mm x 13 mm) until fully viscous. 400µl of 
buffer AL and 400µl of ethanol (96-100%) were added and samples vortexed. The mixture 
was then added to mini spin columns and centrifuged for 1 minute at 8000rpm. The flow 
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through was discarded and the spin column was placed into a new collection tube. The 
columns were then washed twice with 500µl of buffer AW1 (1 minute at 8000rpm) and 
washed once with 500µl of buffer AW2 (3 minutes at 13000rpm to ensure the spin column 
membrane was dry).  DNA was eluted by adding 150µl of buffer AE and centrifuged for 1 
minute at 8000rpm. Sample DNA concentration and purity (260/280 ratio >1.8) was 
determined using a ND-1000 NanoDropTM spectrophotometer from Thermo Fisher 
Scientific. Samples were kept at -80oC for long term storage.  
 
2.9. Viral genome detection 
MCMV glycoprotein B (gB) was assayed by real-time quantitative PCR (qPCR) using 
Platinum SYBR green mastermix reagent (Invitrogen) and a Mini Opticon (Biorad 
Laboratories, Hercules, CA). For each 20µl reaction, the following components were 
added; 1.6µl DNA (as extracted using protocol in section 2.8), 10µl SYBR green, 0.4µl 
forward primer, 0.4µl reverse primer and 7.6µl DNase/RNase free water (Invitrogen). 
MCMV gB was measured relative to the amount of housekeeping gene β-actin. The 
primer sequences used for detection of the β-actin were forward: 
GATGTCACGCACGATTTCC and reverse: GGGCTATGCTCTCCCTCAC; primers used 
for detection of gB were forward: GAAGATCCGCATGTCCTTCAG and reverse: 
AATCCGTCCAACATCTTGTCG. 100ng aliquots of DNA were used as templates for each 
reaction, and diluted in DNase/RNase free water. Samples were run in triplicate and an 
average taken. Cycling parameters were as follows: 
1. Incubate at 95°C for 15 minutes 
2. Incubate at 95°C for 15 seconds 
3. Incubate at 60°C for 1 minute 30 seconds 
4. Plate read 
5. Go to line 2 for 40 more times 
6. Melting curve from 70°C to 90°C, read every 0.3°C, hold for 15 seconds 
7. End  
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Relative amounts of viral genome were calculated using the following formula: 
 
 Ratio gB:β-actin =             1                                 
2
^ (Average reading for β-actin - Average reading for gB) 
 
Relative levels of viral genome were converted to genome copy numbers by extrapolating 
from a titration curve produced using the pARK25 MCMV plasmid (a gift from A. 
Redwood, University of Western Australia, Perth, Western Australia, Australia) by using 
Graphpad Prism software. The limit of detection was 10 genome copies/100ng DNA.  
 
2.10. RNA extraction 
RNA was isolated from liver, spleen and lung tissue or from populations of cells following 
MACS separation (section 2.13) using an RNeasy mini kit (Qiagen). Tissue samples 
taken for RNA extractions were frozen on dry ice in RNA later stabilisation reagent and 
then stored at -80°C. All RNA extraction work was done in an area that had been cleaned 
thoroughly with ethanol and then with RNase ZAP reagent (Invitrogen). All plastic-ware 
used was certified DNase and RNase free. Tissue samples were removed from the 
stabilisation buffer and transferred to 12ml screw cap tubes (Greiner Bio-one, Austria) 
containing buffer RLT and β-mercaptoethanol and mechanically broken down using an 
IKA T10 electric tissue homogeniser. Samples were centrifuged at full speed (13000rpm) 
for 5 minutes to pellet cellular debris. To remove the genomic DNA, the sample 
supernatant was added to a gDNA eliminator spin column and centrifuged at 8000rpm for 
30 seconds. 70% ethanol (50% for liver samples) was added to the flow through. The 
mixture was then transferred to an RNeasy spin column provided and centrifuged at 
8000rpm for 15 seconds. The RNeasy spin column was washed with buffer RW1, then 
twice with buffer RPE. The spin column was placed in a new collection tube and 
centrifuged at full speed for 1 minute to completely dry the membrane. The column was 
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then placed in a new collection tube and RNase free water was added. Tubes were 
centrifuged at 8000rpm for 1 minute to elute the RNA. 
 
RNA concentration and purity (260/280 ratio <1.6) was determined using a ND-1000 
NanoDropTM spectrophotometer. Samples were kept at -80oC for long-term storage. 
Stable complementary DNA (cDNA) was made from the RNA (refer to section 2.11). 
 
2.11. cDNA synthesis 
RNA was converted into cDNA using a reverse transcription kit (Applied Biosystems, UK). 
All work was done in an area that had been cleaned thoroughly with ethanol and then with 
RNase ZAP reagent. All plastic-ware used was certified DNase and RNase free. A master 
mix of reaction components was prepared and added to each RNA sample. For each 10µl 
reaction, the following components were added: 3.85µl RNA, 1.0µl 10 x Taqman RT 
buffer, 2.2µl MgCl2 (25mM), 2.0µl deoxyNTPs (2.5mM), 0.5µl random hexamers (50µM), 
0.2µl RNase inhibitors (20U/L) and 0.25µl of multiscribe reverse transcriptase (500U/L). 
 
Samples were then synthesised using a DNA Engine DYAD Peltier Thermal Cycler 
(Biorad Laboratories) using the following cycling parameters: 
1. Incubate at 25oC for 10 minutes 
2. Incubate at 48oC for 45 minutes 
3. Incubate at 95oC for 5 minutes 
4. Incubate at 4oC for ever 
 
Samples were kept at -80oC for long term storage. 
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2.12. qPCR reactions for gene expression 
Levels of gene expression were measured by qPCR using the SYBR green master mix 
reagent as in section 2.9. For each 20µl reaction, the following components were added; 
1.6µl cDNA (section 2.11), 10µl SYBR green, 0.4µl forward primer, 0.4µl reverse primer 
and 7.6µl DNase/RNase water. Amount of each gene of interest was measured relative to 
the house keeping gene β-actin. The primer sequences for each gene are listed in Table 
3. Samples were run in duplicate and an average taken. The cycling parameters were the 
same as in section 2.9. Relative amounts of each gene were calculated using the 
following formula: 
 
 Ratio of gene of interest:β-actin =                   1                                        
       2
^ (Average reading for β-actin - Average reading for gene of interest)
 
 
 
Table 3. Primer sequences for qPCR reactions to analyse gene expression 
Gene of 
interest 
Forward primer Reverse primer 
β-actin GGGCTATGCTCTCCCTCAC GATGTCACGCACGATTTCC 
Cathepsin C CCGGGCATTTTACCCTCAT TTGAAAAACGCAAACCATTTGT 
CXCL1 CTCAAGAATGGTCGCGAGGCT GCACAGTGGTTGACACTTAGTGGTCTC 
CXCL2 CTCAAGAATGGTCGCGAGGCT TACGATCCAGGCTTCCCGGGT 
CXCL5 CTCAGTCATAGCCGCAACCGAGC CGCTTCTTTCCACTGCGAGTGC 
CXCL15 GGTGATATTCGAGACCATTTACTG GCCAACAGTAGCCTTCACCCAT 
IFNα GTCAGTGTCAGAAGCTCCTGTGGC CTATGGTCCAGGCACAGTGACTG 
IFNβ GAATCTCTCCTTTCTCCTG CTGACAACCTCCCAGGCAC 
IFNγ GCCGTGGCAGTAACAGCC AACGCTACACACTGCATCTGGG 
iNOS GGCAGCCTGTGAGACCTTTG GCATTGGAAGTGAAGCGTTTC 
LTα AACCCAAGAATTGGATTCCAGG TGTGACCCTTGAAACAACGGT 
LTβ TGTCTCCAGCTGCGGATTCTA TTTGGCAGCTGTTGAACCC 
Mx1 TCTGAGGAGAGCCAGACGAT ACTCTGGTCCCCCAATGACAG 
TNFα CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACACCCC 
Viperin CTTCAACGTGGACGAAGACA GACGCTCCAAGAATGTTTCA 
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2.13. Cell separation 
2.13.1. Positive selection 
Leukocytes were isolated from the livers of MCMV-infected wt mice and separated by 
MACS separation according to manufacturer’s instructions. Briefly, cells were stained with 
anti-Ly6G at 4°C, then washed with MACS buffer (section 2.23) and incubated with 
anti-PE beads (Miltenyi Biotec, Germany) also at 4°C. Cells were washed, resuspended 
in MACS buffer and run down an LS column (Miltenyi Biotec) attached to a magnet. The 
flow through was the negative fraction. The column was then removed from the magnet 
and magnetically labelled Ly6G+ cells were flushed out with MACS buffer; this flow 
through was the positive fraction. The purity of the separated cell fractions were analysed 
by flow cytometry. For RNA analysis of the Ly6G+ population, a purity of >80% was used 
and for the Ly6G- population, <2% of cells were Ly6G+. 
 
2.13.2. Sequential negative and positive selection 
Splenic neutrophils from Rag-/- mice were isolated and sorted by using a negative 
selection kit (Stemcell technologies, France) and a positive selection kit (Miltenyi Biotec) 
according to manufacturer’s instructions. Briefly, for negative selection, cells were 
incubated with EasySep mouse neutrophil enrichment cocktail, washed and then 
incubated with EasySep biotin selection cocktail. The cells were then incubated with 
EasySep magnetic particles and then run through an LS column. The flow through was 
the negative fraction which was then subjected to the positive selection process as 
described in 2.13.1. The purity of the separated cell fractions were analysed by flow 
cytometry and cells were used at a purity of >90%. 
 
2.14. Nitric oxide and reactive oxygen species analysis 
Purified neutrophils (section 2.13.2) from wt and Rag-/- mice were plated out at a 
concentration of 1 x 104/200µl well and incubated at 37°C with APF (Aminophenyl 
fluorescein), which is an indicator for reactive oxygen species, or DAF-FM Diacetate (4-
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amino-5-methylamino-2’,7’-difluorofluorescein diacetate), which detects low 
concentrations of nitric oxide (both from Invitrogen). After 1 hour, cells were centrifuged 
(1500rpm, 5 minutes) and supernatants containing unbound reagents were discarded. 
Cells were then incubated with 1 x 104 PFU MCMV overnight. Neutrophils were then 
washed and stained with anti-Ly6G-PE and anti-CD11b-APC-Cy7 before being analysed 
on the BD Canto II. 
 
2.15. Neutrophil in vitro killing assay 
3T3 cells were plated out at a concentration of 5 x 104 in a 48 well plate (Nunc) and 
incubated overnight at 37°C in D10 media. The next day, media was removed and cells 
were infected with MCMV at a multiplicity of infection (MOI) of 0.02 in 200µl volumes by 
centrifugation at 1200g for 30 minutes followed by 30 minutes incubation at 37°C. 
Supernatant was then flicked off and purified neutrophils (section 2.13.2) were added to 
the 3T3s at varying effector to target ratios (neutrophils:3T3s), with 0:1 being the lowest, 
and 1:1 the highest. Freeze-thawed neutrophils were used as a negative control. Plates 
were then incubated for 7 days at 37°C. Supernatants were then removed and analysed 
for levels of replicating virus in a standard plaque assay (section 2.7). 
 
2.16. Recombineering 
A bacterial artificial chromosome (BAC) containing almost the full length genome of the 
low passage HCMV strain Merlin was kindly made available by Dr Richard Stanton (58). 
This BAC is a self-exercising Merlin BAC containing a gene encoding Cre recombinase 
which upon transfection into mammalian cells, mediates removal of the BAC vector by 
recombination between loxP sites. The E. coli plasmid cloning vector used for the 
construction of this BAC is pBeloBAC11 (see Fig. 2.1). The technique of recombineering 
(as described in (155, 156)) was then used to modify the Merlin BAC, described in detail 
in sections 2.16.1 and 2.16.2. 
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Fig 2.1. pBeloBAC11 vector diagram 
The pBeloBAC11 vector was used in the construction of the Merlin BAC kindly made 
available by Dr Richard Stanton (58) 
 
 
2.16.1. Generation of selectable cassette for first round of recombineering 
A selectable cassette encoding lacZ, ampicillin resistance and sacB was inserted into the 
BAC during the first round of recombineering. The sacB gene encodes the secreted 
enzyme levansucrase which catalyzes the hydrolysis of sucrose and synthesis of levans 
and expression of this gene in E. coli in the presence of sucrose is lethal. The cassette 
was amplified by PCR using primers with overlapping homology of ~20bp to the cassette 
and ~80bp to the target insertion site in the BAC. The primer sequences are listed in 
Table 4. PCR products were amplified using the Roche (UK) Expand Hi-Fi kit. For each 
50µl reaction, the following components were added; 42µl double-distilled water (ddH2O), 
5µl 10 x buffer 2 (containing MgCl2), 1µl dNTPs, 1µl forward primer, 1µl reverse primer, 
0.5µl template DNA and 0.5µl enzyme. Samples were synthesised using a T3 
Thermocycler (Biometra, Germany) using the following parameters: 
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1. Incubate at 95°C for 2 minutes 
2. Incubate at 95°C for 30 seconds 
3. Incubate at 55°C for 30 seconds 
4. Incubate at 68°C for 4 minutes and 30 seconds 
5. Go to line 2 for 9 more cycles 
6. Incubate at 95°C for 30 seconds 
7. Incubate at 55°C for 30 seconds 
8. Incubate  68°C for 4 minutes and 30 seconds plus 20 seconds/cycle 
9. Go to line 6 for 24 more cycles 
10. Incubate at 68°C for 15 minutes 
 
The PCR product was then run on a 0.7-0.8% agarose gel (section 2.23) and gel purified 
using GE Healthcare (Waukesha, WI) GFX columns following manufacturer’s instructions. 
 
2.16.2. First round of recombineering  
SW102 bacteria containing the full length Merlin genome were incubated overnight in 5ml 
Luria-Bertani (LB) (Melford Laboratories, UK) media (section 2.23) containing 12.5µg/ml 
chloramphenicol (Sigma-Aldrich) in a shaking incubator at 32°C. 0.5ml of overnight 
culture was then cultured in 25ml of LB media containing chloramphenicol in a shaking 
incubator at 32°C until an optical density600 of ~0.6 was reached. Optical density was 
measured on an Ultraspec 3000 (Pharmacia Biotech, Golden Valley, MN). To make the 
bacteria competent and activate the lambda red genes, the culture was then transferred 
to a 50ml falcon tube and incubated in a water bath at 42°C for 15 minutes and then 
chilled on ice for 20 minutes before begin centrifuged for 5 minutes at 4000rpm at 0°. The 
pellet was then washed twice with 25ml ice-cold ddH2O and resuspended in ~400µl 
ddH2O. 25µl was added to an eppendorf along with 4µl purified PCR product and 
transferred to a pre-cooled 0.2cm cuvette (Biorad Laboratories), left to rest on ice for 5 
minutes and then electroporated at 2.5kV using a Biorad Micropulser. Bacteria were then 
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recovered in 1ml of LB media for 1 hour at 32°C. Bacteria were then spun down and the 
pellet resuspended in ~150µl LB media and spread onto an LB plate containing ampicillin 
(section 2.23) and incubated at 32°C until blue colonies appear. To check for sacB 
functionality, 4 different blue colonies were picked and streaked onto both LB plates 
containing ampicillin and LB plates containing sucrose but no salt (section 2.23), and also 
inoculated into 5mls of LB media and incubated overnight at 32°C. 
 
 
Table 4. Primer sequences used in recombineering 
Amplifying 
sacB 
cassette 
Forward primer: 
ACGGCACGCGGAAAGGTCTCAGCGAGTTGGACACGTTGTTTAGCCGTCTC
GAAGAGTATCTGCACTCGAGAAAGTAGCCTGGTACGGAAGATCACTTCG 
Reverse primer: 
CACGACGCAACGTGGTTAAACAGTACGTTTATTAAAGTAACTGGGTGAACG
ACATCGGAGCGGACTGCAAATCGCAACGCTGAGGTTCTTATGGCTCTTG 
Sequencing 
sacB 
cassette 
Primer 1: ACGGAAATGTTGAATACTCATACTCT 
Primer 2: TTGAAAAACGCAAACCATTTGT 
Amplifying 
GFP for 
insertion 
after 
UL111A 
Primer 1: 
CGGATAACGGCACGCGGAAAGGTCTCAGCGAGTTGGACACGTTGTTTAGC
CGTCTCGAAGAGTATCTGCACTCGAGAAAGGGTAGCGCTGGATCAGCAGG 
Primer 2: 
CGACGCAACGTGGTTAAACAGTACGTTTATTAAAGTAACTGGGTGAACGAC
ATCGGAGCGGACTGCAAATCGCAACGTTACTTGTACAGCTCGTCCATGC 
Amplifying 
GFP to 
replace 
UL111A 
Primer 1: 
TGACAAAAACATCATAACATAAAGGACCACCTACCTGGGACGCGCAGTTGG
GCGGCGGATTGGGGCGGCATGCTGCGGCGATGGTGAGCAAGGGCGAGGA 
Primer 2: 
CGACGCAACGTGGTTAAACAGTACGTTTATTAAAGTAACTGGGTGAACGAC
ATCGGAGCGGACTGCAAATCGCAACGTTACTTGTACAGCTCGTCCATGC 
Oligo. to 
delete 
UL111A 
CTACCTGGGACGCGCAGTTGGGCGGCGGATTGGGGCGGCATGCTGCGGC
GCGTTGCGATTTGCAGTCCGCTCCGATGTCGTTCACCCAGTTACTTTAATA 
Sequencing 
deleted 
UL111A 
GCCGGAGACAACGGCGGCGG 
Sequencing  
inserted 
GFP 
From start of GFP running towards end: GCAAGGGCGAGGAGCTGT 
From after ATG running backwards: CAGGGTCAGCTTGCCGTAGGT 
From middle of GFP out past TAG: CCAGCAGAACACCCCCATCG 
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2.16.3. Minipreps, restriction digest and sequencing 
Miniprep kits (Qiagen) were used to isolate DNA from colonies showing a functional sacB 
gene following manufacturer’s instructions. Briefly, the 5ml overnight cultures (section 
2.16.2) were centrifuged at 4000rpm for 5 minutes and resuspended in 250µl buffer P1. 
250µl buffer P2 was then added and incubated for 5 minutes at RT before 250µl buffer N3 
was added, and then centrifuged at 13000rpm for 10 minutes. To precipitate DNA, 250µl 
isopropanol was added and centrifuged at 13000rpm for 10 minutes at 4°C. Supernatant 
was removed and 500µl 70% ethanol was added and then centrifuged at 13000rpm for 10 
minutes. Supernatant was discarded and pellet left to air dry before being re-dissolved in 
30µl Tris. Restriction digest was performed using the restriction endonucleases BamHI or 
Hind-III (New England Biolabs, Ipswich, MA), by combining 8µl DNA, 1µl enzyme and 1µl 
buffer, incubated for 1 hour at 37°C, and then loaded and run on a 1% agarose gel. 
 
For sequencing, 2 primers were used which read out of the sacB cassette, the sequences 
of which are in Table 4. For each 10µl reaction, the following components were used; 5µl 
DNA, 1µl primer and 4µl BigDye Mix (ABI, Applied Biosystems) and run using the 
following cycling parameters; 
 
1. Incubate at 95°C for 5 minutes 
2. Incubate at 95°C for 30 seconds 
3. Incubate at 55°C for 10 seconds 
4. Incubate at 60°C for 4 minutes 
5. Go to line 2 for 99 more times 
 
The reactions were cleaned up by running on a Performa DTR column (Edge Biosystems, 
Gaithersburg, MD). The cleaned up products were then run on an ABI Prism 3130xl 
genetic analyzer (Applied Biosystems) for sequence analysis. 
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2.16.4. Second round of recombineering (negative selection) 
SW102 bacteria containing the sacB cassette generated above were prepared and made 
competent following the protocol described in section 2.16.2. PCR products were also 
prepared following protocol described in section 2.16.1 and the primer sets used are listed 
in Table 4. 
The competent SW102 bacteria and the PCR products were then combined and 
electroporated as described in section 2.16.2. To delete UL111A, 1µl of an 
oligonucleotide with ~40bp of homology to the left and to the right of UL111A was 
electroporated into the competent SW102 bacteria instead of a PCR product. The 
sequence of the oligonucleotide is listed in Table 4. 
After electroporation, the bacteria were recovered for 4 hours at 32°C before being spread 
onto LB plates containing sucrose but no salt. After 48-36 hours, 4 white colonies were 
picked and minipreps, restriction digest and sequencing were performed as described in 
section 2.16.3. The primer for sequencing of the UL111A deletion and the primers for 
sequencing GFP are listed in Table 4. 
 
2.17. Isolation and transfection of BAC DNA 
500mls of recombineered bacteria was cultured overnight in a shaking incubator at 32°C 
and BAC DNA was isolated by maxiprep using a NucleoBond BAC100 kit (Machery 
Nagel, Germany) according to manufacturer’s instructions. Briefly, cultures were 
centrifuged at 6000g for 15 minutes, the pellet was resuspended in 24mls of buffer S1 
and then 24mls of buffer S2 was added and inverted 6-8 times to mix and rested at RT for 
4 minutes. 24mls of buffer S3 was immediately added, mixed by inversion and then 
chilled at 4°C for 5 minutes. The mixture was then centrifuged at 6000g for 15 minutes, 
filtered through filter paper and poured onto a column provided. The column was washed 
twice with buffer N3 and then eluted with 15mls of buffer N5. DNA was precipitated by 
adding 11mls of isopropanol and centrifuged at 15000g for 30mins at 4°C. After 
discarding supernatant, 5mls 70% ethanol was added and centrifuged at 15000g for 10 
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minutes at RT. Ethanol was removed and the pellet was air-dried for 20 minutes and then 
resuspended in ~200µl Tris-HCl (10nM, pH8). Concentration of DNA was measured on an 
ND-1000 NanoDropTM spectrophotometer. 
 
BAC DNA was transfected into the human retinal pigment epithelial cell line ARPE-19 
obtained from the internal Cardiff University cell bank, using an effectene transfection kit 
(Qiagen) according to manufacturer’s instructions. Briefly, 1 x 106 cells were plated out 
into a 25cm3 flask and grown overnight in D10 medium (section 2.23). The next day, 1µg 
DNA was diluted into buffer EC to a total of 150µl and to this, 8µl enhancer was added, 
mixed by vortexing and incubated for 5 minutes. 25µl of effectene transfection reagent 
was added, mixed by pipetting and incubated for 5-10 minutes. 1ml of D10 media was 
then added to the DNA mixture which was then added dropwise to the cells. Cells were 
then incubated at 37°C to allow the virus to grow. 
 
2.18. Generation of modified viruses 
Supernatants from ARPE-19 infected cells were used to infect HFF cells. Once plaques 
were visible and HFF cells started to round up, supernatants were collected every 2-3 
days and stored at -80°C until infection destroyed all the cells. Supernatants were then 
centrifuged at 12000rpm for 2 hours at RT. Pellets were resuspended in 1ml D10 media 
by pipetting up and down and then forced through a G27 gavage needle (0.4 mm x 13 
mm) until fully viscous and aliquoted into ~300µl samples and stored at -80°C until use. 
 
2.19. Titration of viruses 
Purified viruses (section 2.18) were titrated by plaque assay by adding serial dilutions of 
virus in duplicate to confluent HFF cells in a 6 well plate (plated out at 6 x 105 cells per 
well the previous day) and incubated on a rocking platform for 2 hours at 37°C. Media 
containing the virus was then removed and 10mls of 1% avicel (FMC Biopolymer, 
Philadelphia, PA) overlay (section 2.23) was added and the cells cultured for 14 days at 
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37°C. Avicel overlay was then removed and plates were washed with PBS. Visible 
plaques were then counted and virus titre calculated as PFU/ml.  
 
2.20. Western Blots 
HFFs were infected with modified viruses at an MOI of 3 for 24, 72 and 144 hours. The 
media was collected and ~40µl of diluted (1:3) NuPAGE LDS sample buffer (Invitrogen) 
was added to the cells which were then gently scraped off and collected. DTT (~3µl) 
(Sigma-Aldrich) was then added to cell lysates and samples were heated at 99°C for 10 
minutes and then cooled to 37°C. Samples were then vortexed and centrifuged at 
13000rpm for 5 minutes. Samples were then loaded onto pre-cast NuPAGE 4-12% Bis-
Tris gels (1mm x 10 well, Invitrogen) and run at 200V for 50 minutes. Gels were then 
transferred onto Hybond ECL nitrocellulose membranes (GE Healthcare) at 13V for 2 
hours before being incubated for 10 minutes on a rocking platform with antibody extender 
solution (Thermo Fisher Scientific) and then washed with ddH2O. Membranes were then 
blocked by incubating overnight with TBST (section 2.23) containing 5% powdered milk 
(Marvel, UK), washed with TBST and then incubated overnight with primary antibody (see 
Table 5 for antibodies used) in TBST containing 5% milk on a rocking platform at 4°C. 
The next day, membranes were thoroughly washed with TBST containing 5% milk before 
being incubated with secondary antibody (see Table 5 for antibodies used) for 1 hour at 
RT and then washed thoroughly in TBST. Membranes were then incubated for 5 minutes 
in SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific) and 
exposed to film. To re-probe the membranes, they were washed in TBST and incubated 
with stripping buffer (Thermo Fisher Scientific) for 1 hour, washed, and re-probed as 
above.  
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Table 5. Primary and secondary antibodies for western blotting 
Primary antibody Host Concentration Company 
α-actin Rabbit 1:10000 Sigma-Aldrich 
α-GFP Rabbit 1:200 Santa Cruz Biotechnology 
α-viral-IL-10 Mouse 1:1000 In-house, ascites 
Normal IgG Mouse 1:1000 Santa Cruz Biotechnology 
Secondary antibody Host Concentration Company 
α-mouse-HRP Goat 1:2000 Biorad Laboratories 
α-rabbit-HRP Goat 1:10000 Biorad Laboratories 
 
 
2.21. Generation of monocyte-derived DCs 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood using the standard 
ficol separation method and separated by MACS separation according to manufacturer’s 
instructions. Briefly, cells were stained with anti-CD14-PE (BD Parmingen) at 4°C, then 
washed with MACS buffer (section 2.23) and incubated with anti-PE beads (Miltenyi 
Biotec) also at 4°C. Cells were washed, resuspended in MACS buffer and run down an 
MS column (Miltenyi Biotec) attached to a magnet. The flow through was the negative 
fraction. The column was then removed from the magnet and magnetically labelled CD14+ 
cells were flushed out with MACS buffer; this flow through was the positive fraction. The 
purity of the separated cell fractions were analysed by flow cytometry. The purified 
monocytes were then cultured for 5-7 days at 1 x 106/ml in monocyte-derived DC growth 
media (section 2.23). Culture was replenished every 2 days by removing 50% of spent 
media and adding back fresh growth media.  
 
2.22. Statistics 
Statistical significance was determined using the two-tailed Student’s t test (flow 
cytometry data), the Mann-Whitney U test (viral load analysis comparing two groups) or 
one-way ANOVA following logarithmic transformation (viral load analysis comparing more 
than two groups). * = p<0.05, ** = p<0.01, *** = p<0.005. 
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2.23. Buffers, media, gels and agarose plate preparations 
Sorbitol cushion: 20% (w/v) sorbitol (Thermo Fisher Scientific) in ddH2O and then sterile 
filtered. 
Collagenase-containing buffer: RPMI (Invitrogen), 5% heat inactivated fetal calf serum 
(FCS), 1mg/ml collagenase D (Roche), 5mM sterile CaCl2, 50μg/ml DNase 1 
(Sigma-Aldrich). 
Lysis buffer: 500ml ddH2O, 4.145g NH4Cl, 0.5g KHCO3, 18.6mg EDTA (all Thermo 
Fisher Scientific). 
R10 media: RPMI, 10% heat inactivated FCS, 250units Penicillin/Streptomycin, 
0.26mg/ml L-Glutamine, 97mg/ml Sodium pyruvate (all from Gibco, UK). 
Facs buffer: PBS, 2% heat inactivated FCS, 0.05% sodium azide (Sigma-Aldrich). 
Saponin buffer: PBS, 2% heat inactivated FCS, 0.05% sodium azide (Thermo Fisher 
Scientific) and 0.5% saponin (Sigma-Aldrich). 
ELISA wash buffer: 0.05% Tween-20 (Thermo Fisher scientific) in PBS. 
D10 media for mouse cells: DMEM (Invitrogen), 10% heat inactivated foetal calf serum, 
250units Penicllin/Streptomycin, 0.26mg/ml L-Glutamine, 97mg/ml Sodium pyruvate. 
CMC media: DMEM, 10% FCS, 250units Penicllin/Streptomycin, 0.26mg/ml L-Glutamine, 
97mg/ml Sodium pyruvate, 4g carboxy methyl cellulose (Thermo Fisher Scientific DMEM, 
10% heat inactivated FCS, 250units Penicllin/Streptomycin.). 
Crystal violet solution: 0.1% (w/v) crystal violet (Sigma-Aldrich) in ddH2O. 
MACS buffer: 2mM EDTA and 0.5% BSA in PBS. 
Agarose gel (1%): 1% agarose powder (AGTC Bioproducts, UK) in 1 x TAE buffer 
(National Diagnostics, Atlanta, GA). Adjust amount of agarose accordingly as required. 
LB media: 20g/L of LB low salt broth (Melford Laboratories) in ddH2O. 
LB plates containing ampicillin: LB low salt media, 1.5% agar, 1:1000 chloramphenicol, 
1:1000 ampicillin, 1:500 IPTG and 1:500 X-GAL (all from Sigma-Aldrich). 
LB plates containing sucrose: 10g/L tryptone (Thermo Fisher Scientific), 5g/L yeast 
extract (Sigma-Aldrich), 5% sucrose (Thermo Fisher Scientific), 1.5% agar, 1:1000 
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chloramphenicol, 1:500 IPTG and 1:500 X-GAL. 
D10 media for human cells: DMEM (Invitrogen), 10% heat inactivated foetal calf serum, 
250units Penicllin/Streptomycin. 
1% Avicel overlay: 250mls 2% avicel, 125mls ddH2O, 50mls 10 x MEM (Gibco), 50mls 
FCS, 15mls sodium bicarbonate (Gibco), 10mls Penicllin/Streptomycin, 5mls glutamine. 
TBST: 20mM Tris pH7.5-8, 500mM NaCl, 0.05% Tween-20, 0.05% TritonX-100 (Thermo 
Fisher Scientific) in ddH2O. 
Monocyte-derived DC growth media: RPMI, 50ng/ml GM-CSF, 20ng/ml IL-4 (both 
Peprotech). 
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Chapter 3 - Investigating the modulation of NK cells by IL-10 during acute murine 
cytomegalovirus infection 
 
3.1. Introduction 
3.1.1. IL-10 regulation of NK cell responses 
The regulation of T cell responses by IL-10, both directly and indirectly via regulation of 
APCs, has been discussed in depth in section 1.9.1. However, the role that IL-10 plays in 
regulating NK cell responses requires more research investigation.   
 
Human NK cells express the IL-10R transcript in vitro (157) and binding studies revealed 
that the IL-10R protein is constitutively expressed on resting NK cells with approximately 
90 IL-10R molecules per cell (158), implying that NK cells can directly respond to IL-10. 
Therefore, the functional consequences of IL-10 binding directly to human NK cells were 
investigated. In vitro studies showed that IL-2-induced proliferation of human NK cells is 
enhanced with addition of IL-10 (158), and IL-2 activated murine NK cells exhibit 
increased proliferation when incubated with IL-10 alone. Moreover, when stimulated with 
IL-18 in conjunction with IL-10, NK cell proliferation is further enhanced (159).  
Interestingly, the combination of IL-10 and IL-18 also significantly increases NK cell 
cytotoxicity, as assessed by NK cell killing of MHC-deficient target (YAC-1) cells in vitro 
(159). The ability of IL-10 to enhance NK cell killing was further supported by an in vitro 
study showing that IL-10 production by regulatory DCs could activate NK cells and 
enhance their ability to kill YAC-1 cells (160); a finding corroborated by experiments 
demonstrating that incubation of human NK cells with IL-10 increased in vitro cytotoxicity 
(161).  
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In addition to increased proliferation and cytotoxicity, several in vitro studies have also 
demonstrated that IL-10 augments IFNγ production by NK cells in conjunction with other 
cytokines. IFNγ levels were significantly enhanced when NK cells were simultaneously 
stimulated with IL-10 and IL-18 with (162) or without (159) IL-12. Paradoxically however, 
in vivo experiments revealed that IL-10 suppresses NK activation and IFNγ production. In 
a mouse model of polymicrobial peritonitis, treatment with anti-IL-10 led to a considerable 
increase in NK cell activation as measured by CD69 expression, as well as a significant 
increase in IFNγ production (163). Furthermore, blockade of IL-10 signalling mobilises 
IFNγ producing NK cells in LPS-challenged lungs of aged mice (164).  
 
3.1.2. The role of IL-10 in MCMV infection 
Induction of pro-inflammatory cytokines is a critical part of the host response to viral 
infections and is necessary for control and clearance of viruses. As previously discussed 
(section 1.9.2), IL-10 plays an important role in limiting the detrimental effects to the host 
that could arise from an excessive pro-inflammatory response elicited by infection. 
Several studies have utilised the MCMV infection model in an attempt to understand more 
clearly the role that IL-10 plays in the host response to herpesvirus infection. IL-10 
deficient mice have been shown to suffer from more severe MCMV-induced disease than 
wt background strain, including increased weight loss thought to be driven by over-
exuberant T cell responses (165). Furthermore, MCMV infection of the brain causes lethal 
disease in IL-10 knockout mice as compared to wt animals that could control the virus 
(166). Importantly, increased mortality seen in the knockout mice is not due to a failure in 
controlling viral replication, as levels of replicating virus were comparable to wt mice.  
These studies suggest that IL-10 is important in protecting the host during acute infection. 
However, during the persistent and chronic phases of infection, the absence of IL-10 
appears to be advantageous to the host. Memory T cell inflation in IL-10 deficient mice is 
dramatically amplified during infection, with T cells being oligoclonal and exhibiting a 
highly activated phenotype, leading to a reduction in latent virus load (167). Importantly, 
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these results were recapitulated when IL-10R blockade in wt mice was utilised (167). In 
addition, blockade of IL-10R in wt mice markedly reduced virus load in the salivary glands 
during persistent infection, with some mice clearing the virus from this organ completely 
(168). Collectively, these data demonstrate that IL-10 limits virus-induced pathology 
during acute infection yet, paradoxically, impairs antiviral immunity during virus chronicity. 
The role that IL-10 plays in regulating protective immunity to acute infection, however, is 
unclear.   
 
3.1.3. Hypothesis 
The impact that IL-10 has in regulating NK cell responses, particularly in vivo, remains 
poorly understood. Furthermore, nothing is known regarding the role of this cytokine in 
modulating antiviral NK cell responses. NK cells are critical in controlling early MCMV 
infection. Utilising an antagonistic, non-depleting anti-IL-10R antibody in this model, I 
tested the following hypothesis: 
 
 “Virus induced IL-10 suppresses NK cell-mediated protective immunity during 
acute virus infection”. 
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3.2. Results 
3.2.1. IL-10 expression is induced in the lung and spleen during acute MCMV 
infection  
During acute MCMV infection in C57BL/6 (wt) mice, the visceral organs including the lung 
and the spleen are two major sites targeted by the virus. Lung and spleen homogenates 
were taken 4 days p.i, analysed for IL-10 protein expression and compared to levels 
found in homogenates from naïve control mice. IL-10 protein expression was significantly 
up-regulated upon MCMV infection in both organs (Fig. 3.1A). Infected lungs and spleens 
showed on average a 3-fold and 6-fold increase in expression compared to uninfected 
organs respectively. 
 
In order to identify the source of IL-10 during MCMV infection, pulmonary and splenic 
lymphocytes from day 4 infected mice and naïve controls were polyclonally stimulated ex 
vivo and IL-10 production by different cell types was examined. B cells (CD19+CD3-) 
derived from the lung (Fig. 3.1B) and spleen (Fig. 3.1C) were one of the predominant cell 
types capable of expressing IL-10 after 4 days of infection. Inflammatory macrophages 
(7/4hiF4/80intLy6G-CD11clow/intCD11bhi/int) and splenic dendritic cells (CD11chiMHC IIhi) also 
represented significant populations of IL-10 expressing cells after ex vivo stimulation. To 
assess the specificity of the anti-IL-10 antibody, splenic B cells from MCMV-infected wt 
mice (Fig. 3.2A) and IL-10-/- mice (Fig. 3.2B) were stained for intracellular IL-10 
production. As a further control, a fluorescence minus one (FMO) negative staining 
control was also included (Fig. 3.2C). Both the IL-10-/- and the FMO control showed no 
positive staining for IL-10. 
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Figure 3.1. IL-10 expression in the lung and spleen of naïve and MCMV-infected 
mice 4 days post-infection 
(A) IL-10 protein concentrations in lung and spleen homogenates from naïve wt mice 
(closed bars) and MCMV-infected wt mice 4 days p.i (cross hatched bars). Results 
represent the mean ± SEM of 4-6 mice per group. (B and C) IL-10 expression by 
pulmonary (B) and splenic (C) lymphocytes following ex vivo stimulation (see section 
2.4.3) in naïve mice (closed bars) and mice infected for 4 days with MCMV (open bars). 
Results show the mean ± SEM of 7 mice per group and represent 3 independent 
experiments. *p<0.05, **p<0.01, ***p<0.001 
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Figure 3.2. Analysis of intracellular IL-10 antibody staining by flow cytometry  
(A and B) Representative bivariate flow cytometry plots showing IL-10 expression by 
splenic B cells from MCMV-infected wt mice (A) and IL-10-/- mice (B) 4 days p.i. Cells 
were incubated for 4 hours with PMA/Ionomycin and LPS. Following surface staining, 
cells were then stained for intracellular IL-10 production with anti-IL-10-APC (A and B) or 
without anti-IL-10-APC (C) as an FMO staining control. 
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3.2.2. IL-10R blockade exacerbates weight loss during acute MCMV infection 
I hypothesised that virus-induced IL-10 suppressed protective immunity during acute 
infection. To test this, MCMV-infected mice were administered an antagonist non-
depleting anti-IL-10R antibody on the day of infection (in all experiments described in this 
chapter). As previously reported in experiments utilising IL-10 deficient mice (165), 
impaired IL-10R signalling with anti-IL-10R antibody prolonged and exacerbated virus-
induced weight loss as compared to IgG controls (Fig. 3.3A and B) over the first 7 days of 
MCMV infection, suggesting that IL-10R blockade enhanced the clinical signs of disease. 
 
3.2.3. Inhibition of IL-10R signalling increases virus load during acute MCMV 
infection 
Virus load was then assessed at days 2, 4 and 7 p.i by measuring MCMV DNA in the 
lungs and spleens of mice treated with anti-IL-10R or IgG control, as detected using 
MCMV gB-specific primers. Contrary to my initial hypothesis, viral DNA loads at day 2 p.i 
in the lungs (Fig. 3.4A) and spleen (Fig. 3.4B) were not influenced by anti-IL-10R 
treatment. Interestingly, virus genome content by day 4 p.i in the lungs and spleen was 
actually significantly increased following IL-10R blockade. However, anti-IL-10R treatment 
did not significantly influence the low levels of replicating virus detectable in the lungs 
(IgG: 2.1x103 pfu/g versus αIL-10R: 3.4x103 pfu/g; Fig. 3.4C) and spleens (IgG: 1.4x104 
pfu/g versus αIL-10R: 1.9x104 pfu/g; Fig. 3.4D). This suggests that in the absence of 
IL-10R signalling, MCMV genome load is moderately enhanced.  
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Figure 3.3. IL-10R blockade exacerbates weight  loss during acute MCMV infection  
Mice were infected with MCMV and treated with IgG (closed bars/circles) or anti-IL-10R 
(open bars/circles). (A) Average daily weight shown in grams. (B) Weight loss shown as 
percent of starting weight. Results are expressed as mean ± SEM of 4 mice per group 
and represent 2 independent experiments. *p<0.05, **p<0.01 
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Figure 3.4. IL-10R blockade transiently increases viral genome load during acute 
MCMV infection  
Mice were infected with MCMV and treated with IgG (closed circles) or anti-IL-10R (open 
circles). (A and B) Genomic DNA was isolated from the lungs (A) and spleens (B) 2, 4 and 
7 days p.i and MCMV gB was detected by qPCR. Data was normalized to -actin and is 
expressed as genome copy number per 100ng genomic DNA. Median of 4-6 mice/group 
± interquartile range is shown. (C and D) Homogenates from the lungs (C) and spleens 
(D) of mice infected for 4 days were prepared for high sensitivity plaque assays to detect 
replicating virus. Data is expressed as PFU per gram of tissue. Horizontal bars show 
median values. Data represent 2-5 independent experiments. *p<0.05, ns=not significant. 
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3.2.4. Anti-IL-10R treatment impedes the accumulation of NK cells during acute 
MCMV infection 
NK cells have been shown to play a critical role in controlling early MCMV infection (87, 
169, 170). To determine whether elevated viral DNA load after IL-10R blockade was 
associated with an NK cell defect, NK cell accumulation was examined. During infection, 
a significant population of NK1.1+CD3- cells was present in the lung (Fig. 3.5A) and 
spleen (Fig. 3.5B). When tracked over the course of acute infection, NK1.1+CD3- cell 
numbers routinely contracted by 2 days p.i compared to numbers observed in uninfected 
controls, before recovering and expanding. This transient reduction in NK cell numbers 
has been previously observed (171-173). Interestingly, IL-10R blockade prolonged this 
contraction of pulmonary (Fig. 3.5A and C) and splenic (Fig. 3.5B and D) NK cells and 
impeded their expansion from 4 days p.i and beyond.  
 
3.2.5. NK cells are critical for early control of MCMV infection 
To assess the potential importance of IL-10 regulation of NK cells in this infection model, 
mice were infected with MCMV, treated with or without depleting anti-NK1.1 antibodies, 
and administered IgG or anti-IL-10R. To demonstrate that NK cells were depleted to a 
sufficient level, lung leukocytes from mice treated with or without depleting anti-NK1.1 
were stained for NKp46 at 4 days p.i, demonstrating efficient (<0.05% of remaining cells) 
NK cell depletion (Fig. 3.6A). Virus load in the lung (Fig. 3.6B) increased from 
approximately 103 genome copies/100ng DNA in control mice to 105 genome copies in NK 
depleted mice, and in the spleen (Fig. 3.6C) from 104 to 107 genome copies/100ng of 
DNA, demonstrating the importance of NK cells in controlling early MCMV infection. 
Interestingly, IL-10R blockade in NK depleted mice did not further elevate viral genome 
copies (Fig. 3.6B and C); implying that defective control of virus load following IL-10R 
blockade was intrinsically linked to NK cell responses. 
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Figure 3.5. IL-10R blockade impedes the accumulation of NK cells during acute 
MCMV infection 
MCMV-infected mice were treated with IgG or anti-IL-10R on day 0 and cellular 
accumulation assessed 2, 4 and 7 days later. (A and B) Representative bivariate flow 
cytometry plots showing NK1.1+CD3- cell accumulation in lungs (A) and spleens (B) of 
IgG (left panel) and anti-IL-10R (right panel) treated mice, 4 days p.i. (C and D) Numbers 
of NK1.1+CD3- cells in the lungs (C) and spleens (D) of IgG (closed circles) and 
anti-IL-10R (open circles) treated mice analyzed over 7 days. Results are expressed as 
the mean ± SEM of 3-6 mice per group and represent 5 independent experiments. 
*p<0.05, **p<0.01, ***p<0.001 
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Figure 3.6. NK cells are critical for early control of MCMV infection 
MCMV-infected mice were treated with IgG or anti-IL-10R, ± depleting anti-NK1.1 
antibody. (A) Representative bivariate flow cytometry plots showing lung leukocytes with 
(right panel) and without (left panel) anti-NK1.1 administration at 4 days p.i. (B and C) 
After 4 days of infection, genomic DNA was isolated from the lungs (B) and spleens (C) 
and MCMV gB-encoding DNA was detected by qPCR. Data was normalized to -actin 
and is expressed as genome copy number per 100ng genomic DNA. Horizontal solid bars 
show median values and horizontal dashed lines depict the lower limit of detection. Data 
from 2-3 independent experiments are shown. **p<0.01, ***p<0.001, ns=not significant. 
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3.2.6. IL-10R blockade does not influence accumulation of hepatic NK cells during 
acute MCMV infection or influence virus load 
The influence of IL-10R signalling on expansion of NK cells at another important site of 
acute MCMV replication, the liver, was examined. Interestingly, anti-IL-10R treatment did 
not reduce the proportion (Fig. 3.7A) or total numbers (Fig. 3.7B) of hepatic NK cells at 
day 4 p.i as compared to IgG treated controls. In accordance with the observation that NK 
cell numbers were not affected, IL-10R blockade did not influence hepatic virus load, as 
determined by detection of MCMV gB (Fig. 3.7C) or replicating virus (Fig. 3.7D). These 
data imply that hepatic NK cells are differentially responsive to IL-10, and highlight the 
association between NK cell accumulation in infected tissue and subsequent control of 
MCMV replication. 
 
3.2.7. Anti-IL-10R treatment enhances accumulation of virus-specific CD4+ T cells 
Reduced NK cell accumulation 7 days after IL-10R blockade was not associated with 
increased viral burden at this time (Fig. 3.4A and B). Strikingly, IL-10R blockade led to a 
large increase in accumulation of virus-specific CD4+ T cells at day 7 p.i (Fig. 3.8A and B), 
suggesting that increased accumulation of antiviral T cells may compensate for reduced 
NK cell responsiveness at later times during acute infection.  
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Figure 3.7. Anti-IL-10R blockade does not influence accumulation of hepatic NK 
cells during acute MCMV infection or influence virus load 
MCMV-infected mice were treated with IgG or anti-IL-10R on day 0 and NK+CD3- cell 
accumulation assessed 4 days later. (A) Representative bivariate flow cytometry plots 
showing NK1.1+CD3- cell accumulation in the liver of IgG (left panel) and anti-IL-10R (right 
panel) treated mice. (B) Numbers of NK+CD3- cells in the liver of IgG (closed bars) and 
anti-IL-10R (open bars) treated mice 4 days p.i. Results are expressed as the mean ± 
SEM of 5 mice per group. (C and D) Virus load in the liver was assessed at 4 days p.i. (C) 
Genomic DNA was isolated from the livers and MCMV gB-encoding DNA was detected by 
qPCR. Data was normalized to -actin and is expressed as genome copy number per 
100ng genomic DNA. (D) Replicating virus in the livers was detected by plaque assay.  
Data is expressed as PFU per liver; horizontal bars represent median values. ns=not 
significant. 
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Figure 3.8. Anti-IL-10R treatment enhances accumulation of virus-specific CD4+ T 
cells 
Proportion (A) and total numbers (B) of virus-specific splenic CD4+ T cells of IgG (closed 
bars) and anti-IL-10R (open bars) treated mice, 7 days p.i, following ex vivo stimulation 
with MHC class II specific MCMV peptides. Results are expressed as mean ± SEM of 4 
mice per group and represent 2 independent experiments. *p<0.05, **p<0.01 
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3.2.8. IL-10R blockade does not preferentially inhibit Ly49H+ NK cell accumulation 
during infection 
 C57BL/6 mice are capable of mounting a large NK cell response against MCMV due to 
the presence of the NK cell activating receptor Ly49H, which recognises the MCMV-
encoded MHC-like protein m157 (see section 1.8.2). After the initial contraction of NK 
cells following MCMV infection, NK cell numbers expand between 2 and 7 days p.i, which 
is thought to be largely a consequence of Ly49H-dependent activation (95, 171). The 
proportion (Fig. 3.9A and B) and total numbers (Fig. 3.9C and D) of Ly49H+ and Ly49H- 
NK cells were examined at days 2, 4 and 7 p.i in both the lung and spleen (Fig. 3.9A and 
C and Fig. 3.9B and D, respectively) of wt mice. In both organs, a preferential expansion 
of the Ly49H+ NK cells was observed from 4 to 7 days p.i.  
 
To elucidate whether the absence of IL-10R signalling preferentially inhibited the Ly49H+ 
NK cell response in the lung and spleen, accumulation of Ly49H+ and Ly49H- NK cells 
was examined. Comparable ratios of Ly49H+ and Ly49H- NK cells in the lung (Fig. 3.9E) 
and spleen (Fig. 3.9F) were observed over time in IgG and anti-IL-10R treated mice. A 
comparable enrichment of the Ly49H+ compartment was observed in both groups, from 
50-56% of all NK1.1+CD3- cells at day 0, to 75-85% by day 7 p.i. These data suggests 
that IL-10R blockade did not preferentially inhibit Ly49H+ NK cell accumulation during 
MCMV infection. 
 
3.2.9. Impaired cellular accumulation following anti-IL-10R treatment during MCMV 
infection is restricted to NK1.1+CD3- cells 
To assess whether the impairment in cellular accumulation observed following IL-10R 
blockade was restricted to the NK1.1+CD3- cell compartment, the influence of IL-10R 
blockade on numbers of T cells, neutrophils and APCs present in MCMV-infected tissues 
were assessed. Populations of pulmonary (Fig. 3.10A) and splenic (Fig. 3.10B) 
neutrophils (Ly6Ghi7/4lo/intF4/80loCD11bhiCD11clo/int) and APCs including DCs 
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(CD11chiMHCIIhi), inflammatory macrophages (Ly6Glo7/4hiF4/80intCD11bint/hiCD11clo/int) 
and alveolar macrophages (CD11chiCD11blo/int; lung only) were unaffected following 
anti-IL-10R treatment of MCMV-infected mice. Total numbers of T cells (CD3+NK1.1-) 
were also comparable in mice treated with either anti-IL-10R or IgG in both organs (Fig. 
3.10A and B). Collectively, these data show that blockade of IL-10R signalling exclusively 
reduced NK cell accumulation during acute MCMV infection. 
 
3.2.10. Inhibition of IL-10R signalling inhibits the accumulation of cytotoxic NK cells 
during acute MCMV infection 
Having established that NK cell accumulation is inhibited during acute infection in the 
absence of IL-10R signalling, it was important to then evaluate whether IL-10R blockade 
influenced NK cell function. Recent degranulation was first quantified using a flow 
cytometry based assay for detecting CD107a mobilisation (for antibody specificity and 
staining controls, refer to Fig. 3.11A-C). The percentage of NK cells that were 
degranulating directly ex vivo without any further stimulation (CD107a+) in the lung (Fig. 
3.12A) and the spleen (Fig. 3.12B) were comparable in IgG (left hand panels) and 
anti-IL-10R (right hand panels) treated mice at 4 days p.i. However, when total numbers 
of CD107a+ NK cells were calculated, reduced numbers of degranulating NK cells were 
observed in the  lung (Fig. 3.12C) and spleen (Fig. 3.12D) of anti-IL-10R treated mice. In 
addition, granzyme B expression by NK cells was assessed (for staining controls, refer to 
Fig. 3.11D-E), and was also comparable between both groups of mice in the lungs (Fig. 
3.13A) and spleen (Fig. 3.13B) at day 4 p.i. However, when calculated back to total 
numbers, there were less granzyme B+ NK cells in mice treated with anti-IL-10R (Fig. 
3.13C and D). Therefore, these data suggest that the loss of cytotoxic NK cells following 
anti-IL-10R treatment reflected the overall reduction in NK cells rather than a specific 
IL-10-dependent regulation of cytotoxicity.  
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Figure 3.9. Ly49H+ NK cells preferentially expand between day 4 and 7 
post-infection 
NK cells of MCMV-infected mice were examined for expression of Ly49H over 7 days. (A 
and B) Representative bivariate flow cytometry plots showing Ly49H- and Ly49H+ NK cells 
in lungs (A) and spleens (B) at 4 (left panel) and 7 (right panel) days p.i. (C and D) Total 
numbers of Ly49H- (closed bars) and Ly49H+ (open bars) NK cells in the lungs (C) and 
spleens (D) over 7 days. Results are expressed as the mean ± SEM of 6 mice per group. 
(E and F) Ly49H- and Ly49H+ NK cells expressed as a percentage of the total NK+CD3- 
population in the lungs (A) and spleens (B) of IgG (left-hand bars) and anti-IL-10R (right-
hand bars) treated mice. Results are expressed as the mean of 4-6 mice per group. Data 
represent 3 independent experiments. *p<0.05, **p<0.01 
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Figure 3.10. Impairment of cellular accumulation by IL-10R blockade during MCMV 
infection is restricted to the NK1.1+CD3- compartment 
Numbers of antigen presenting cells and CD3+ T cells in the lungs (A) and spleens (B) of 
IgG (closed bars) and anti-IL-10R (open bars) treated mice, 4 days p.i. Results are 
expressed as mean ± SEM of 6 mice per group and represent 2 independent 
experiments. 
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Figure 3.11. Analysis of CD107a and intracellular granzyme B antibody staining by 
flow cytometry 
(A-C) Representative bivariate flow cytometry plots showing CD107a expression by 
pulmonary NK cells from MCMV-infected mice at 4 days p.i. Expression was analysed 
after 5 hours incubation with monensin and medium alone (A) or with monesin and 
PMA/Ionomycin (B). (C) FMO staining control following incubation with monensin and 
PMA/Ionomycin. (D-E) Representative bivariate flow cytometry plots showing intracellular 
granzyme B production by pulmonary NK cells from MCMV-infected mice 4 days p.i. 
Following surface staining, cells were stained with (D) or without (FMO) (E) intracellular 
granzyme B-FITC. 
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Figure 3.12. IL-10R blockade inhibits the accumulation of cytotoxic NK cells during 
acute MCMV infection 
MCMV-infected mice were treated with IgG or anti-IL-10R on day 0 and cytotoxicity 
assessed by surface CD107a at days 2, 4 and 7 p.i. (A and B) Representative bivariate 
flow cytometry plots showing surface CD107a expression by NK cells following incubation 
with monensin. NK cells were derived from the lungs (A) and spleens (B) of IgG (left 
panel) and anti-IL-10R (right panel) treated mice, 4 days p.i. (C and D) Numbers of 
CD107a+ NK cells in the lungs (C) and spleens (D) of IgG (closed bars) and anti-IL-10R 
(open bars) treated mice, after ex vivo incubation with monensin. Results are expressed 
as the mean ± SEM of 5-6 mice per group and represent 3 independent experiments. 
*p<0.05, **p<0.01 
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Figure 3.13. IL-10R blockade inhibits the accumulation of granzyme B expressing 
NK cells during acute MCMV infection  
MCMV-infected mice were treated with IgG or anti-IL-10R on day 0 and granzyme B 
production assessed 4 days p.i. (A and B) Representative bivariate flow cytometry plots 
showing intracellular granzyme B expression directly ex vivo by NK cells from the lungs 
(A) and spleens (B) of IgG (left panel) and anti-IL-10R (right panel) treated mice. (C and 
D) Numbers of granzyme B+ NK cells in the lungs (C) and spleens (D) of IgG (closed 
circles) and anti-IL-10R (open circles) treated mice, directly ex vivo. Data represent 2 
independent experiments. **p<0.01 
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3.2.11. Anti-IL-10R treatment increases IFNγ expression by NK cells but does not 
influence overall accumulation of IFNγ producing NK cells 
In addition to controlling acute infection by direct killing, IFNγ production is also an 
important antiviral effector function of NK cells. The effect of IL-10R blockade on 
spontaneous ex vivo IFNγ production was therefore evaluated by flow cytometry (for 
antibody specificity and staining controls, refer to Fig. 3.14A-C). At 4 days p.i, blockade of 
IL-10R signalling led to an increase in the percentage of NK cells in both the lung (Fig. 
3.15A) and the spleen (Fig. 3.15B) that were producing IFNγ directly ex vivo. NK cells 
from anti-IL-10R treated mice also expressed more IFNγ on a per cell basis (as indicated 
by mean fluorescent intensity (MFI); Fig. 3.15A and B). However, when total IFNγ 
producing NK cells were calculated over a 7 day time course, a trend towards decreased 
numbers following IL-10R blockade was observed, although this did not reach statistical 
significance (Fig. 3.15C-D). Thus, in the absence of IL-10R signalling MCMV-induced 
accumulation of cytotoxic but not IFNγ expressing NK cells is impaired.  
 
3.2.12. IL-10R blockade increases pro-inflammatory cytokine production in the lung 
and spleen of MCMV-infected mice 
Pro-inflammatory cytokines have been shown to be critical for the accumulation of NK 
cells during viral infection (24, 92, 174). I hypothesised that a possible mechanism for 
impaired accumulation of NK cells following IL-10R blockade was reduced levels of 
pro-inflammatory cytokines. However, in the absence of IL-10R signalling, a significant 
increase in IL-6, IFNγ and IL-12 protein was observed in homogenates from the lung (Fig. 
3.16A) and spleen (Fig. 3.16B), as well as a significant increase in IL-1α and TNFα (lung 
only) at 4 days p.i. Therefore, reduced pro-inflammatory cytokine production in 
anti-IL-10R treated mice was not responsible for defective NK cell responsiveness 
observed. 
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Figure 3.14. Analysis of intracellular IFNγ antibody staining by flow cytometry  
Representative bivariate flow cytometry plots showing intracellular IFNγ production by 
pulmonary NK cells from MCMV-infected mice at 4 days p.i. Cells were incubated for 4 
hours with 2µg/ml brefeldin A and medium alone (A and C) or with 2µg/ml brefeldin A and 
PMA/Ionomycin (B). Following surface staining, cells were stained with (A and B) or 
without (FMO) (C) intracellular IFNγ-FITC. 
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Figure 3.15. Anti-IL-10R treatment increases spontaneous IFNγ expression on a per 
cell basis but does not affect overall accumulation of IFNγ producing NK cells 
MCMV-infected mice were treated with IgG or anti-IL-10R on day 0 and ex vivo IFNγ 
production by NK cells was assessed over 7 days. (A and B) Representative zebra flow 
cytometry plots showing direct ex vivo IFNγ production by NK+CD3- cells in lungs (A) and 
spleens (B) of IgG (left panel) and anti-IL-10R (right panel) treated mice, 4 days p.i. 
Percentage and MFI are shown and are representative of over 18 mice per group. (C and 
D) Proportion of IFNγ producing NK+CD3- cells in the lungs (C) and spleens (D) of IgG 
(closed bars) and anti-IL-10R (open bars) treated mice analysed over 7 days. (E and F) 
Total numbers of IFNγ producing NK+CD3- cells in the lungs (A) and spleens (B) of IgG 
(closed bars) and anti-IL-10R (open bars) treated mice analysed over 7 days. Results are 
expressed as the mean ± SEM of 6 mice per group and represent 3 independent 
experiments. ns=not significant. 
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Figure 3.16. Anti-IL-10R treatment increases pro-inflammatory cytokine production 
in the lung and spleen of MCMV-infected mice  
Mice were infected with MCMV and treated with IgG (closed bars) or anti-IL-10R (open 
bars). Levels of cytokines were assessed at 4 days p.i. Cytokine protein concentrations in 
lung (A) and spleen (B) homogenates were measured by either cytometric beads (IL-1α, 
IL-6, IL-10, IFNγ and TNFα) or ELISA (IL-12). Results represent the mean ± SEM of 6 
mice per group. **p<0.01, ***p<0.001, ns=not significant. 
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3.2.13. Anti-IL-10R treatment does not influence NK cell proliferation 
To further investigate how IL-10R blockade was inhibiting NK cell accumulation, NK cell 
proliferation was examined by monitoring intracellular Ki67 expression, a protein 
expressed during all active phases of the cell cycle. In accordance with the kinetics of NK 
cell expansion (Fig. 3.5A and B) and previously published data (171), proliferation in the 
lungs and spleens was highest between 4 and 7 days p.i (Fig. 3.17A and B). However, 
anti-IL-10R treatment did not influence Ki67 expression by either pulmonary (Fig. 3.17A 
and C) or splenic (Fig. 3.17B and D) NK cells at any time point during acute infection, 
therefore demonstrating that reduced proliferation was not the mechanism for reduced NK 
cell numbers following IL-10R blockade. 
 
3.2.14. Inhibition of IL-10R signalling enhances NK cell apoptosis during acute 
MCMV infection 
Next, I measured NK cell apoptosis over a time course to investigate whether IL-10R 
blockade was triggering cell death. Interestingly, a high proportion of apoptotic NK cells, 
as measured by Annexin V binding, in the lungs (Fig. 3.18A and C) and spleens (Fig. 
3.18B and D) was observed during the first 4 days of infection, demonstrating that the 
contraction of NK cell numbers during this period, as shown in Fig. 3.5C and D, was a 
consequence of apoptosis. The percentage of apoptotic NK cells at 2 days p.i was 
comparable between anti-IL-10R and control treated mice (Fig. 3.18C and D). Importantly 
however, the frequency of apoptotic NK cells further increased in mice treated with 
anti-IL-10R at 4 days p.i in the lung (Fig. 3.18A and C) and spleen (Fig. 3.18B and D) as 
compared to IgG controls.  
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The engagement of the TNF family member Fas upon encounter with cells expressing 
Fas-ligand is one mechanism that triggers cellular apoptosis (175). Therefore Fas 
expression on NK cells 4 days p.i was examined. The proportion of NK cells that 
expressed Fas in the lungs (Fig. 3.19A and C) and spleens (Fig. 3.19B and C) was 
significantly higher in mice treated with anti-IL-10R as compared to IgG treated mice. NK 
cells from anti-IL-10R treated mice also expressed more Fas on a per cell basis (as 
indicated by MFI; Fig. 3.19D). This increase in Fas expression is in accordance with the 
time point where the highest levels of apoptosis are observed in the anti-IL-10R treated 
mice (Fig. 3.19C and D). Furthermore, Fas-ligand mediated apoptosis is caspase-
dependent, and caspase-3 is considered to be a major executioner of apoptosis (175). 
Elevated frequencies of Fas expressing NK cells following IL-10R blockade were 
accompanied by increased frequencies of pulmonary NK cells positive for intracellular 
active caspase-3 (Fig. 3.20A and B). Collectively, these data suggest that impaired NK 
cell responses in the absence of IL-10R signalling were a consequence of increased 
apoptosis. 
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Figure 3.17. Anti-IL-10R treatment does not influence NK cell proliferation 
Mice were infected with MCMV and treated with IgG or anti-IL-10R. Proliferation of 
pulmonary (A and C) and splenic (B and D) NK cells assessed by detection of intracellular 
Ki67 expression directly ex vivo. (A and B) NK cell proliferation in the lung and spleen (B) 
of mice treated with IgG (closed bars) or anti-IL-10R (open bars). Results represent the 
mean ± SEM of 4-6 mice per group (C and D) Representative zebra flow cytometry plots 
showing direct ex vivo Ki67 expression by NK+CD3- cells in lungs (C) and spleens (D) of 
IgG (left panel) and anti-IL-10R (middle panel) treated mice, 4 days p.i. Isotype staining 
controls are also shown (right panel). Data represent 2 independent experiments. 
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Figure 3.18. IL-10R blockade enhances NK cell apoptosis during acute MCMV 
infection 
Mice were infected with MCMV and treated with IgG or anti-IL-10R and apoptosis of NK 
cells was assessed by Annexin V binding. (A and B) Representative overlay histograms of 
Annexin V binding of NK cells in the lungs (A) and spleens (B) of mice following treatment 
with anti-IL-10R (solid line) or IgG (dashed line) 4 days p.i (shaded histogram = FMO 
control). (C and D) Annexin V binding by NK cells in the lungs (C) and spleens (D) of mice 
treated with IgG (closed circles) or anti-IL-10R (open circles) shown as percentage of 
NK+CD3- cells over a 7 day time course. Results are expressed as the mean ± SEM of 
4-6 mice per group and represent 2-3 independent experiments. *p<0.05, **p<0.01 
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Figure 3.19. IL-10R blockade leads to increased expression of Fas by NK cells  
MCMV-infected mice were treated with IgG or anti-IL-10R on day 0 and Fas expression 
analysed 4 days p.i. (A and B) Representative bivariate flow cytometry plots showing Fas 
expression by NK cells from the lungs (A) and spleens (B) of IgG (left panel) and 
anti-IL-10R (middle panel) treated mice. FMO negative staining controls are also shown 
(right panel). (C) Proportion of NK+CD3- cells expressing Fas in the lungs and spleens of 
mice treated with IgG (closed bars) or anti-IL-10R (open bars). (D) MFI of Fas expression 
by pulmonary and splenic NK cells from IgG (closed bars) and anti-IL-10R (open bars). 
Results are expressed as the mean ± SEM of 5 mice per group and represent 3 
independent experiments. *p<0.05, **p<0.01 
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Figure 3.20. Enhanced NK cell apoptosis following IL-10R blockade is associated 
with increased expression of intracellular caspase-3 
(A) Proportion of NK+CD3- cells expressing intracellular caspase-3 (active form) in the 
lungs and spleens of mice 4 days p.i, treated with IgG (closed bars) or anti-IL-10R (open 
bars) directly ex vivo. Results are expressed as the mean ± SEM of 4 mice per group. (B) 
Representative overlay histograms of caspase-3 expression by NK cells in the lungs (top) 
and spleens (bottom) of mice following treatment with anti-IL-10R (solid line) or IgG 
(dashed line) 4 days p.i (shaded histogram = FMO control). Data represent 3 independent 
experiments. *p<0.05, ns=not significant. 
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3.2.15. Anti-IL-10R treatment increases the frequency of apoptosis in multiple NK 
cell subsets 
As NK cell function was affected by IL-10R blockade, I hypothesised that the phenotype 
of NK cells would also be modulated in the absence of IL-10R signalling. Therefore, 
phenotypic analysis comparing NK cells from anti-IL-10R and IgG treated mice was 
performed. Expression of CD11b and CD27 defines the maturation status of murine NK 
cells, as well as CD27 expression being associated with cytotoxic effector functions (176, 
177). The proportion of NK cells in both the lung (Fig. 3.21A) and spleen (Fig. 3.21B) that 
resided in each defined subset of maturation was comparable between anti-IL-10R and 
IgG treated mice (for antibody specificity and staining controls, refer to Fig. 3.22A-D). 
These individual subsets were then assessed for levels of apoptosis. Splenic 
CD11bhighCD27high NK cells were the predominant NK cell subset that bound Annexin V 
(Fig. 3.21D); whereas high frequencies of apoptosis were observed in CD27high and 
CD27low pulmonary NK cell populations (Fig. 3.21C). However, anti-IL-10R blockade 
further increased the frequency of apoptotic pulmonary and splenic CD11bhighCD27high 
mature NK cells, as well as the less mature CD11blowCD27high NK cells (Fig. 3.21C and 
D), which is in accordance with the increased levels of apoptosis observed at 4 days p.i in 
the absence of IL-10R signalling (Fig. 3.18).  
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Figure 3.21. Anti-IL-10R blockade increases the frequency of apoptosis in both 
mature and less mature NK cell subsets  
MCMV-infected mice were treated with IgG (closed bars) or anti-IL-10R (open bars). After 
4 days, NK cell subsets in the lung (A) and spleen (B) were defined based on CD11b and 
CD27 co-expression (FMOs were used to define gating as shown in Fig. 3.22). Proportion 
of Annexin V binding NK cells in each subset was then assessed (C and D) Annexin V 
binding by NK cell subsets in the lungs (C) and spleens (D) of mice treated with IgG or 
anti-IL-10R. Results are expressed as the mean ± SEM of 8 mice per group and 
represent 2 independent experiments. *p<0.05, **p<0.01 
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Figure 3.22. Analysis of CD11b and CD27 antibody staining by flow cytometry  
Representative bivariate flow cytometry plots showing surface CD11b and CD27 
expression by pulmonary NK cells from MCMV-infected mice 4 days p.i. Cells were 
incubated with Live/Dead Fixable Aqua and then surface stained with CD11b-APC-Cy7 
(A) or CD27-PE (C). FMO staining panels were used as negative controls (B and D). 
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3.2.16. IL-10R blockade enhances NK cell activation-induced cell death 
To establish why IL-10R blockade preferentially induced NK cell apoptosis, the activation 
status of NK cells was first assessed. Strikingly, NK cell expression of activation markers 
CD25 (lung and spleen) and CD69 (lung only) was associated with increased Annexin V 
binding (Fig. 3.23A and B) at day 4 p.i, suggesting that NK cells exhibiting a heightened 
activation status were preferentially undergoing apoptosis.  
Importantly, when CD25 and CD69 expression by NK cells was compared in mice treated 
with anti-IL-10R and control IgG, a marked increase in the proportion of NK cells that 
were positive for CD25 (lung and spleen, Fig. 3.24A) and CD69 (lung only, Fig. 3.24B) 
was observed at 4 days p.i. This elevation in activation marker expression was also 
evident on a per cell basis as shown by MFI, with the exception of splenic CD69 
expression (Fig. 3.24C and D). These data, taken with enhanced IFNγ expression by NK 
cells from anti-IL-10R treated mice (Fig. 3.15A and B); imply that IL-10R blockade 
enhanced NK cell activation. Critically, anti-IL-10R treatment significantly enhanced the 
proportion of NK cells that co-expressed activation markers (CD25, lung and spleen; 
CD69, lung only) and active caspase-3 in the lung (Fig. 3.25A) and the spleen (Fig. 
3.25B). Thus, these data demonstrate that impaired NK cell accumulation following 
IL-10R blockade was the consequence of enhanced activation-induced death of NK cells.  
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Figure 3.23. Increased apoptosis is associated with expression of activation 
markers CD25 and CD69 
Expression of CD25 (A) and CD69 (B) by Annexin V- (closed bars) and Annexin V+ (open 
bars) NK cells in the lungs and spleens 4 days p.i. Results are expressed as the mean ± 
SEM of 6 mice per group and represent 2 independent experiments. **p<0.01, 
***p<0.001, ns=not significant. 
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Figure 3.24. Anti-IL-10R blockade increases the expression of activation markers 
CD25 and CD69 on NK cells  
(A and B) Representative histograms of CD25 (A) and CD69 (B) expression by pulmonary 
(top) and splenic (bottom) NK cells from IgG (dashed line) and anti-IL-10R (solid line) 
treated mice, 4 days p.i with MCMV. Results are representative of 2 independent 
experiments, each constituting of 6 mice per group. (C and D) MFI of CD25 and CD69 
expression by pulmonary (C) and splenic (D) NK cells from IgG (closed bars) and 
anti-IL-10R (open bars) treated mice 4 days after infection. Results are expressed as 
mean ± SEM of 4-6 mice per group and represent 3 independent experiments. **p<0.01, 
***p<0.001, ns=not significant. 
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Figure 3.25. Anti-IL-10R blockade increases co-expression of activation markers 
and active caspase-3 by NK cells  
Percentages of NK cells in the lung (A) and spleen (B) co-expressing intracellular active 
caspase-3 and CD25 or CD69, 4 days p.i. Results are expressed as mean ± SEM of 8 
mice per group and represent 2 independent experiments. *p<0.05, ns=not significant.  
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3.2.17. IL-10 does not directly inhibit activation-induced NK cell death 
The mechanism(s) by which NK cells from anti-IL-10R treated mice were undergoing 
activation-induced cell death was unclear. To determine whether IL-10 directly acted on 
NK cells to regulate this process, IL-10R expression on NK cells was first examined. NK 
cells from the lung (Fig. 3.26A and C) and the spleen (Fig. 3.26B and C) expressed low 
levels of IL-10R constitutively and up-regulated expression upon infection. The 
anti-IL-10R antibody clone used for IL-10R detection by flow cytometry was the same 
used for in vivo IL-10R blockade. Subsequently, I observed low staining of IL-10R in 
treated mice (Fig. 3.26A and B) thus demonstrating the blocking anti-IL-10R antibody 
remained bound to IL-10R expressing NK cells during the 4-day experiment.   
 
Because IL-10R was expressed on NK cells during MCMV infection, I investigated 
whether IL-10 was directly influencing their survival. Splenocytes and pulmonary 
leukocytes were isolated 4 days after MCMV infection and incubated in the presence or 
absence of recombinant IL-10.  Importantly, IL-10 did not reduce ex vivo NK cell 
apoptosis as compared to NK cells incubated without IL-10 (Fig. 3.27A). Furthermore, a 
trend of increased IFNγ expression by pulmonary and splenic NK cells was observed 
following incubation with IL-10 in vitro (Fig. 3.27B). In accordance with published data 
(159, 161, 162), these observations suggest that IL-10 has a stimulatory role in direct NK 
cell regulation, and imply that IL-10 inhibits activation-induced NK cell death during acute 
MCMV infection via an indirect mechanism. 
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Figure 3.26. IL-10R expression by pulmonary and splenic NK cells 
(A and B) Expression of IL-10R on NK+CD3- cells in the lungs (A) and spleens (B) of 
naïve mice and MCMV-infected mice treated with IgG (closed bars) or anti-IL-10R (open 
bars) over a 7 day time course. Results are expressed as the mean ± SEM of 4-6 mice 
per group. (C) Representative overlay histograms showing surface IL-10R expression 
(open histograms) and FMO staining controls (shaded histograms) by pulmonary (top 
panel) and splenic (bottom panel) NK cells from MCMV-infected mice 4 days p.i. 
***p<0.001 
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Figure 3.27. IL-10 does not directly inhibit NK cell apoptosis during MCMV infection  
(A and B) Lung leukocytes and splenocytes were isolated 4 days p.i. Cells were cultured 
in a 96-well plate for 18 hours in the presence (open bars) or absence (closed bars) of 
50ng/ml of recombinant murine IL-10. (A) Proportion of NK cells from the lungs (left) and 
spleens (right) of MCMV-infected mice that bound Annexin V. (B) To assess IFNγ 
production, 2µg/ml brefeldin A was added to some of the wells for the last 8 hours of 
culture. Proportion of IFNγ producing NK cells isolated from the lungs (left) and spleens 
(right) of MCMV-infected mice are shown. Results are expressed as the mean ± SEM of 3 
mice per group and represent 2 independent experiments.  
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3.3. Discussion 
It has been previously shown that MCMV is a potent inducer of IL-10 production (167, 
178). The visceral organs are significant sites targeted by the virus during the acute-
phase of infection, therefore it was important to establish if MCMV infection up-regulated 
IL-10 expression in these organs. As seen during persistent infection, virus induced IL-10 
was detected in the spleen within the first 4 days of infection. Acute MCMV infection also 
induced IL-10 production in the lung, and both organs showed significantly higher IL-10 
levels than seen in uninfected controls. Previous work using IL-10-GFP reporter mice 
showed B cells to be a significant source of IL-10 during MCMV infection (179). My 
analysis of different cell types after ex vivo polyclonal stimulation 4 days p.i was in 
agreement with this data, with B cells representing one of the predominant cell types 
capable of expressing IL-10. Inflammatory macrophages from the lung and dendritic cells 
from the spleen were other populations of cells expressing high levels of IL-10. As shown 
previously, MCMV-infected macrophages secrete IL-10 in vitro (178). Whether or not 
IL-10 producing APCs observed during in vivo infection were infected or not remains to be 
determined in experiments utilising GFP-expressing MCMV. There is some evidence, 
albeit limited, suggesting that HCMV and MCMV can infect B cells (180, 181). Again, it is 
not possible to say if the B cells producing the IL-10 in my experiments were infected or 
not. However, in numerous non-infectious models, B cells are an important source of 
IL-10 (179, 182, 183), thus demonstrating that viral infections of B cells is not a necessity 
for the induction of IL-10 expression by this lymphocyte subset.   
 
An antagonistic antibody was used to block IL-10R signalling during acute MCMV 
infection. Surprisingly, the absence of IL-10R signalling led to a transient, but statistically 
significant increase in viral DNA load, suggesting IL-10 affords protection from acute 
MCMV infection. Interestingly however, this increase in virus load did not reach a 
statistically significant level when measured by plaque assay to detect replicating virus, 
implying that some caution must be taken when interpreting these results. It is however 
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important to note that the levels of detectable replicating virus, especially in the lung, are 
extremely low. This is due in part to the crude methodology used to homogenise infected 
tissues that results in a large loss of infectious virions. Therefore, measurement of viral 
DNA load affords a more representative insight into the degree of virus burden in vivo. 
Using this method of virus load measurement, a substantial increase of 2-3 logs was 
observed when mice were depleted of NK cells. The huge increase in virus load shows 
that NK cells are critical for controlling early MCMV infection. This finding is in agreement 
with previous studies that have shown the importance of NK cells in MCMV infection by a 
number of different methods including adoptive transfer of NK cells into suckling mice 
(87), utilising NK cell deficient mice (169), or depletion of NK cells by administering a NK 
specific antibody (89, 170). Crucially, a further increase in virus load in NK cell deficient 
mice following IL-10R blockade was not observed, strongly implying that anti-IL-10R 
treatment was having a negative effect on NK cells and their ability to control the virus at 
this early time point. 
 
No differences in virus load were observed in anti-IL-10R treated and IgG treated mice at 
day 7 p.i. At this time, I concurrently observed elevated virus-specific CD4+ T cell 
responses. Different cellular immune mechanisms can compensate for each other during 
MCMV infection (184, 185). I therefore hypothesise that the absence of a significant 
increase in virus burden 7 days p.i in anti-IL-10R treated mice was due to enhanced T cell 
control of the elevated virus load.  
 
MCMV infection induced a decline in NK cell numbers in the lung and spleen. This has 
been previously observed in the spleen when NK cell numbers were tracked during 
MCMV infection (171-173), although this initial NK cell contraction was overlooked in 
these studies. I investigated the mechanisms driving this contraction and observed a high 
frequency of NK cell apoptosis at this time point in both organs, suggesting that cell death 
is a likely explanation for NK cell contraction. Expansion of the NK cell compartment from 
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2 days p.i was accompanied by a decrease in apoptosis over time, in conjunction with an 
increase in NK cell proliferation. The increase in NK cell numbers was due largely to a 
rapid expansion of the Ly49H+ population between days 4 and 7, as previously shown in 
acute infection of C57BL/6 mice (171, 186). To ascertain whether IL-10 influenced this 
process, NK cell accumulation was assessed in the absence of IL-10R signalling. 
Blockade of IL-10R did not influence initial NK cell contraction but reduced later 
expansion of NK cell numbers. Importantly, it was not the preferential expansion of the 
Ly49H+ NK cells that was inhibited by anti-IL-10R treatment, rather apoptosis of the NK 
cell population as a whole was substantially enhanced and prolonged, as demonstrated 
by enhanced levels of Annexin V binding accompanied by increased expression of Fas 
and intracellular caspase-3 (pulmonary NK cells only). 
 
As previously discussed, two major antiviral functions of NK cells during viral infection are 
the production of IFNγ and direct lysis of infected cells. As NK cell accumulation was 
impaired in the absence of IL-10R signalling, NK cell IFNγ production and cytotoxicity 
were assessed in order to ascertain if functionality was also impaired. Interestingly, 
cytotoxic NK cell numbers were reduced following IL-10R blockade whereas the 
frequency of IFNγ producing cells was comparable in both groups. Indeed on a per cell 
basis, more IFNγ was produced in the absence of IL-10R signalling. Therefore, the data 
suggest that IL-10 preferentially limits apoptosis of cytotoxic NK cells subsequently 
promoting their accumulation. NK cells have been shown to exhibit dual functionality of 
IFNγ expression and degranulation (187), therefore I cannot rule out the differential 
regulation of the dual-functioning NK cells by IL-10. This could be addressed by 
co-staining for IFNγ and CD107a. Irrespective, my data clearly demonstrates that by 
limiting apoptosis of the cytotoxic NK cells capable of killing virally infected cells, IL-10 
promotes antiviral responses early in MCMV infection. 
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Maturation of murine NK cells has been defined as a four-stage process, each stage 
being characterised by the expression of CD11b and CD27 (176), with higher expression 
of CD27 being synonymous with greater effector/cytotoxic functions. The proportion of NK 
cells that fell into each defined subset of maturation was not influenced by IL-10R 
blockade, but critically, the CD27high NK cells were the ones exhibiting increased levels of 
apoptosis in the absence of IL-10R signalling. This observation, in concordance with the 
CD107a data, further strengthens the argument that IL-10 promotes antiviral responses 
by limiting apoptosis of those NK cells capable of mediating effector/cytotoxic functions. 
 
Phenotypic analysis of the Annexin V positive versus negative cells revealed that those 
NK cells undergoing apoptosis were more activated (as characterised by CD69 and CD25 
expression). By comparing the expression of CD69 and CD25 on NK cells from control 
mice and anti-IL-10R treated mice, it transpired that in the absence of IL-10R signalling, a 
higher frequency of NK cells were activated and expressed significantly higher levels of 
the activation markers on a per cell basis. In conjunction with amplified IFNγ expression, 
these data imply that IL-10R blockade enhanced NK cell activation. Taken with my data 
demonstrating that IL-10R blockade results in increased NK cell apoptosis, I therefore 
conclude that IL-10 reduces activation-induced cell death of NK cells during acute MCMV 
infection.  
 
NK cells in the lung and spleen were found to constitutively express low levels of IL-10R, 
and expression was slightly up-regulated upon infection. Therefore, IL-10 could exert 
protective effects directly on the NK cells by signalling through the IL-10R. However, 
incubation with recombinant IL-10 in vitro did not reduce NK cell apoptosis or IFNγ 
expression. In fact, a trend towards increased IFNγ was observed, implying that, in 
accordance with published work (159, 162) incubation of NK cells with IL-10 increases 
IFNγ expression. These data therefore suggest that IL-10 does not directly inhibit NK cell 
activation induced death in vivo.  
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Previous studies have demonstrated the importance of MCMV-induced IL-12 and TNFα in 
early NK cell IFNγ production and viral control (24, 92, 174). Although these cytokines are 
important for optimal NK cell responses to MCMV, it has also been shown that over-
expression of IFNγ actually reduces NK cell development (188) and, intriguingly, that 
TNFα and IL-12 enhance apoptosis of IL-2 stimulated human NK cells (189). Interestingly, 
elevated levels of NK cell apoptosis and reduced NK cell accumulation following IL-10R 
blockade was accompanied by significantly elevated expression of IFNγ, IL-12 (lung and 
spleen) and TNFα (lung only). The finding that pro-inflammatory cytokines are found in 
greater amounts in the absence of IL-10R signalling is in itself not surprising. However, 
these heightened levels of pro-inflammatory cytokines after IL-10R blockade may 
contribute to increased NK cell apoptosis. The data therefore implies that IL-10 indirectly 
regulates NK cell survival by limiting the expression of pro-inflammatory cytokines.  
 
The liver is another site targeted by MCMV during acute infection. However, unlike the 
lung and spleen NK cell responses in this organ were unaffected by IL-10R blockade and, 
importantly, nor was virus load. Thus, these data imply that the mechanisms regulating 
hepatic NK cell responses to MCMV differ from those in splenic and pulmonary infection. 
Indeed, previous studies have shown that splenic NK cells provide antiviral immunity in a 
perforin-dependent manner whereas in the liver, the production of IFNγ by NK cells is 
critical for antiviral protection (170, 190). Furthermore, during acute infection, the NK cell 
population in the liver does not undergo the same initial contraction as that observed in 
the lung and spleen (171, 172). Also, Vα14 iNKT cells are found in high numbers in the 
liver and participate in protective immunity to MCMV (191, 192). Although the numbers of 
Vα14 iNKT cells were not assessed in the liver during acute MCMV infection, based on 
hepatic virus load, I hypothesise that hepatic iNKT cell responses are unlikely to be 
regulated by IL-10.  
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In a separate study, Oakley et al (165) utilised IL-10-deficient mice to demonstrate that, in 
agreement with my findings, the absence of IL-10R signalling during MCMV infection led 
to more weight loss and severe disease. However, contrary to my experiments, they 
found that virus replication in the spleen in the IL-10 gene deficient mice was actually 
reduced in comparison to wt controls. Unfortunately, the absence of NK cell 
characterisation in this study precludes direct comparison with my own experiments. 
Furthermore, their analysis of virus load in the spleens of wt mice over 12 days of 
infection revealed comparable levels of replicating virus at days 3 and 12 p.i. This finding 
has never been observed in my model of infection where Ly49H+ NK cell expansion 
rapidly controls the virus, thus levels of replicating virus in the spleen at day 12 are 
undetectable. Therefore, direct comparisons between the two studies are not possible. A 
separate study by Tang-Feldman et al (193) found that repletion of IL-10 into IL-10 
knockout mice did not influence splenic or hepatic viral DNA load despite suppressing the 
exaggerated pro-inflammatory cytokine response observed in these mice. However, a 
comparison of virus load between wt and IL-10 knockout mice was not performed which 
would have allowed a more direct evaluation with my results. Despite the inability to 
directly compare the results of these two studies with my current findings, it is clear that 
subtle differences exist between the two systems of using either IL-10 gene deficient mice 
or antibody blockade of IL-10R.  Importantly, however, my experimental approach of 
inhibiting IL-10R signalling prevents the possibility of developmental factors or 
compensatory mechanisms associated with gene-deficient mice that may influence 
results obtained from these experiments.  
 
In summary, I have uncovered a surprising antiviral role for IL-10 during acute MCMV 
infection through the limitation of activation-induced NK cell death. These experiments 
highlight the importance of the balance between pro-inflammatory and inhibitory signals 
during acute viral infection and demonstrate that without sufficient regulation, an NK cell 
response can be driven to apoptosis, leading to impaired control of acute virus infection.  
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Chapter 4 - Generating HCMV virus constructs with modifications to cmvIL-10 
 
4.1. Introduction 
4.1.1. Functions of cmvIL-10 
The long co-evolution of HCMV with its mammalian host has resulted in the virus 
developing an array of mechanisms to modulate host immune responses, as discussed in 
section 1.7.3. One such HCMV-encoded immune-modulatory protein is cmvIL-10, a 
homologue of human IL-10. The cmvIL-10 protein is encoded by an ORF (UL111A) 
composed of five exons and has two introns within the cmvIL-10 gene which match the 
position of the first and third introns of the IL-10 gene, suggesting that these genes are 
related (130). However it is unclear whether HCMV captured the partially spliced 
IL-10mRNA sequence from infected cells or captured the IL-10 gene, which subsequently 
evolved into the cmvIL-10 gene. Despite limited homology to human IL-10 (27%) it binds 
to IL-10R1 with essentially the same affinity as IL-10, and is capable of inducing signal 
transduction events characteristic of IL-10 signalling (130, 194).  
 
One of the first studies demonstrating the biological activity of cmvIL-10 used recombinant 
protein expressed in either human cells or bacteria. Protein expressed in human cells 
profoundly inhibited proliferation of PBMCs, decreased production of pro-inflammatory 
cytokines from PBMC and monocyte cultures, and down-regulated monocyte surface 
expression of MHC class I and class II proteins. Bacterium-expressed cmvIL-10 reduced 
mitogen-stimulated proliferation of PBMCs comparable to that of human IL-10 (195). In 
addition, cmvIL-10 also decreased production of pro-inflammatory cytokines by PBMCs 
and monocytes, and decreased cell surface expression of both MHC class I and class II 
molecules (195). 
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Given the role for IL-10 in suppressing maturation and cytokine production of DCs 
(section 1.9.1), it was hypothesised that cmvIL-10 would also antagonise DC function. 
This was tested by incubating DCs with supernatants from cells infected with HCMV 
(AD169 strain) or infected with a UL111A-deletion variant of AD169. In the absence of 
cmvIL-10 containing supernatant, LPS-stimulated DCs progressed to maturity. In contrast, 
LPS-stimulated DCs cultured with AD169-conditioned media exhibited reduced 
maturation, decreased migration in response to the lymph node homing chemokine 
CCL19, and significantly impaired pro-inflammatory cytokine production (196). This 
inability to secrete cytokines, IL-12 in particular, is in part potentiated by the induction of 
endogenous cellular IL-10 expression by the DCs themselves (196). Moreover, cmvIL-10 
inhibits inflammatory cytokine transcription, in particular TNFα and IL-1β, by blocking 
NFκB transcriptional activity in human monocytes (197). 
 
Additional investigation into the effects of cmvIL-10 on DCs revealed that incubation with 
recombinant protein enhanced the density of the molecule DC-SIGN, which is a lectin 
expressed on the cell surface of immature DCs and functions as a receptor for several 
viruses including HCMV, thus enhancing HCMV-infection and possibly increasing 
dissemination (198). Furthermore, in the presence of recombinant cmvIL-10, LPS-induced 
up-regulation of both MHC class I and class II molecules was partially blocked, as was the 
enhancement of the co-stimulatory molecules CD40, CD80, CD86, B7-H1 and B7-DC, 
hence impairing DC function (198). CmvIL-10 also increases apoptosis associated with 
DC maturation by blocking up-regulation of anti-apoptotic molecules (198).  
 
In addition to the potent anti-inflammatory functions that IL-10 exerts, it also plays a role in 
promoting the growth and differentiation of B cells (section 1.9.1). In accordance, 
incubation of human B cells with recombinant cmvIL-10 stimulated B cell proliferation and 
autocrine production of cellular IL-10 in a dose-dependent manner (199). 
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Intriguingly, UL111A expression is also detected in natural and experimental latent 
infection (200). This latency-associated cmvIL-10 transcript (LAcmvIL-10) was identified 
from the alternate splicing of the cmvIL-10 transcript and contains only the first of the two 
introns contained in the full length transcript of UL111A (131, 200). Subsequently, 
LAcmvIL-10 retains only some of the functional characteristics of the full length cmvIL-10. 
Unlike cmvIL-10, LAcmvIL-10 does not stimulate B cell proliferation (199), trigger 
phosphorylation of STAT3 or inhibit expression of co-stimulatory molecules or maturation 
markers on DCs (131). LAcmvIL-10 has the ability however to down-regulate MHC class 
II molecules on the surface of monocytes (131), and as monocytes support latent 
infection, HCMV may express LAcmvIL-10 to avoid immune recognition during this phase 
of infection. An AD169 virus with a deleted UL111A gene was used to demonstrate that 
MHC class II levels were increased significantly on latently infected myeloid progenitor 
cells, which was associated with an increase in PBMC and CD4+ T cell responses against 
these cells as compared to wt-infected cells, suggesting that this gene provides an 
immune evasion strategy during latency (201). However, the conclusions of this study 
should be treated with caution due to the use of a highly mutated strain of HCMV (AD169) 
and also that the full length UL111A gene was deleted, therefore cmvIL-10 as well as 
LAcmvIL-10 would be deleted, thus the phenotype observed may not be dependent on 
the absence of LAcmvIL-10 alone. 
 
Importantly, using a rhesus CMV (RhCMV) model of infection, which unlike other 
experimental models encodes a functional IL-10 homologue (rhcmvIL-10), Barry and 
colleagues demonstrated that infection with a rhcmvIL-10 deleted virus results in a greater 
macrophage infiltrate to the site of infection, increased DC accumulation in the draining 
lymph nodes, and enhanced both humoral responses and virus-specific T cell responses 
compared to infection with a wt virus (202). Furthermore, vaccination of rhesus macaques 
with a virus containing a mutated rhcmvIL-10 gene that could not bind to the IL-10R1 
resulted in production of antibodies against wt rhcmvIL-10 that neutralised its biological 
 123 
 
activity but did not cross-react with rhesus cellular IL-10 (203, 204). Thus, these studies 
demonstrated that targeting cmvIL-10 could aid in the design of vaccines or therapeutic 
strategies against HCMV infection, therefore an understanding of the functions of 
cmvIL-10 in a biologically relevant system is critical. 
 
4.1.2. The role of the UL128-UL131A genes in HCMV infection 
In early studies, MD-DCs were reported to be susceptible to infection with HCMV strains 
that had been propagated in endothelial cell cultures with an infection rate of ~80-90%, 
whereas the rate of infection with fibroblast-adapted HCMV strains was negligible (205). 
Based on experimental evidence from loss-of-function phenotypes in knockout mutants 
and natural variants, and the gain-of-function phenotypes by trans-complementation with 
individual genes, the UL128 gene locus of HCMV, which contains the UL128, UL130 and 
UL131A genes, was identified as being indispensible for both productive infection of 
endothelial cells and transmission to leukocytes (57). It was then documented that the 
same genetic determinants were also required for HCMV to productively infect DCs (206). 
Furthermore, the UL128-131A gene products are also essential for infection of 
monocytes, and that the UL128 protein in particular can block chemokine-driven migration 
and chemokine receptor internalisation (207). 
 
Interestingly, two independent studies examining the coding sequences of the UL131A, 
UL130 and UL128 genes of HCMV among field isolates and low passage clinical isolates 
found them to be highly conserved, suggesting that all were essential for growth in 
endothelial cells and virus transfer to leukocytes (208, 209). Entry of HCMV into 
biologically relevant epithelial and endothelial cells involves endocytosis followed by low-
pH-dependent fusion facilitated by the UL128, UL130 and UL131 gene products. These 
form complexes with the virion envelope glycoprotein gH/gL. Utilising knockout mutants 
lacking UL128, UL130 and UL131 proteins revealed that all three proteins must bind 
simultaneously to gH/gL for the production of complexes that can function to allow entry 
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into epithelial and endothelial cells (210).  Therefore, a mutation in any one of the ORFs 
can abolish endothelial cell tropism. Hence, a single nucleotide insertion in UL131A exon 
1 encoded by the highly passaged laboratory HCMV strain AD169 results in the inability 
of this virus to efficiently infect endothelial cells (57). Repair of this mutated gene restores 
the ability of AD169 to infect both epithelial and endothelial cells (211).  
 
The broad cell tropism shown by clinical isolates of HCMV is lost during adaptation of the 
virus during propagation in fibroblasts in vitro; a result strongly associated with mutations 
in the UL128 locus. The gene products of UL128-131A have no apparent role for 
replication in fibroblasts. Indeed, there appears to be a selective advantage for HCMV to 
lose or inactivate these genes during replication and spread in this cell type (210). 
Furthermore, viruses with a mutation in the UL128 locus produced greater yields of 
infectious progeny than those with intact genes (56). Due to the genetically unstable 
nature of clinical isolates cultured in fibroblasts, it is therefore necessary to use caution 
when choosing and monitoring HCMV strains for experimental studies of vulnerable 
functions, particularly those involved in cell tropism (56). 
 
4.1.3. Hypothesis 
Studies of the function of cmvIL-10 have so far utilised either recombinant protein or 
strains of HCMV that contained mutations due to propagation in the laboratory. To date, 
our lab has been unable to reliably detect cmvIL-10 during productive infection using 
monoclonal antibodies, and at the time of starting these investigations, no good evidence 
showing that the protein is expressed by the virus had been published. Therefore I aimed 
to test the following hypothesis; 
 
“CmvIL-10 protein is expressed during acute HCMV infection” 
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Furthermore, in chapter 3, I identified an important role for mammalian IL-10 during acute 
MCMV infection, and consequently, wanted to investigate if virally expressed IL-10 
homologues may also have the potential to influence pathogenesis. However, MCMV 
does not express a viral IL-10 homologue and therefore this cannot be tested in the 
MCMV infection model. If cmvIL-10 protein is expressed during acute HCMV infection, the 
functions of cmvIL-10 during infection in biologically relevant cells can be tested. 
Therefore, utilising the Merlin BAC containing the almost fully intact HCMV genome, I also 
aimed to test the following hypothesis; 
 
“CmvIL-10 suppresses anti-viral immune responses during acute HCMV infection”. 
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4.2. Results 
4.2.1. Insertion of a selectable cassette at the end of the UL111A gene 
In order to first visualise the expression of cmvIL-10 protein during infection, a gene 
encoding GFP was to be inserted at the C-terminus end of the UL111A gene. Further, to 
assess the immune suppressive effects of cmvIL-10, a UL111A knockout mutant would 
be generated. To assess expression and function of UL111A during infection of 
biologically relevant cells, modified viruses would require an intact UL128 locus to enable 
infection of endothelial and epithelial cells, and MD-DCs. Thus, a BAC containing almost 
the full-length genome of the low passage HCMV strain Merlin was utilised (58). This BAC 
(pAL1120) is a self-exercising Merlin BAC containing a gene encoding Cre recombinase. 
This version of Cre has a synthetic intron to prevent expression in E. Coli, but upon 
transfection into mammalian cells, Cre recombinase is expressed and mediates removal 
of the BAC vector by recombination between loxP sites engineered at the junctions with 
the virus genome (58) (see Fig 4.1A for visual representation). pAL1120 also has a fully 
intact UL128-131A region and contains only one mutation as compared  to the Merlin 
clinical isolate, which is a frameshift in RL13. RL13 encodes a highly glycosylated protein 
located in the virion envelope and expression of this gene severely impairs HCMV 
replication in fibroblasts and epithelial cell cultures (58). Thus pAL1120 represents the 
best possible construct for the generation of modified viruses. 
 
To create the modified viruses, the technique of recombineering was utilised. In the first 
round of recombineering, a selectable cassette was inserted at the C-terminus end of the 
UL111A gene of pAL1120 (see Fig 4.1B for visual representation). The selectable 
cassette encodes a gene for ampicillin resistance (positive selection), a sacB gene which 
confers susceptibility to sucrose (negative selection), and a lacZ gene encoding β-
galactosidase which causes bacteria to appear blue when grown in the presence of X-gal 
(colourogenic selection). The cassette was amplified with primers containing overlapping 
homology to both the cassette and the target site of insertion, i.e. the end of the UL111A 
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gene (section 2.16.1). The SW102 bacteria containing the HCMV genome have a 
defective phage expressing the lambda red genes which mediate homologous 
recombination between stretches of DNA. The bacteria were made competent and the 
amplified cassette was inserted by electroporation (section 2.16.2). The bacteria were 
grown on plates containing ampicillin, IPTG (an inducer of the lacZ gene and necessary 
for galactosidase production) and X-gal (a modified galactose sugar). Correct insertion of 
the cassette resulted in the bacteria becoming resistant to ampicillin as well as appearing 
blue in colour after ~24 hours (Fig. 4.2A). In the second round of recombineering, the 
sacB gene would be selected against, consequently it was important to check that the 
sacB was functional, as PCR errors that prevent it from working properly occur in 25% of 
colonies. Therefore, 4 blue colonies were streaked onto plates containing ampicillin and 
onto plates containing sucrose (Fig. 4.2B). Three of the 4 colonies picked were inhibited 
on the sucrose plates, thus representing bacteria containing a fully functional sacB gene 
(colonies A-C were inhibited but D was only partially inhibited, see Fig. 4.2B). DNA from 
these 3 colonies was then extracted and restriction digest was performed with the 
restriction endonucleases BamHI and Hind-III (section 2.16.3). Recognisable restriction 
endonuclease cleavage patterns for the Merlin BAC were observed (Fig. 4.2C). To test 
that recombination had occurred in the correct place with no errors, a sequencing PCR 
reaction was performed and the subsequent PCR product was sequenced (section 
2.16.3). The 80 base pairs at either end of the cassette were checked to ensure no errors 
had been introduced during recombination. This new BAC containing the sacB cassette at 
the end of UL111A was designated the number pAL1307. 
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Figure 4.1. Diagramatic representation of the HCMV Merlin BAC and insertion of a 
selectable cassette through recombineering 
(A) Diagram of the Merlin BAC (pAL1120) showing approximate insertion site of the BAC 
vector. Pink boxes indicate protein-coding regions, blue circles denote loxP sites, the blue 
BAC box represents pBeloBAC11 (see section 2.16, Fig. 2.1), and the black Cre box 
represents a Cre recombinase gene containing a synthetic intron. (B) Diagram of the 
selectable cassette containing genes for ampicillin resistance, lacZ and SacB inserted at 
the C-terminus of the UL111A via recombineering. 
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Figure 4.2. Recombineering of a Merlin BAC  
(A and B) Positive, negative and colourogenic selection. Recombineering was used to 
insert a selectable cassette encoding genes for ampicillin resistance, sucrose 
susceptibility and lacZ at the end of the UL111A gene of the Merlin BAC, pAL1120. (A) 
Recombineered SW102 bacteria were grown on plates containing ampicillin for 24 hours. 
(B) To check for correct insertion of the cassette by inhibition of growth by sucrose, 4 blue 
colonies were picked and grown on 2 separate plates containing either ampicillin (left-
hand plates) or sucrose (right-hand plates). (C) Restriction endonuclease profiles of DNA 
from pAL1120 and pAL1307 (Merlin UL111A_selection cassette).  
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 4.2.2. Generation of new viruses with modifications in the UL111A gene 
A second round of recombineering was performed to create 3 new viruses from pAL1307 
with modifications to the UL111A gene: a UL111A knockout virus (MerlinΔUL111A), a 
virus encoding GFP at the end of the UL111A gene (Merlin UL111A_GFP) to enable 
visualisation of cmvIL-10 expression, and a virus construct in which the UL111A gene 
was replaced with a gene encoding GFP (MerlinΔUL111A/GFP), thus representing a 
control for GFP expression and the absence of UL111A. These modified constructs are 
visually represented in Fig 4.3A. 
 
To delete UL111A, an oligonucleotide with regions of homology flanking UL111A and the 
sacB cassette was electroporated into pAL1307, thus removing both the UL111A gene 
and the sacB cassette. To insert GFP into the place of UL111A for generation of the 
MerlinΔUL111A/GFP construct, GFP-encoding DNA amplified with arms of homology 
flanking both UL111A and the sacB cassette was electroporated into pAL1307, thus 
removing both UL111A and the sacB cassette, leaving GFP in this region. To insert GFP 
at the C-terminus end of UL111A (for generation of Merlin UL111A_GFP), GFP-encoding 
DNA amplified with arms of homology flanking the sacB cassette was electroporated into 
pAL1307, thus replacing the cassette with GFP.   
 
After electroporation and recovery, bacteria were grown on sucrose plates. If the 
selectable cassette had been removed and/or replaced, bacteria would no longer be 
sensitive to sucrose and would appear white instead of blue. DNA from 4 of these white 
colonies was then extracted, restriction endonuclease digests performed (Fig. 4.3B), and 
the deleted/inserted sequences were PCR-amplified, sequenced and analysed to make 
sure no errors had been introduced. These new Merlin BACs were designated the 
numbers pAL1308 (MerlinΔUL111A), pAL1309 (MerlinΔUL111A/GFP) and pAL1310 
(Merlin UL111A_GFP).  
 131 
 
 
Figure 4.3. Generation of modified Merlin BACs through recombineering  
(A) Diagramatic representation of the Merlin BAC pAL1120 before recombineering and 
the 3 new modified Merlin BACs after recombineering (pAL1308 (MerlinΔUL111A), 
pAL1309 (MerlinΔUL111A/GFP) and pAL1310 (Merlin UL111A_GFP)). (B) Restriction 
endonuclease profiles of DNA from pAL1308, pAL1309 and pAL1310.  
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4.2.3. Transfection of viruses into ARPE-19 cells 
As previously discussed, the UL128 locus of HCMV mutates relatively rapidly when 
propagated in fibroblasts but remains intact when cultured in epithelial or endothelial cells. 
Therefore, DNA derived from the newly generated Merlin BACs was transfected into the 
human retinal pigment epithelial cell line ARPE-19 in order to preserve the intact HCMV 
genome. Once plaques appeared, cells were trypsinised and re-propagated in order to 
increase virus spread via cell-to-cell contact. After re-propagation, infected cells were 
analysed for GFP expression (Fig. 4.4). GFP was observed in the cells transfected with 
Merlin UL111A_GFP (Merlin 1310) (Fig. 4.4E and F). Interestingly, under the same 
magnification and exposure time, GFP expression could hardly be detected in cells 
transfected with MerlinΔUL111A/GFP (Merlin 1309) under x10 magnification (Fig. 4.4C) 
and expression was only detected very weakly under x40 magnification (Fig. 4.4D). No 
GFP was seen in cells transfected with MerlinΔUL111A (Merlin 1308) (Fig. 4.4A and B) as 
the GFP gene was not inserted into this virus, and this therefore served as a negative 
control. In cells infected with both Merlin 1309 and Merlin 1310, the GFP expression 
appeared to be diffused throughout the cells.  
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Figure 4.4.  Growth of BAC-derived viruses in ARPE-19 cells 
DNA from pAL1308 (A and B), pAL1309 (C and D) and pAL1310 (E and F) Merlin BACs 
was transfected into ARPE-19 cells. After the appearance of plaques, cells were 
trypsinised and re-propagated to enhance virus spread via cell-to-cell contact. Images 
show infected cells under light microscopy (left-hand images) and under fluorescence 
microscopy (right-hand images) to analyse GFP expression. Infected cells were analysed 
under x10 magnification (A, C and E) and x40 magnification (B, D and F).  
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4.2.4. Utilising GFP to visualise cmvIL-10 expression during infection 
The production of each virus was initially scaled up by propagation in HFFs grown in 6 x 
T175 flasks. To minimise the chance of mutations occurring in the UL128, UL130 or 
UL131A genes due to growth in fibroblasts, virus propagation in HFFs was kept to just 
two passages in order to keep the number of rounds of replications to a minimum. Since 
the intact UL128 locus in these viruses limits cell-to-cell transmission in fibroblasts, growth 
was very slow and yields were extremely low (for example, from 6 x T175 flasks, titres 
varied from as low as 2 x 105 PFU/ml to maximum titres of 1.2 x 106 PFU/ml of highly 
concentrated stock of no more than 3mls total volume). Once a virus stock was 
generated, a time course of infection was performed to determine growth kinetics and 
temporal control of expression from the UL111A promoter. HFFs were mock-infected, or 
infected with Merlin 1120, Merlin 1308, Merlin 1309 and Merlin 1310 at an MOI of 3.  
 
At 24 hours, infected cells (Fig. 4.5B-E) began to look rounded as compared to mock 
infected control (Fig. 4.5A), but expression of GFP could not be detected at this early time 
point in cells infected with Merlin 1309 (Fig. 4.5D) and Merlin 1310 (Fig. 4.5E). At 72 
hours p.i (Fig. 4.6), GFP expression could be seen, with more robust expression in cells 
infected with Merlin 1310 (Fig. 4.6E) than Merlin 1309 (Fig. 4.6D). The reason for Merlin 
1310 showing far greater intensity of GFP expression than Merlin 1309 is unclear 
although this differential was also observed in ARPE-19 cells (Fig. 4.4). By 144 hours p.i 
(Fig. 4.7), intensity of GFP expression was even further enhanced in cells infected with 
Merlin 1310 (Fig. 4.7E), therefore these data provide evidence that cmvIL-10 is expressed 
during productive infection. GFP expression was again diffuse throughout the cells, the 
same expression pattern that was observed in the ARPE-19 infections (Fig. 4.4). There is 
a chance that proteases could have cleaved and released GFP and therefore it was 
important to establish by western blot if the observed GFP expression was a reliable 
representation of cmvIL-10 protein expression and intracellular localisation. 
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Figure 4.5.  HFF cells 24 hours post-infection with Merlin BAC-derived viruses 
HFF cells were infected with BAC-derived viruses at an MOI of 3 and examined for 
infection and GFP expression after 24 hours. (A and B) Light microscopy images of mock-
infected cells (A) and cells infected with Merlin 1120 (B). (C-E) Light microscopy images 
(left-hand pictures) and fluorescence images (right-hand pictures) of cells infected with 
Merlin1308 (C), Merlin 1309 (D) and Merlin 1310 (E) under x25 magnification.  
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Figure 4.6. HFF cells 72 hours post-infection with Merlin BAC-derived viruses 
HFF cells were infected with BAC-derived viruses at an MOI of 3 and examined for 
infection and GFP expression after 72 hours. (A and B) Light microscopy images of mock-
infected cells (A) and cells infected with Merlin 1120 (B). (C-E) Light microscopy images 
(left-hand pictures) and fluorescence images (right-hand pictures) of cells infected with 
Merlin1308 (C), Merlin 1309 (D) and Merlin 1310 (E) under x25 magnification.  
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Figure 4.7. HFF cells 144 hours post-infection with Merlin BAC-derived viruses 
HFF cells were infected with BAC-derived viruses at an MOI of 3 and examined for 
infection and GFP expression after 144 hours. (A and B) Light microscopy images of 
mock-infected cells (A) and cells infected with Merlin 1120 (B). (C-E) Light microscopy 
images (left-hand pictures) and fluorescence images (right-hand pictures) of cells infected 
with Merlin1308 (C), Merlin 1309 (D) and Merlin 1310 (E) under x25 magnification.  
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4.2.5. Detection of cmvIL-10 protein and GFP during infection 
The result obtained with the GFP construct provided both confidence that the IL-10 
promoter was functional and evidence that a cmvIL-10 fusion construct was being 
expressed. The generation of deletion mutants also made it possible to test for the 
expression of cmvIL-10 from the virus with a relevant control that would distinguish non-
specific binding. In western blot experiments, cmvIL-10 protein was not detected at the 
early time point of 24 hours p.i, but was present in lysates from cells infected with the wt 
Merlin 1120 at 72 hours and 144 hours p.i (Fig. 4.8A). In agreement with the lack of GFP 
expression observed in cells infected with Merlin 1309 and Merlin 1310 at 24 hours p.i 
(Fig. 4.5), GFP was not detected by western blot at this time point (Fig. 4.8B). Also in 
agreement with the expression of GFP shown in Fig. 4.6 and Fig. 4.7, GFP was detected 
in lysates from cells infected with Merlin 1309 and Merlin 1310 at 72 hours and 144 hours 
p.i, with intensity of GFP expression greatest 144 hours p.i (Fig. 4.8B). Intriguingly, 
cmvIL-10 protein could not be detected at any time point in the lysates from cells infected 
with Merlin 1310, either in isolation or as a fusion protein with GFP (the fusion protein 
having a predicted size of 42-45k Daltons) (Fig. 4.8A and B). 
 
These initial experiments revealed that the cmvIL-10_GFP virus Merlin 1310 expressed 
GFP during infection but as the cmvIL-10_GFP fusion protein could not be detected, GFP 
expression in this virus could not be used as a reliable read out for cmvIL-10 protein, as 
was initially planned. Due to the large amounts of time taken to grow enough virus to 
perform assays with, it was not feasible to repeat this finding or resolve this issue in the 
available time.  
 
 
 
 
 139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Detection of cmvIL-10 protein and GFP during infection with modified 
Merlin viruses 
HFF cells were infected with BAC-derived viruses at an MOI of 3 and cells collected at 24 
hours, 72 hours and 144 hours p.i. Lysates were prepared and examined for cmvIL-10 
protein expression (A), GFP expression (B) and actin expression (C).  
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4.2.6. Infection of DCs with a modified Merlin strain of HCMV 
To enable utilisation of the UL111A knockout virus to elucidate the functions of cmvIL-10 
in infections, the issue of very low virus yields needed to be addressed. The strains of 
HCMV TB40/E and FIX are remarkable in apparently being relatively stable endothelial 
and epithelial cell tropic. While the Merlin 1308, 1309 and 1310 viruses were being 
generated and characterised in the above experiments, Dr Richard Stanton developed 
two new Merlin-BAC vectors in which the complete endogenous UL128 locus was 
replaced with the equivalent region from TB40/E-BAC4 (pAL1477-2) or strain FIX 
(pAL1477-3). I hypothesised that viruses derived from these modified BACs may resolve 
the issue of low virus yields from virus propagation in fibroblasts, yet still enable infection 
of different cell types, including DCs. It was necessary to first establish whether Merlin 
1477-2 and Merlin 1477-3 were capable of infecting DCs.  
 
MD-DCs were generated according to the protocol described in section 2.21. MD-DCs 
were then infected at an MOI of 30 with Merlin 1477-2, Merlin 1477-3 and a TB40/E 
positive control virus. All 3 viruses contained an IRES-GFP at the end of the IE2 gene and 
therefore GFP expression was utilised to differentiate between infected and non-infected 
cells. After 3 days, MD-DCs were harvested and analysed for GFP expression by flow 
cytometry. To assess the efficiency of infection, gates were drawn around the GFP 
positive cells. Infection with the TB40/E virus resulted in ~66% of the MD-DCs becoming 
infected, Merlin 1477-2 infected ~19% of DCs and Merlin 1477-3 infected ~56% of cells 
(Fig. 4.9). This experiment demonstrated that MD-DCs could indeed be infected with 
these modified Merlin viruses.  
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Figure 4.9. Infection of monocyte-derived DCs with TB40/E and modified Merlin 
strains of HCMV 
Representative overlay histograms of GFP expression (blue solid line) within MD-DCs 
infected at an MOI of 30 with TB40/E (A), Merlin 1477-2 (B) or Merlin 1477-3 (C) at 3 days 
p.i. Shaded histograms represent uninfected MD-DCs.  
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4.3. Discussion 
The aims of the experiments in this chapter were to visualise cmvIL-10 protein during 
productive HCMV infection as well as to elucidate a possible role for viral IL-10 during 
infection of biologically relevant cells. This would enable comparisons to be made 
between the roles of mammalian IL-10 in acute MCMV infection which were uncovered in 
chapter 3, with the role of cmvIL-10 in HCMV infection.  
 
To address the first aim, a Merlin virus that encoded GFP at the end of the UL1111A 
gene, which would be expressed as a fusion protein with cmvIL-10, was constructed in 
order to track expression of this protein during infection of biologically relevant cells. This 
virus was successfully created and GFP expression was observed during productive 
infection of both ARPE-19 and HFF cells. Further analysis by western blot of these 
infected cells revealed that although GFP expression could be detected throughout a 144 
hour period of infection, the GFP_cmvIL-10 fusion protein could not. However, during 
infection of cells with the wt virus, cmvIL-10 protein was detected. It is likely that the 
fusion protein is being expressed but cmvIL-10 does not survive, and possible 
explanations for this are that the GFP was being cleaved from the fusion protein, or that 
cmvIL-10 is subject to post-transcriptional regulation and the presence of a large protein 
at the C-terminus of the UL111A gene might alter the mechanisms for this regulation, or 
that the GFP is being picked up from an endogenous promoter, hence the high 
expression observed. If this was the case, the fusion protein should also be expressed, 
but I did not find evidence of this in the lysates of infected cells. However, there is also a 
strong possibility that the protein is secreted and therefore it would not be detected in cell 
lysates. The supernatants from these infections were analysed for protein expression by 
western blot but no protein was detected. This was only attempted once and it is possible 
that by repeating this experiment and improving the supernatant concentrating process, 
that the cmvIL-10_GFP fusion protein may be detected from supernatants. Unfortunately, 
due to the limitation of low virus yields, detailed investigation may be problematical.  
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A second aim of this chapter was to create a UL111A knockout virus that otherwise 
contained the full length HCMV genome (other than the mutated RL13), including the fully 
intact UL128 locus to allow infection of biologically relevant cells including epithelial and 
endothelial cells as well as DCs, with the aim to further elucidate the functions of 
cmvIL-10 and compare this to the roles found for mammalian IL-10 during acute MCMV 
infection. This virus was also successfully created, however the issue of low virus yields 
again caused significant limitations. It had been previously demonstrated in initial studies 
that the Merlin virus with no mutations in the UL128 gene locus produced much smaller 
plaques, had restricted cell-to-cell transmission and resulted in clear reductions in the 
levels of infectious virus released into the supernatant as compared to the Merlin virus 
containing mutations in this gene region (58). However, from these initial studies the 
extent to which virus yields were reduced were not apparent and consequently the large 
time scales needed to generate enough usable virus were overlooked. Therefore, due to 
the time constraints of my studies, it was decided that the time and effort required to 
obtain usable titres of these viruses was no longer feasible; therefore the investigations 
with this virus were halted. 
 
To prevent a similar problem in future investigations, a slightly modified approach is 
proposed. This would involve using modified Merlin viruses containing the UL128 locus 
from either a TB40/E virus or an HCMV clinical isolate VR1814 as described in section 
4.2.6, thus making these viruses permissive to DCs and epithelial and endothelial cells 
(212, 213). These viruses could then be modified by recombineering to make a UL111A 
knockout virus. A knockout virus from the TB40/E strain was not created due to the 
possibility that more than one virus was involved in the derivation of TB40/E, and 
therefore caution against its use as a general laboratory strain, especially when making 
correlations between phenotypes is essential (55). Before knocking out UL111A from 
either of these viruses, it was critical to establish that they were capable of infecting 
MD-DCs; therefore both were tested alongside the TB40/E virus. Incubation with the 
 144 
 
TB40/E virus resulted in approximately two thirds of the DCs becoming infected. Merlin 
1477-2 and Merlin 1477-3 viruses were also successful at infecting DCs, however Merlin 
1477-3 reached a much higher percentage of infected cells than Merlin 1477-2. By 
optimising the infection technique by increasing the MOI and/or by using centrifugation to 
aid virus entry, it is likely that this infection rate could be increased further. However, time 
constraints unfortunately meant that I could not explore this possibility further. 
Nevertheless, for future studies to elucidate HCMV gene functions that might require a 
deletion mutant, such as a UL111A knockout virus, the above approach appears to 
provide a virus which is both permissive to DCs and other biologically relevant cell types, 
and also contains a near complete wt HCMV genome which is far more clinically relevant 
than any other laboratory strains used to date.   
 
Determining the functions of cmvIL-10 during acute and latent infection still represents an 
important area of research, as exploitation of immune inhibitory receptors such as the 
IL-10R are important targets for herpesviruses in dampening down antiviral immune 
responses and establishing latency within the host. Consequently, virus-encoded proteins 
that manipulate these receptors, such as cmvIL-10, represent possible therapeutic targets 
by promoting antiviral responses. As discussed in section 4.1.1, studies demonstrating 
rhcmvIL-10 as a viable vaccine candidate because of its high immunogenicity during 
natural infection combined with the lack of cross-reactivity with rhesus cellular IL-10 (203, 
204) reveal the possible usefulness of targeting UL111A to improve immune responses to 
HCMV. Importantly, the relatively low sequence homology between human IL-10 and 
cmvIL-10 is also critical in offering the potential of targeting UL111A in a vaccine setting 
without affecting endogenous IL-10. Enhancing our current understanding of not only the 
initial effects cmvIL-10 has in dampening antiviral immune responses during acute 
infection but also how it shapes the long-term virus-host balance will be critical in 
facilitating the development of both prophylactic and therapeutic strategies. 
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Chapter 5 - Investigating the immune protective role of IL-22 during acute MCMV 
infection 
 
5.1. Introduction 
5.1.1. The role of IL-22 in viral infections 
IL-22 plays an important role in host defence, inflammation and tissue repair, as 
discussed in chapter 1.10.1 and reviewed by Sonnerburg et al (135). However, the 
importance of IL-22 in viral infections has been less well explored. One of the first studies 
that linked IL-22 with viral infections showed that repeatedly HIV-1 exposed, uninfected 
individuals had up-regulated levels of T cell-derived IL-22 in their serum and cell 
supernatants, suggesting IL-22 and the subsequent acute-phase protein pathway it 
induces is associated with host resistance to HIV infection (214). Furthermore, Indian 
patients infected with HIV-1 subtype C were found to have high levels of systemic IL-22, 
along with IL-10 and C-reactive protein, and this was associated with low viral replication 
in vitro (215). In mice, IL-22 exerts a protective function in LCMV infection; IL-7 driven 
induction of IL-22 provides cytoprotection in the liver as shown by enhanced hepatitis 
following IL-22 neutralisation (216). Conversely, a study analysing the role of IL-22 in 
human HCV infection found that despite an up-regulation of hepatic IL-22 during infection, 
IL-22 did not directly regulate antiviral proteins and had no effect on HCV replication 
(217). A similar finding was observed in hepatitis B virus (HBV) infection. In HBV 
transgenic mice, IL-22 increased the expression of pro-inflammatory genes and reduced 
the severity of liver damage, but did not directly inhibit virus replication (218). In humans, 
patients with acute and chronic HBV infection have a significant increase in the 
concentration of serum IL-22, and the authors speculated that the increase in IL-22 levels 
provides protection against liver inflammation and fibrosis during HBV infection (218, 
219). The role of IL-22 during primary influenza infection in mice has also been 
investigated. Anti-IL-22 neutralisation in vivo did not dramatically affect weight loss and 
survival and surprisingly, mice treated with anti-IL-22 actually showed a moderate 
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reduction in viral titres in the lung and trachea (220). Furthermore, IL-22 protects influenza 
infected airway epithelial cells from death in vitro, but has no effect on viral replication 
(221). Collectively, these data demonstrate that the effect of IL-22 during viral infections is 
unclear and appears to be pathogen-dependent, especially when assessing the effects 
that IL-22 has on control of virus replication. However, the majority of studies to date 
suggest IL-22 provides varying degrees of protection against virus-driven immune 
pathology, especially by those pathogens that cause liver damage. 
 
5.1.2 Hypothesis 
The IL-10 family of cytokines are critical in host defence against various pathogens. Type 
III IFNs (IL-28A, IL-28B and IL-29) preferentially promote antiviral responses and 
co-operate with type I IFNs to aid viral clearance, and the IL-20 subfamily of cytokines, 
including IL-22, provide critical protection against bacterial and yeast infections (reviewed 
in (100)). However, a clearer understanding of the role that IL-22 plays in virus infections 
in vivo is required. Thus, I utilised a neutralising anti-IL-22 antibody during acute MCMV 
infection to test the following hypothesis: 
 
“IL-22 may provide protective immunity during acute MCMV infection”. 
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5.2. Results 
5.2.1. IL-22 is expressed in tissues of both naïve and MCMV-infected mice 
To investigate the hypothesis that IL-22 plays a protective role in acute MCMV infection, I 
first analysed IL-22 expression during the first 4 days of infection. Homogenates from 
organs targeted by MCMV during early infection were taken at 2 and 4 days p.i, analysed 
for IL-22 protein expression and compared to levels found in homogenates from naïve 
control mice. IL-22 protein was detected in the lungs, livers and spleens of both naïve and 
infected mice (Fig. 5.1), with a significant increase in all three organs at day 4 p.i 
compared to uninfected mice.  
 
In order to identify the source of IL-22 during MCMV infection, IL-22 staining for flow 
cytometry was first optimised. Lymphocytes were incubated with or without PMA, 
ionomycin and IL-23 for 4 hours. Cells were then stained for intracellular IL-22 (Fig. 5.2). 
Gates were set according to the FMO control (Fig. 5.2A). IL-22 positive cells increased 
approximately two fold when polyclonally stimulated compared to unstimulated cells (Fig. 
5.2B and C); therefore this ex vivo stimulation technique was used to identify which cell 
populations were capable of expressing IL-22.  
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Figure 5.1. IL-22 expression in the lung, liver and spleen of naïve and MCMV-
infected mice  
IL-22 protein concentrations in lung, liver and spleen homogenates from naïve mice (open 
bars), MCMV-infected mice 2 days p.i (closed bars) and MCMV-infected mice infected 4 
days p.i (cross hatched bars). Results show the mean ± SEM of 4-6 mice per group and 
represent 2 independent experiments. *p<0.05, **p<0.01, ***p<0.001 
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Figure 5.2. Analysis of intracellular IL-22 antibody staining by flow cytometry  
Bivariate flow cytometry plots showing IL-22 expression by pulmonary lymphocytes from 
MCMV-infected mice 4 days p.i. Cells were incubated for 4 hours with medium alone or 
with PMA/Ionomycin and IL-23 in the presence of brefeldin A. Following surface staining, 
cells were stained for intracellular IL-22 production with anti-IL-22-PE. (A) FMO negative 
staining control was used to draw the IL-22 positive gate. (B) IL-22 expression with no ex 
vivo stimulation. (C) IL-22 expression following ex vivo stimulation.   
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Lymphocytes from the lung, liver and spleen from day 4 infected mice, as well as naïve 
controls, were stimulated ex vivo as described above, and IL-22 production by different 
cell types was examined. In naïve mice, IL-22 production was seen in NK cells, γδ T cells, 
and CD4+ and CD8+ T cells in all three organs (Fig. 5.3). At day 4 p.i, IL-22 expression 
was again seen in all 4 cell types (Fig. 5.4A-C). Gates were drawn based on the FMO 
staining controls (Fig. 5.4D). In some instances, the proportion of IL-22 expressing cells 
was higher than naïve controls, for example the NK cell populations had a higher 
proportion of cells expressing IL-22 at day 4 p.i compared to naïve controls (Fig. 5.5). 
However, when calculated back to total numbers, it was only the liver where a significant 
increase in total numbers of IL-22+ cells was observed (Fig. 5.6B). The lung and the 
spleen showed comparable numbers between naïve and day 4 MCMV-infected mice (Fig. 
5.6A and C).  
 
5.2.2. NK cells are a significant source of IL-22 and exhibit a similar phenotype to 
non-IL-22 producing NK cells 
Given that NK cells appeared to be an important source of IL-22 in at least two organs of 
infected mice (Fig. 5.6A and B), IL-22 protein expression was analysed at day 4 p.i in 
mice that were depleted of NK cells during MCMV infection. In NK cell-depleted mice, 
there was a highly significant reduction in IL-22 protein in both the lung and the liver as 
compared to non-depleted mice (Fig. 5.7A and B), but this was not observed in the spleen 
(Fig. 5.7C) where NK cells appear to be a less significant population of cells contributing 
to IL-22 production (Fig. 5.6C). These data suggest that NK cells are an important source 
of IL-22 during MCMV infection in the lung and the liver. A slight caveat of the NK cell 
depletion experiment is that NK cell-depleted mice have a significantly higher virus load 
compared to the non-depleted ones, which may have an effect on IL-22 production. 
However, this will be addressed later on in the chapter (section 5.2.12). 
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Figure 5.3. Expression of IL-22 by lymphocytes of the lung, liver and spleen in 
naïve mice  
Representative bivariate flow cytometry plots showing IL-22 expression by NK cells, γδ T 
cells, CD4+ and CD8+ T cells from the lung (A), liver (B) and spleen (C) of naïve mice. 
Results are representative of 4 individual experiments with 3-4 mice per group.  
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Figure 5.4. Expression of IL-22 by lymphocytes of the lung, liver and spleen in 
MCMV-infected mice  
Representative bivariate flow cytometry plots showing IL-22 expression by NK cells, γδ T 
cells, CD4+ and CD8+ T cells from the lung (A), liver (B) and spleen (C) of day 4 MCMV-
infected mice. (D) FMO staining controls. Results are representative of 4 individual 
experiments with 3-4 mice per group.  
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Figure 5.5. Proportion of IL-22 positive lymphocytes from the lung, liver and spleen 
in naïve and MCMV-infected mice 
Proportion of IL-22 positive NK cells, γδ T cells, CD4+ and CD8+ T cells from the lung (A), 
liver (B) and spleen (C) of naïve (closed bars) and day 4 infected (open bars) mice. 
Results show the mean ± SEM of 3-4 mice per group and represent 4 individual 
experiments. *p<0.05 
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Figure 5.6. Total numbers of IL-22 positive lymphocytes from the lung, liver and 
spleen in naïve and MCMV-infected mice 
Total numbers of IL-22 positive NK cells, γδ T cells, CD4+ and CD8+ T cells from the lung 
(A), liver (B) and spleen (C) of naïve (closed bars) and day 4 infected (open bars) mice. 
Results show the mean ± SEM of 3-4 mice per group and represent 4 individual 
experiments. *p<0.05 
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Figure 5.7. IL-22 expression in the lung and liver of MCMV-infected mice is 
significantly decreased in the absence of NK cells  
IL-22 protein concentrations in lung, liver and spleen homogenates from naïve mice (open 
bars), day 4 MCMV-infected mice (closed bars) and day 4 MCMV-infected mice treated 
with an anti-NK1.1 antibody to deplete NK cells (cross hatched bars). Results show the 
mean ± SEM of 4-7 mice per group and represent 2 independent experiments. ***p<0.001 
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Next, I investigated whether IL-22 positive NK cells were of a different phenotype to the 
IL-22 negative NK cells. Therefore a number of cell surface markers were examined at 
both time points (Fig. 5.8A and B). Expression of Ly49H, an activating receptor which 
specifically recognises the MCMV protein m157; KLRG-1, an inhibitory receptor 
expressed in a subset of mature NK cells (and T cells); and CD127, which is the IL-7 
receptor and is critical in the development of many lymphocytes, and is expressed at 
intermediate levels by a subset of IL-22 producing RORγt+ ILCs (222). Expression of all of 
these markers was comparable between the IL-22 positive and negative NK cells, and at 
both time points. Expression of CD69, a marker of cell activation, was as expected, up-
regulated at 4 days p.i compared to NK cells from naïve mice. CD11b expression was 
higher in the IL-22 negative NK cells, whereas CD122 expression was higher in the IL-22 
positive NK cells at both time points. CD11b is important for NK cell survival (223) and is 
also a marker of NK cell maturity when used in conjunction with CD27 (176). Signalling 
via CD122 is important for NK cell development and peripheral survival (224). Despite the 
slight differences in expression of these two markers, overall it appears that both IL-22 
positive and IL-22 negative NK cells have a mature NK cell phenotype and are activated 
upon infection to similar levels.  
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Figure 5.8. Expression of surface markers on pulmonary NK1.1+IL-22+ and 
NK1.1+IL-22- cells in naïve and MCMV-infected mice 
Representative overlay histograms of pulmonary NK1.1+IL-22+ (dashed purple line) and 
NK1.1+IL-22- (solid blue line) from naïve (A) and day 4 infected mice (B) (shaded 
histogram = FMO control). Results represent 4 mice per group. 
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5.2.3. Neutralising IL-22 in the lung increases virus load during acute MCMV 
infection 
Having established that IL-22 protein expression is increased during acute MCMV 
infection, I hypothesised that IL-22 provided protective immunity during early infection. 
Due to the importance of IL-22 in modulating immune responses in mucosal surfaces 
(140, 141), I first focused on a mucosal site of acute infection, the lung. To achieve this, 
mice were intra-nasally administered an anti-IL-22 antibody on the day of infection. Virus 
load was then assessed at 4 days p.i by measuring MCMV DNA in the lungs and spleens 
of mice treated with anti-IL-22 or an IgG control, as detected using MCMV gB-specific 
primers. In accordance with my hypothesis, viral DNA loads were significantly increased 
in the lungs at 4 days p.i in mice treated with anti-IL-22 as compared to IgG controls (Fig. 
5.9A), but not in the spleens (Fig. 5.9B), implying that IL-22 has an antiviral role in the 
lung during acute MCMV infection. However, intra-nasal neutralisation of IL-22 did not 
affect virus-induced weight loss over the first 4 days of infection (Fig. 5.9B), 
demonstrating that localised administration of anti-IL-22 did not influence clinical signs of 
disease.  
 
To determine whether elevated viral DNA load after anti-IL-22 administration was 
associated with an alteration in the MCMV-induced cellular immune response, 
accumulation of different cell populations was examined at 4 days p.i. No significant 
difference was seen in T cells (CD3+), NK cells (NK1.1+CD3-), alveolar macrophages 
(CD11chiCD11bhi), inflammatory macrophages (CD11b+7/4hiF4/80+) or non-inflammatory 
monocytes/macrophages (CD11b+7/4loF4/80+), either by proportion of cells (Fig. 5.10A) or 
by total numbers (Fig. 5.10B). However there was a trend towards a decrease in both the 
proportion and total numbers of neutrophils (Ly6G+CD11bhi) in the lungs of mice given the 
anti-IL-22 antibody as compared to IgG treated mice (Fig. 5.10A and B).  
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Figure 5.9. Intranasal neutralisation of IL-22 during acute MCMV infection leads to 
an increase in virus load in the lung but is not associated with enhanced weight 
loss  
Mice were infected with MCMV and intra-nasally administered an IgG control (closed 
circles) or an anti-IL-22 neutralising antibody (open circles). (A and B) Genomic DNA was 
isolated from the lungs and spleens of infected mice at 4 days p.i and MCMV gB was 
detected by qPCR. Data was normalized to -actin and is expressed as genome copy 
number per 100ng genomic DNA. Horizontal bars represent the median value. (C) Weight 
loss shown as percent of starting weight. Results are expressed as mean ± SEM of 5 
mice per group. These data are representative of 2 independent experiments. *p<0.05 
 160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Intranasal neutralisation of IL-22 does not affect cellular accumulation 
during acute MCMV infection  
Mice were infected with MCMV and intra-nasally administered an IgG control (closed 
bars) or an anti-IL-22 neutralising antibody (open bars). Leukocytes from the lung were 
isolated 4 days p.i and the proportion (A) and total numbers (B) of different cellular 
populations were analysed by flow cytometry. Results are expressed as the mean ± SEM 
of 5 mice per group. These data are representative of 2 independent experiments. 
*p<0.05 
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5.2.4. Systemic neutralisation of IL-22 increases virus load in the lung and liver 
during acute MCMV infection 
To further explore the hypothesis that IL-22 has a broad antiviral role during acute MCMV 
infection, the model of intra-nasal administration of anti-IL-22 was altered in order to 
neutralise IL-22 systemically. This was achieved by administering the antibody 
intravenously on the day of infection and, in 4 day experiments, also at 2 days p.i. Virus 
load was then assessed by plaque assay at days 2 and 4 p.i in the lungs, livers and 
spleens. Interestingly, levels of replicating virus were significantly higher as early as 2 
days p.i in the lungs and livers of mice treated with the anti-IL-22 antibody as compared to 
IgG treated controls, and remained significantly higher at day 4 p.i (Fig. 5.11A and B). 
However, in the spleen, no significant differences in virus load were observed between 
the two groups at either time point (Fig. 5.11C). In the lung, replicating virus is usually 
difficult to detect as early as 2 days p.i, as seen in the IgG treated control mice, where 
replicating virus was detected in only 4 out of 10 mice (Fig. 5.11A). Conversely, in the 
absence of IL-22, replicating virus could be detected in 8 of 10 mice, 7 of which to a 
higher level than those observed in the control group.  At day 4 p.i, replicating virus could 
be detected in the lungs of all mice, however the anti-IL-22 treated group had on average 
over 3-fold higher virus loads than the controls. In the livers of IL-22 neutralised mice, this 
increase in virus load was even more striking, where levels of replicating virus were on 
average 7- and 9-fold higher at days 2 and 4 p.i respectively, as compared to IgG controls 
(Fig. 5.11B). 
 
Virus-induced weight loss was also assessed following systemic IL-22 neutralisation. 
Unlike the intra-nasal model, the systemic absence of IL-22 led to exacerbated weight 
loss over the first 4 days of infection, which is an indicator of enhanced clinical disease 
(Fig. 5.11D). This observation taken in conjunction with the virus load data demonstrates 
that IL-22 provides protective immunity during acute MCMV infection in a tissue-
dependent manner that influences the clinical outcome of infection.  
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Figure 5.11. Systemic neutralisation of IL-22 leads to an organ specific increase in 
virus load and enhanced virus-induced weight loss  
Mice were infected with MCMV and intravenously administered an IgG control (closed 
symbols) or an anti-IL-22 neutralising antibody (open symbols). (A-C) Homogenates from 
the lungs (A), livers (B) and spleens (C) of mice infected for 2 and 4 days were prepared 
for high sensitivity plaque assays to detect replicating virus. Data is expressed as PFU 
per gram of tissue. Horizontal bars show median values. (D) Weight loss shown as 
percent of starting weight. Results are expressed as mean ± SEM of 6 mice per group. 
Data represent 3 independent experiments. *p<0.05, **p<0.01, ns=not significant 
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3.2.5. Increased virus load in the absence of IL-22 during acute MCMV infection is 
not associated with decreased levels of pro-inflammatory cytokines 
 
Early response to MCMV infection is characterised by a rapid up-regulation of pro-
inflammatory cytokines (193, 225, 226). I hypothesised that the increase in virus load 
observed in the lung and liver in the absence of IL-22 would be associated with reduced 
levels of pro-inflammatory cytokines, as IL-22 induces pro-inflammatory responses such 
as the production of cytokines, chemokines and acute-phase proteins from many cell 
types (227). To test this hypothesis, MCMV-infected mice were treated with either 
anti-IL-22 or an IgG control, and at 2 days p.i, homogenates from the lung and liver were 
analysed for levels of pro-inflammatory cytokines. Homogenates from the spleen, where 
increased virus loads were not observed following IL-22 neutralisation were also 
analysed. Following IL-22 neutralisation, no significant differences in production of any 
cytokines tested were observed in any of the organs analysed (Fig. 5.12A-C). Levels of 
the Th1 and Th2 associated pro-inflammatory cytokines IFNγ, TNFα, IL-5 and IL-6 were 
comparable between anti-IL-22 treated and IgG treated mice. Levels of the 
anti-inflammatory cytokine IL-10 were also analysed, and again, no significant differences 
were observed between the two treatments in any organs examined. Therefore, altered 
expression levels of pro-inflammatory cytokines were not associated with increases in 
virus load following IL-22 neutralisation. 
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Figure 5.12. Anti-IL-22 administration does not influence Th1 and Th2 associated 
cytokine production in MCMV-infected mice  
Mice were infected with MCMV and treated with IgG (closed bars) or anti-IL-22 (open 
bars). Levels of cytokines were assessed at 2 days p.i. Cytokine protein concentrations in 
lung (A), liver (B) and spleen (C) homogenates were measured by cytometric bead array. 
Results represent the mean ± SEM of 6 mice per group. 
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5.2.6. IL-22 neutralisation is associated with an impairment of Ly6G+ neutrophil 
infiltration 
Following administration of anti-IL-22 via the intra-nasal route, a trend towards a reduced 
accumulation of neutrophils was observed (Fig. 5.10). To see if this was repeated 
following systemic neutralisation of IL-22, leukocytes from the lung, liver and spleen were 
isolated from day 2 MCMV-infected mice, and neutrophils along with various APC 
populations were analysed. In the lung and the liver, neutrophils represent a substantial 
population of the total infiltrating immune cells at 2 days p.i, but interestingly, mice treated 
with anti-IL-22 showed a reduction in the percentage of neutrophils that accumulated in 
these two organs as compared to control treated mice (Fig. 5.13A and B). This reduction 
in neutrophil infiltration can also been seen when calculated as total cell numbers (Fig. 
5.13D and E). APC populations were unaffected by IL-22 neutralisation (Fig. 5.13D and 
E). In the spleen, neutrophils account for only a very small proportion of the entire cellular 
infiltrate and the absence of IL-22 does not alter the proportion or total numbers of 
neutrophils accumulating in the spleen (Fig. 5.13C and F).  
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Figure 5.13. IL-22 neutralisation during acute MCMV infection is associated with 
impaired neutrophil accumulation in the lung and liver  
MCMV-infected mice were administered IgG or anti-IL-22 by IV injection and leukocytes 
isolated from lungs, livers and spleens at 2 days p.i. (A-C) Representative bivariate flow 
cytometry plots showing neutrophil accumulation following IgG administration (left-hand 
plots) and anti-IL-22 administration (right-hand plots). (D-F) Total numbers of neutrophils, 
inflammatory macrophages and CD11b+ monocytes/macrophages in naïve (cross hatched 
bars), and day 2 infected mice treated with IgG (black bars)  or anti-IL-22 (white bars). 
Results show mean ± SEM of 6 mice per group and represent 3 independent 
experiments. 
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5.2.7. Chemokines associated with neutrophil recruitment are not down-regulated 
following IL-22 neutralisation 
A possible mechanism for the reduction in neutrophil accumulation in the lung and liver 
following anti-IL-22 treatment could be impaired recruitment. Neutrophils express the 
chemokine receptor CXCR2 which binds to the chemokine CXCL1; therefore a reduction 
in this chemokine could prevent efficient recruitment of neutrophils into infected lungs and 
livers. Homogenates from these organs as well as spleens from naïve mice and MCMV-
infected mice treated with IgG or anti-IL-22 at 2 days p.i were analysed for CXCL1 protein 
expression. Infected mice showed significant upregulation of CXCL1 compared to naïve 
controls. However, no significant differences were observed between IgG and anti-IL-22 
treated mice although a trend towards an decrease in CXCL1 expression was seen in the 
liver of anti-IL-22 treated mice (Fig. 5.14A-C). It was possible that looking even earlier 
during infection may yield significant differences in CXCL1 expression between the IgG 
and anti-IL-22 treated mice, therefore homogenates from day 1 infected mice were also 
examined for CXCL1 protein expression. However, no significant differences were 
observed (Fig. 5.14D-F). 
 
As well as CXCL1, other chemokines are also important in recruitment of neutrophils. To 
assess if IL-22 neutralisation inhibited mRNA expression of CXCL2 and CXCL5, RNA was 
extracted from livers of day 1 MCMV-infected mice and mRNA expression of these 
chemokines, along with CXCL1, was analysed by qPCR (Fig. 5.15A-C). However, 
expression of these genes between IgG treated mice and anti-IL-22 treated mice was 
comparable, as was the expression of G-CSF (Fig. 5.15D) which is important for 
stimulating survival, proliferation, and differentiation of neutrophils. 
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Figure 5.14. Anti-IL-22 treatment does not lead to a reduction in CXCL1  
(A-C) CXCL1 protein concentrations in lung, liver and spleen homogenates from naïve 
mice (squares) or 2 day MCMV-infected mice treated with IgG (closed circles) or 
anti-IL-22 (open circles). (D-F) CXCL1 protein concentrations in lung, liver and spleen 
homogenates from 1 day MCMV-infected mice treated with IgG (closed circles) or 
anti-IL-22 (open circles). Horizontal bars represent the median value. Data are 
representative  of 2 independent experiments.  
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Figure 5.15. Neutralisation of IL-22 does not cause a reduction in expression of 
chemokines associated with neutrophil accumulation and survival  
MCMV-infected mice were treated with IgG (closed circles) or anti-IL-22 (open circles). At 
day 1 p.i, livers were excised and RNA was extracted and converted to cDNA. Expression 
of genes associated with neutrophil chemotaxis and survival was analysed by qPCR. 
Data is shown as gene expression relative to -actin expression. Horizontal bars 
represent the median value. Data represent 2 experiments. 
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5.2.8. CD11b expression on neutrophils is up-regulated upon MCMV infection 
CD11b is a component in the CD11b/CD18 adhesion protein complex, and when rolling 
adherent neutrophils are stimulated, they rapidly immobilise through activation of this 
complex, allowing them to migrate from the blood circulation into target tissue (228, 229). 
Therefore the up-regulation of CD11b expression is a sign of neutrophil activation (229). 
To investigate if MCMV infection led to neutrophil activation, neutrophils were isolated 
from naïve and day 2 MCMV-infected mice and CD11b expression was analysed. In order 
to minimise the possibility of the neutrophils becoming activated during isolation, each 
step was performed on ice. Due to a more involved process of isolating leukocytes from 
the liver, and consequently increasing the chances of ex vivo activation, only neutrophils 
from the lung and spleen were analysed. In naïve mice, neutrophils in both the lung and 
the spleen expressed intermediate levels of CD11b (Fig. 5.16A and B; dashed lines). 
Interestingly, splenic neutrophils isolated from 2 day MCMV-infected mice showed 
enhanced CD11b expression compared to naïve mice, with the MFI of CD11b increasing 
from 323 to 986 (Fig. 5.16B; solid line). This increased expression was even more 
enhanced in neutrophils isolated from the lung of MCMV-infected mice, with the MFI of 
CD11b reaching 1136 compared to 365 in naïve mice (Fig. 5.16A; solid line). Therefore 
this data suggests that neutrophils become activated upon MCMV infection. 
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Figure 5.16. MCMV infection is associated with an up-regulation of CD11b 
expression on neutrophils 
Representative overlay histograms of CD11b expression on neutrophils isolated from the 
lung (A) and spleen (B) of naïve mice (dashed line) and day 2 MCMV-infected mice (solid 
line) (shaded histogram = FMO control). Results represent 3 mice per group. 
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5.2.9 Administration of 1A8 antibody leads to specific loss of neutrophils 
To test the hypothesis that neutrophils are important in controlling MCMV infection, mice 
were administered a Ly6G-specific monoclonal antibody, clone 1A8, to deplete 
neutrophils, during infection. This antibody has been shown to specifically deplete 
neutrophils without depleting Gr-1+ (Ly6C+) monocytes (230).  To ensure neutrophils were 
being depleted without affecting other monocyte populations in my model, mice were 
administered either anti-Ly6G (1A8) or an IgG control and infected with MCMV. Organs 
were taken at 4 days p.i and neutrophils and APC populations in each organ were 
analysed by flow cytometry. Mice treated with anti-Ly6G (Fig. 5.17, right-hand panels) 
showed specific loss of neutrophils in the lung, liver and spleen as compared IgG treated 
controls (Fig. 5.17, left-hand panels). 
 
5.2.10. MCMV-infected mice show exacerbated weight loss following neutrophil 
depletion 
Having established that mice administered with anti-Ly6G were selectively depleted of 
neutrophils during MCMV infection, virus-induced weight loss was measured in mice with 
or without neutrophils. In the absence of neutrophils during early infection, mice exhibited 
exacerbated weight loss compared to non-depleted mice (Fig. 5.18, open circles and 
closed circles respectively), suggesting that neutrophils protected the mice against the 
clinical signs of disease. To rule out the possibility that the absence of neutrophils in 
uninfected mice would also lead to enhanced weight loss, naïve controls were treated 
with either anti-Ly6G or IgG and their weights also measured over 4 days (Fig. 5.18, open 
triangles and closed triangles respectively). No significant weight loss was observed in 
either group. Therefore, this data shows that during acute MCMV infection, neutrophils 
are required to protect the mice from more severe virus-induced weight loss. 
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Figure 5.17. Administration of an anti-Ly6G antibody (1A8) specifically depletes 
neutrophils during  MCMV infection 
MCMV-infected mice were administered an anti-Ly6G depleting antibody (right-hand 
panels) or an IgG control (left-hand panels) on the day of infection and at day 2 p.i. 
Representative bivariate flow cytometry plots showing leukocytes isolated from the lung, 
liver and spleen of 4 day infected mice. Neutrophils are gated on Gr-1hi7/4int cells. Results 
represent 6 mice per group. 
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Figure 5.18. The absence of neutrophils during acute MCMV infection leads to 
enhanced virus-induced weight loss 
Naïve mice (triangles) and MCMV-infected mice (circles) were treated with either an 
anti-Ly6G antibody (open symbols) or an IgG control (closed symbols) on day 0 and day 2 
p.i. Weight loss is shown as percent of starting weight. Results are expressed as mean ± 
SEM of 6 mice per group. Data represent 3 independent experiments. **p<0.01, 
***p<0.001 
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5.2.11. The absence of neutrophils in MCMV-infected mice leads to increased virus 
load in the lung and liver at day 4 post-infection 
Increased virus-induced weight loss observed in mice following neutrophil depletion 
supported my hypothesis that these cells have a protective role during acute MCMV 
infection. To investigate this further, virus load was then assessed by plaque assay at 4 
days p.i in the lungs, liver and spleens. In accordance with my hypothesis, the lungs and 
livers of mice treated with anti-Ly6G had significantly higher virus loads than IgG control 
treated mice (Fig. 5.19A and B). Interestingly, virus loads in the spleen were comparable 
between mice with and without neutrophils (Fig. 5.19C). Thus, these data show that 
neutrophils have an antiviral function in the lung and the liver during acute MCMV 
infection.  
 
5.2.12. Increased virus load does not lead to a significant reduction in IL-22 
As discussed in section 5.2.2, IL-22 protein expression was markedly reduced in the lung 
and liver following NK cell depletion during acute MCMV infection, suggesting NK cells 
were an important source of IL-22. However, NK cell depletion during infection leads to a 
significant increase in virus load. To investigate whether increased virus load contributes 
to the reduction in IL-22 levels, perhaps via induction (directly or indirectly) of death of 
IL-22 producing cells, I examined homogenates from neutrophil depleted mice for IL-22 
protein expression, as these mice also exhibited increased virus loads as compared to 
IgG controls. However, unlike the NK cell depleted mice (Fig. 5.20A and C), the neutrophil 
depleted mice did not show a significant reduction in IL-22 expression levels (Fig. 5.20B 
and D). This suggests that it was in fact the lack of NK cells that led to the observed 
reduction in IL-22 and not the increase in virus load, and highlights that neutrophils are 
not a significant source of IL-22 in MCMV infection. 
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Figure 5.19. The absence of neutrophils during acute MCMV infection leads to 
increased virus load in the lung and liver at 4 days post-infection 
Mice were infected with MCMV and administered an IgG control (closed symbols) or an 
anti-Ly6G antibody (open symbols). Homogenates from the lungs (A), livers (B) and 
spleens (C) of mice infected for 4 days were prepared for high sensitivity plaque assays to 
detect replicating virus. Data is expressed as PFU per gram of tissue. Horizontal bars 
show median values. Data is representative of 3 independent experiments. **p<0.01, 
ns=not significant.  
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Figure 5.20. Increased virus load does not lead to a significant reduction in IL-22 
expression 
IL-22 protein concentrations in lung (A and B) and liver (C and D) from homogenates from 
day 4 MCMV-infected mice treated with IgG (open bars), anti-NK1.1 (A and C, closed 
bars) or anti-Ly6G (B and D, closed bars). Results show the mean ± SEM of 4-7 mice per 
group. ***p<0.001, ns=not significant.  
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5.2.13. The absence of neutrophils in MCMV-infected mice does not lead to 
increased virus load at day 2 post-infection 
Increased virus load at day 4 p.i in the lung and the liver was observed in mice following 
neutrophil depletion (Fig. 5.19). However, to see if this antiviral protection afforded by 
neutrophils also occurred earlier in infection, virus load was assessed by plaque assay 
after 2 days of infection in mice treated with IgG or anti-Ly6G. Interestingly, no significant 
differences in virus load were observed in the lungs, livers or spleens of mice depleted of 
neutrophils as compared to non-depleted controls at this time point (Fig. 5.21).  
 
5.2.14. NK cell function is not enhanced by the presence of neutrophils during 
acute MCMV infection 
It has recently been demonstrated that neutrophils are required for NK cell development 
during normal homeostasis (231) and are also critical for NK cell activation during 
Legionella pneumophila infection (231, 232). I therefore hypothesised that neutrophil-NK 
cell crosstalk could be important in limiting virus load during the acute-phase of infection. 
To explore this hypothesis further, mice were administered either anti-Ly6G or an IgG 
control and infected with MCMV. At 4 days p.i, hepatic lymphocytes were isolated from 
livers and NK cell function was analysed under different ex vivo stimulating conditions. 
However, the absence of neutrophils in mice treated with anti-Ly6G did not inhibit either 
CD107a mobilisation or IFNγ expression by NK cells either directly ex vivo or after 
stimulation with plate-bound anti-NKp46 or by PMA/Ionomycin stimulation (Fig. 5.22A and 
B). In fact, mice treated with anti-Ly6G actually showed increased expression of CD107a 
on NK cells directly ex vivo and following PMA/Ionomycin stimulation as compared to IgG 
treated controls (Fig. 5.22A). This suggests that neutrophils do not enhance NK cell 
function during acute MCMV infection. However, to further confirm this, MCMV-infected 
mice were administered either an IgG control, anti-Ly6G, anti-NK1.1 or both anti-Ly6G 
and anti-NK1.1. At 4 days p.i, livers were taken and homogenates were analysed for 
replicating virus levels by high-sensitivity plaque assay. Both anti-Ly6G and anti-NK1.1 
 179 
 
treatment led to a significant increase in virus load compared to control treated mice, but 
a further significant increase in virus load was observed in mice given both depleting 
antibodies (Fig. 5.22C). This suggests that both cell types play a protective role in early 
MCMV infection and the absence of both has an additive effect on levels of replicating 
virus.  
 
5.2.15. Neutrophils from MCMV-infected mice express a distinct gene transcription 
profile 
Having ruled out the possibility that activation of NK cells was enhanced by neutrophils 
during acute MCMV infection, the question of how neutrophils were providing antiviral 
immunity was still to be answered. In an attempt to elucidate the mechanism(s) through 
which neutrophils protect against MCMV, leukocytes from 2 day infected mice were 
isolated from the liver. MACs separation was then performed in order to purify Ly6G+ 
neutrophils from the remaining Ly6G- leukocyte population. The two populations were 
then analysed by flow cytometry to assess purity levels. The Ly6G positive population had 
a purity of approximately 80% (Fig. 5.23A) and the Ly6G negative population contained 
less than 2% of neutrophils (Fig. 5.23B).  
 
RNA was then extracted from the Ly6G+ and Ly6G- populations and mRNA expression 
levels of pro-inflammatory and neutrophil-associated genes were analysed by qPCR (Fig. 
5.24). Viperin was originally identified as being induced in fibroblasts upon HCMV 
infection (233). Viperin is rapidly induced upon IFN stimulation or infection with various 
viruses, including acute and chronic LCMV, where viperin has been shown to contribute 
to the antimicrobial activity of neutrophils (234). Expression of inducible nitric oxide 
synthase (iNOS) produces large amounts of nitric oxide which has been reported to be 
important in the elimination of various viruses including CMV. iNOS knockout mice 
develop significantly higher titres of infectious virus in the lung (235) and are more 
susceptible to lethal infection with MCMV than wt mice (236). The expression of both 
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viperin and iNOS at the mRNA level was significantly higher in the Ly6G+ population than 
the Ly6G- population, suggesting that neutrophils are a significant source of viperin and 
iNOS during acute MCMV infection. Cathepsin C activates a number of serine proteins 
including granzymes A and B. Cathepsin C knockout mice have organ specific defects in 
the ability to control MCMV replication and is therefore important in limiting viral 
replication (237). The interferon-induced Mx1 protein confers resistance to influenza virus 
by inhibiting viral mRNA synthesis in the nucleus of virally infected cells (238). Both of 
these genes are expressed at significantly higher levels in the Ly6G- population, 
suggesting that these proteins do not contribute to the antiviral activity of neutrophils.  
 
Acute MCMV infection induces production of type I interferons which are potent activators 
of antiviral pathways. There are two known waves of IFNα/β production during early 
infection, the first occurring as early as 8 hours p.i which is driven by the engagement of 
the LTβ receptor with a membrane-bound heterodimer of LTα and LTβ (239). 
Interestingly, the second wave of IFNαβ expression correlates with the kinetics of 
neutrophil accumulation, at least in MCMV-infected livers (240). IFNα/β knockout mice 
and mice deficient in LTβ signalling are highly susceptible to MCMV infection (241) 
therefore these are important molecules for resistance to MCMV. However, when the 
mRNA expression of these was analysed, levels of IFNα/β and LTα/β were all significantly 
higher in the Ly6G- population as compared to the Ly6G+ population, therefore suggesting 
that neutrophils are not a major source of these antiviral molecules. Expression levels of 
IFNγ and TNFα were also analysed as positive and negative controls respectively, based 
on known low and high expression of these molecules in neutrophils. As expected, 
neutrophils expressed significantly higher levels of TNFα but significantly less IFNγ than 
the Ly6G- cell population.   
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Figure 5.21. The absence of neutrophils during acute MCMV infection does not lead 
to increased virus at day 2 post-infection 
Mice were infected with MCMV and administered an IgG control (closed symbols) or an 
anti-Ly6G antibody (open symbols). Homogenates from the lungs (A), livers (B) and 
spleens (C) of mice infected for 2 days were prepared for high sensitivity plaque assays to 
detect replicating virus. Data is expressed as PFU per gram of tissue. Horizontal bars 
show median values. Data is representative of 2 independent experiments. 
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Figure 5.22. Neutrophils do not enhance NK cell function during acute MCMV 
infection  
(A-B) Mice were infected with MCMV and administered an IgG control (closed bars) or an 
anti-Ly6G antibody (open bars). Lymphocytes were isolated from the livers at 4 days p.i 
and incubated for 4 hours with medium alone, plate-bound NKp46 or PMA/Ionomycin and 
analysed for expression of CD107a at the cell surface as well as intracellular IFNγ. 
Results show mean ± SEM of 6 mice per group. (C) Mice were infected with MCMV and 
administered an IgG control (closed circles), anti-Ly6G (open circles), anti-NK1.1 (open 
triangles) or anti-Ly6G and anti-NK1.1 (open diamonds). Homogenates from the livers of 
4 day infected mice were prepared for high sensitivity plaque assays to detect replicating 
virus. Data is expressed as PFU per gram of tissue. Horizontal bars show median values. 
*p<0.05, **p<0.01, ns=not significant.  
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Figure 5.23. Analysis of Ly6G+ cells following MACS separation 
Leukocytes were isolated from the livers of day 2 MCMV-infected mice. Ly6G positive 
cells were separated from the Ly6G negative cells by MACS separation. The positive 
fraction (A) and negative fraction (B) were then analysed by flow cytometry for the 
proportion of Ly6G positive cells. Results represent 3 mice per group. 
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Figure 5.24. Neutrophils from MCMV-infected mice express a distinct gene 
transcription profile  
Leukocytes were isolated from the livers of day 2 MCMV-infected mice. Ly6G positive 
cells (closed circles) were separated from the Ly6G negative cells (open circles) by 
MACS separation. RNA was then extracted from both populations of cells and converted 
to cDNA. Expression of different genes was detected by qPCR. Data is shown as gene 
expression relative to -actin expression. Horizontal bars represent the median value. 
*p<0.05, **p<0.01, ***p<0.001 
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5.2.16. MCMV-infected livers from neutrophil depleted mice show a similar gene 
transcription profile as non-depleted mice 
Neutrophils from MCMV-infected mice show a different pro-inflammatory transcription 
profile compared to non-neutrophils, and express significantly higher levels of viperin, 
iNOS and TNFα (Fig. 5.24). Therefore, to assess if the production of any of these 
molecules contributed to the protective immunity that neutrophils provide during early in 
vivo MCMV infection, livers from day 2 infected mice that were depleted of neutrophils 
were analysed for the same pro-inflammatory genes and compared to livers from non-
depleted mice.  However, livers from neutrophil depleted mice showed a very similar level 
of expression in all of the genes analysed (Fig. 5.25).  
 
5.2.17 Nitric oxide expression in neutrophils increases in the presence of MCMV 
As gene expression analysis of livers from IgG and anti-Ly6G MCMV-infected mice did 
not reveal any differences in the antiviral genes tested, other possible mechanisms for 
how neutrophils provide antiviral immunity were explored. Reactive oxygen species 
(ROS) and nitric oxide (NO) are known products of neutrophils which act as broad 
spectrum inhibitors of pathogens. To assess if neutrophils could be directly activated by 
MCMV, neutrophils were purified from naïve mice. High levels of purity (>90%) were 
reached by using sequential negative followed by positive selection (Fig. 5.26A) (section 
2.13.2). These neutrophils were then incubated overnight in the presence or absence of 
MCMV and analysed for APF fluorescence, which is an indicator of ROS, and DAF-FM 
diacetate fluorescence, which is a read out for NO production. Neutrophils incubated with 
MCMV did not show an up-regulation in APF fluorescence compared to those without 
virus (Fig. 5.26B) in either percentage (6.68% vs. 5.67%) or MFI (217 vs. 194), but 
interestingly NO expression was significantly increased (Fig. 5.26C) both by percentage 
(89.5% vs. 58.4%) and MFI (15900 vs. 2703), suggesting that neutrophils are directly 
activated by MCMV and up-regulate NO expression in response to the virus.  
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Figure 5.25. MCMV-infected livers from neutrophil depleted mice show a similar 
gene transcription profile as non-depleted mice  
MCMV-infected mice were treated with IgG (closed circles) or anti-Ly6G (open circles). At 
day 2 p.i, livers were excised and RNA was extracted and converted to cDNA. Expression 
of different genes was detected by qPCR. Data is shown as gene expression relative to 
-actin expression. Horizontal bars represent the median value. 
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Figure 5.26. Increased release of nitric oxide by neutrophils in the presence of 
MCMV 
(A) Representative facs plot showing purified neutrophils isolated from spleens of naïve 
mice following sequential negative and positive selection. (B and C) Representative 
overlay histograms of APF (B) and DAF-FM diacetate (C) fluorescence in purified 
neutrophils  incubated overnight in the presence (solid blue line) or absence (dashed blue 
line) of MCMV (shaded histogram = FMO control). Results represent 3 independent 
experiments.  
 188 
 
5.2.18. Neutrophils directly inhibit MCMV replication in vitro 
To determine if neutrophils could directly inhibit MCMV replication, purified neutrophils 
from naïve mice were incubated with MCMV-infected 3T3 cells at varying effector to 
target ratios for 7 days. Supernatants were then taken and analysed for levels of 
replicating virus by standard plaque assay. Interestingly, the levels of replicating virus in 
the supernatants decreased proportionately as the ratio of neutrophils to targets 
increased (Fig. 5.27). The levels of replicating virus decreased significantly from an 
average of 405 PFU/ml when no neutrophils were present (ration of 0:1) to an average of 
50 PFU/ml when the ratio of neutrophils to 3T3s was 1:1, thus demonstrating that 
neutrophils can directly inhibit MCMV replication in vitro. A freeze/thawed control was also 
included to demonstrate that it an the inhibition of MCMV replication was not an artefact of 
dying neutrophils. 
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Figure 5.27. Neutrophils directly inhibit MCMV replication in vitro  
Purified neutrophils were incubated with MCMV-infected 3T3 cells (MOI of 0.02) for 7 
days at varying effector:target (neutrophil:3T3) ratios. Supernatants were then taken for 
plaque assays and amounts of replicating virus were measured. Data is expressed as 
PFU/ml and results are representative of 2 independent experiments. F/T = freeze thawed 
control. 
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5.3 Discussion 
It has been previously shown that IL-22 mRNA expression is increased in the livers of 
mice with MCMV-induced hepatitis as compared to uninfected controls (242). During 
acute MCMV infection, the virus targets not only the liver, but other visceral organs 
including the lung and the spleen. Analysis of IL-22 at the protein level revealed that IL-22 
is expressed in the visceral organs of naïve mice as well as in infected mice, where a 
significant increase in IL-22 expression was observed. This observation supports and 
expands on the findings of Brand et al who showed an increase in IL-22 mRNA in the liver 
(242).  
 
The ability of many different cell types to express IL-22 has been extensively reviewed 
(100, 135, 136, 227, 243). Unsurprisingly, CD4+ and CD8+ T cells were found to express 
IL-22 in both naïve and infected mice. IL-22 derived from γδ T cells was shown to protect 
against lung fibrosis in a mouse model of hypersensitivity pneumonitis (148), therefore 
this cell type was also analysed for IL-22 expression in my MCMV model. Although IL-22 
was found to be expressed by a small proportion of the γδ T cells, when calculated back 
to total numbers, they were found to be a relatively minor population contributing to 
overall IL-22. As well as the widely discussed sub-population of RORγt+ mucosal NK cells 
(244), conventional NK1.1+ cells capable of producing IFNγ, have also been shown to 
produce IL-22 in influenza infected mice (220). Similar to the findings of Guo and Topham 
(220), IL-22 producing NK1.1+ CD3- cells were also detected in MCMV infection, and were 
actually the dominant population of cells in the lung and the liver of MCMV-infected mice 
that produced IL-22. The phenotype of these IL-22 producing NK cells was then analysed 
further. They were found to express conventional NK cell surface markers including 
Ly49H, KLRG-1, CD11b and CD122, as well as CD69 upon MCMV infection, suggesting 
that these were mature, conventional NK1.1+ NK cells, distinct from the more immature-
like RORγt+ mucosal NK cells. This conclusion is supported by the previously published 
observation that lung NK cells capable of producing IL-22 during influenza infection are 
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also of a mature phenotype, similar to that found in splenic NK cells, and are likely to be 
distinct from the gut innate lymphoid-like NK-IL-22 cells previously described (220). ILCs 
that lack expression of most linage markers have also been shown to be important 
producers of IL-22 (reviewed in (135)). NKp46+ ILCs express IL-22 but are found 
predominantly in the skin and small intestine, and CD4+ ILCs are a dominant source of 
IL-22 in the large intestine and are therefore likely to be an irrelevant source of IL-22 in 
the organs of interest in this MCMV model. Interestingly, in humans, a subset of IL-22 
producing ILCs can be detected in the adult lung and gut but these express CD127 (245), 
so are again likely to be distinct from mature, conventional NK cells capable of producing 
IL-22.  
 
 
Analysis of IL-22 expression by flow cytometry revealed that NK cells were the dominant 
source of IL-22 in the lung and liver at 4 days p.i, which was confirmed by NK cell 
depletion experiments. In the absence of NK cells during acute MCMV infection, IL-22 
protein levels were markedly reduced, although not completely abolished, again 
suggesting NK cells are the predominant source of lung and liver IL-22, however, other 
cell populations also contribute. Depletion of NK cells during influenza infection also leads 
to a reduction in total IL-22 protein in the lung, although this reduction was not as great as 
was observed in my MCMV model (220). Associated with a lack of NK cells during acute 
MCMV infection is a significant increase in virus load, therefore to rule out that the 
increase in virus load wasn’t the cause of reduced IL-22, levels of IL-22 protein were 
measured following depletion of neutrophils which also leads to an increase in virus load. 
As no significant reduction was seen, this validates the conclusion that NK cells 
significantly contribute to IL-22 production in the lung and liver of MCMV-infected mice.  
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A neutralising anti-IL-22 antibody was administered intravenously on the day of infection 
to explore the hypothesis that IL-22 has an antiviral role during acute MCMV infection. As 
early as 2 days p.i, a significant increase in virus load was observed in mice given the 
neutralising antibody in both the lung and liver and this persisted until day 4 p.i. 
Interestingly, IL-22 neutralisation did not influence virus load in the spleen. This is not that 
surprising, given what is so far known about the expression of the IL-22R. IL-22Rα is 
expressed exclusively on non-haematopoietic cells and its expression is predominantly 
found in epithelial cells of barrier surfaces including the oral/gastrointestinal tract, skin and 
lung, and is also found to be strongly expressed in the liver (246, 247). Therefore, if there 
is limited IL-22Rα expression in cells of the spleen, IL-22 is unlikely to play an important 
role in this organ and thus, neutralisation of IL-22 would have limited, if any, effects.    
 
As well as the increase in virus load in the lung and liver following IL-22 neutralisation, 
interestingly, a reduction in neutrophil accumulation was also observed in these two IL-22 
responsive organs. IL-22Rα is not usually expressed on leukocytes, but in anaplastic 
lymphoma kinase-positive (ALK+) anaplastic large cell lymphoma (ALCL) patients, this 
receptor is expressed on T cells. In an investigation to examine the consequences of 
aberrant expression of this receptor, a mouse model of ALK+ALCL was set up by 
generating transgenic mice expressing IL-22Rα on lymphocytes (248). The IL-22Rα 
transgenic mice developed severe neutrophilia in association with increased serum IL-22, 
IL-17 and G-CSF. However, no other direct link with IL-22 and neutrophil recruitment has 
been reported. In humans, patients with ulcerative colitis and Crohn’s disease have 
increased levels of IL-22 in the inflamed mucosa, and IL-22 was shown to promote pro-
inflammatory gene expression in epithelial cells, including IL-8 (CXCL8), a chemo-
attractant for human neutrophils (249, 250). Mice do not have an IL-8 homologue but 
other known neutrophil attractants include CXCL1, CXCL2 and CXCL5. G-CSF is also 
important in stimulating survival, proliferation, differentiation and function of neutrophils 
(251).  
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To investigate if IL-22 neutralisation during MCMV infection resulted in a reduction in 
chemokines associated with neutrophil chemotaxis, expression of these at both the 
mRNA and protein level was measured and compared to expression in IgG treated mice. 
However, no significant effect on these chemokines was seen following anti-IL-22 
treatment, although a slight trend towards reduced CXCL1 was observed in the livers of 
anti-IL-22 treated mice. Interestingly, neutralisation of IL-22 during Klebsiella pneumoniae 
infection is not associated with diminished G-CSF or CXCL1 levels (143). Lower amounts 
of CXCL1 and G-CSF in the lungs during infection were only seen when IL-22 was 
neutralised in IL-17 knockout mice, suggesting IL-17 and IL-22 work in conjunction to 
induce expression of these chemokines. Furthermore, CXCL1 and CXCL5 expression 
were induced in human bronchial endothelial cells when stimulated with both IL-17 and 
IL-22 (143). However, treatment with recombinant IL-22 during infection resulted in an 
increase in CXCL1 and CXCL2 transcripts in the bronchial epithelium (143). Interestingly, 
a single IP injection of recombinant IL-22 into wt mice resulted in increased neutrophil 
counts in the blood as well as increased levels of CXCL1 at 1 hour post-injection but was 
not observed 24 hours post-injection (142). These data suggest that IL-22 has the 
potential of inducing neutrophil-associated chemokines and hence lead to an increase in 
neutrophil accumulation, possibly in conjunction with IL-17, depending on the model 
system used. It is possible that in my MCMV model, looking 24 hours p.i for differences in 
chemokine expression was actually too late. Therefore, I cannot rule out the possibility 
that the reduction in neutrophils observed following anti-IL-22 treatment in MCMV-infected 
mice was a consequence of reduced neutrophil-associated chemokines. Also, it is 
conceivable that IL-22 may act to enhance neutrophil mobilisation from the bone marrow. 
Further analysis at different time points, as well as looking in different compartments 
including the blood, would be needed to answer this question more definitively. 
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To date, the majority of studies investigating the relationship between CMV and 
neutrophils have been in vitro experiments with HCMV. Infection of fibroblasts with HCMV 
results in increased expression of the neutrophil chemo-attractant IL-8 at the mRNA and 
protein level (252) and infection of endothelial cells by HCMV also resulted in increased 
levels of both IL-8 and GROα (now known as CXCL1) (253). Both studies showed that 
release of these chemokines enhanced neutrophil migration in a transendothelial 
migration assay. Further work on HCMV-induced chemokines revealed that the HCMV 
genes, UL146 and UL147, encode the viral homologues of CXCL1 and CXCL2 (vCXCL1 
and vCXCL2). As yet, there is no evidence to suggest that vCXCL2 is a functional 
chemokine, however, vCXCL1 has been shown to act as an agonist on both CXCR1 and 
CXCR2; further adding to the premise that HCMV infection enhances neutrophil migration 
(254, 255). The consensus by the authors of all these studies for why HCMV would 
induce neutrophil recruitment is that neutrophils can be infected directly by HCMV or 
acquire infectious virus particles during transmigration and therefore aid virus 
dissemination.  
 
Crucially however, no direct in vivo evidence regarding the role that neutrophils play in 
herpesvirus infections exists. Two early studies demonstrated that in vitro, MCMV 
infection reduced chemotactic activity of neutrophils (256) and that during acute infection 
in vivo, migration of neutrophils out of the blood was impaired (257). The authors suggest 
that direct viral infection of neutrophils may contribute to altered function. This reduction in 
chemotactic activity was also observed in a guinea pig model of CMV (258). Interestingly, 
a study into the antiviral effects of leukotrine B4 (LTB4) on CMV infection revealed that 
stimulation with LTB4 could activate neutrophils via the LTB4 receptor which led to a 
reduction in virus titres in CMV-infected human leukocytes (259). This was further 
supported by ex vivo experiments using LTB4 treated neutrophils from mice which also 
displayed antiviral activity towards CMV via release of antimicrobial peptides (259).  
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Given the results of the studies described above in conjunction with my observations that 
a reduction in neutrophil accumulation was associated with an increase in virus load 
following anti-IL-22 administration, the hypothesis that neutrophils perform an antiviral role 
during acute MCMV infection was tested. Neutrophils were depleted using an anti-Ly6G 
specific antibody (1A8), which was shown to be neutrophil specific and did not cause 
depletion of any other cell subset. Enhanced virus-induced weight loss was observed in 
mice depleted of neutrophils, suggesting the mice were suffering from more severe 
clinical symptoms of disease, but importantly, virus load was significantly increased in the 
lung and the liver at 4 days p.i. Interestingly, neutrophil depletion did not influence virus 
load in the spleen. An explanation for why neutrophil depletion does not have an effect on 
virus load in the spleen is that at 4 days p.i, neutrophils only account for a very small 
proportion of the total cells (approximately 1%) and therefore deleting these is likely to 
have far less of an impact than in other organs where neutrophils make up a much more 
significant cell population, such as in the lung and liver. None the less, this data supports 
the hypothesis that neutrophils do have an antiviral role but in an organ specific manner.  
 
The novel finding that neutrophils have a protective role against acute MCMV led me to 
investigate if they provided this antiviral immunity as early as 2 days p.i. Interestingly, no 
difference in virus load following neutrophil depletion was seen in the lung or liver at this 
earlier time point, despite neutrophils making up a significant population of cells in both 
organs. The long held view of neutrophils as short-lived effector cells of an acute 
inflammatory response whose primary role is to clear extracellular pathogens is no longer 
considered accurate. This is due to recent evidence showing their importance in the 
regulation of innate and adaptive immunity in response to various infections and 
inflammatory disorders (reviewed in (8, 260)). Neutrophils have been shown to engage in 
complex bidirectional interactions with macrophages, DCs, NK cells and T and B cells (8). 
The delayed kinetics of antiviral immunity provided by neutrophils in this model of acute 
MCMV infection suggested at first a non-direct mechanism for how neutrophils are 
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providing protection. Given the capability of neutrophils for crosstalk and the known 
importance of NK cells during early MCMV infection, NK cell function was examined in the 
presence or absence of neutrophils at 4 days p.i. Interestingly, levels of IFNγ production 
by NK cells were comparable between both groups and in fact, in the absence of 
neutrophils, CD107a expression was slightly enhanced when neutrophils were depleted, 
suggesting that neutrophils play no role in NK cell function during acute MCMV infection. 
It is also worthwhile to note that depletion of both NK cells and neutrophils during MCMV 
infection resulted in a significant increase in virus load compared to virus loads seen 
when just one cell type was depleted, suggesting that both populations are important in 
providing antiviral immunity during acute MCMV infection.  
 
Following on from the lack of evidence in support of the hypothesis that neutrophil-NK cell 
crosstalk led to protection from MCMV, the possibility that neutrophils were exerting their 
antiviral activities directly was next explored.  When first comparing mRNA expression of 
a range of pro-inflammatory and neutrophil associated genes from hepatic Ly6G+ 
neutrophils with Ly6G- cells from the liver, viperin, iNOS and TNFα were expressed at 
significantly higher levels in the neutrophil population as compared to the non-neutrophil 
cell population. Therefore, if expression of one or more of these was significantly lower in 
livers from neutrophil depleted mice, this could provide an insight into a possible 
mechanism for how neutrophils were providing antiviral immunity. However, no 
differences were seen at the mRNA level of any of the genes analysed. On the other 
hand, this is not that surprising given that it is not exclusively neutrophils that express 
these molecules, but a whole range of immune cells and therefore depleting just one of 
the populations of cells that produce these is unlikely to have an effect on expression 
when analysing the tissue as a whole. Furthermore, my analysis only addressed a very 
small proportion of neutrophil associated genes, whereas neutrophils have been shown to 
express numerous cytokines, chemokines and angiogenic factors either spontaneously or 
under stimulation (8), and therefore, more in depth analysis would need to be done in 
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order to address exactly which of these genes were up-regulated in neutrophils upon 
infection with MCMV.  
 
To further explore the question of how neutrophils provided antiviral protection, in vitro 
assays were set up to investigate if neutrophils inhibited MCMV replication directly. 
Interestingly, when highly purified neutrophils from naïve mice were incubated with MCMV 
overnight, a significant up-regulation in fluorescence of DAF-FM diacetate was seen. This 
increase in fluorescence is caused when DAF-FM diacetate reacts with NO, suggesting 
NO production within the neutrophils was enhanced in the presence of MCMV. NO has 
been shown to be important for antiviral inflammatory and immune defences in the human 
lung (261). It has also been demonstrated that NO has antiviral effects during Japanese 
encephalitis virus infection (262, 263), as well as having important anti-inflammatory and 
antiviral roles during human rhinovirus infections (264). It is possible therefore that an 
increase in NO production by neutrophils may also have antiviral effects against MCMV. 
 
To attempt to elucidate further if MCMV replication could be directly inhibited by 
neutrophils, 3T3 cells were infected with MCMV and then incubated with highly purified 
neutrophils in varying ratios of effector cells to target cells. Remarkably, as the ratio of 
neutrophils to targets was titrated upwards, a significant decrease in replicating virus was 
observed, demonstrating that neutrophils could directly inhibit MCMV replication. Future 
studies could be performed by repeating this in vitro assay but also encompassing the 
presence of a range of different neutralising antibodies and inhibitors such as anti-TNFα, 
anti-IFNα/β, anti-IFNγ as well as more specific neutrophil inhibitors such as iNOS 
inhibitors, protease inhibitors, DPI to prevent superoxide release and cytochalasin B or D 
to scramble actin and impact on phagocytosis and degranulation, in order to elucidate the 
mechanism for this antiviral activity. 
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Finally, it is important to note that neutralising IL-22 during acute MCMV infection led to 
the observation of impaired neutrophil accumulation, which consequently uncovered a 
novel role for neutrophils during early infection. However, as discussed, depletion of 
neutrophils caused a significant increase in virus load in the lung and liver at 4 days p.i, 
but not at 2 days p.i. Crucially, neutralisation of IL-22 caused significant increase in virus 
load in these two organs at both time points. This suggests that IL-22 is playing an 
antiviral role via additional mechanisms other than just in the recruitment of neutrophils. 
To date, mechanisms by which IL-22 provides protection through regulating host defence 
and inflammation include the induction of pro-inflammatory cytokines and chemokines to 
recruit various leukocytes to control invading pathogens, the production and secretion of 
antimicrobial peptides and defensins, the secretion on mucins from goblet cells, and 
finally the activation of STAT3 in epithelial cells to enhance wound healing (100, 135, 149, 
227). One or more of these mechanisms may also contribute to the control of early MCMV 
infection, such as IL-22-induced production of beta-defensins from epithelial cells, which 
could potentially provide antimicrobial activity against MCMV. However, further 
investigation into these possible mechanisms is required. This could be achieved by using 
a mucosal challenge model of MCMV infection to assess the role that IL-22 may play in 
infections via mucosal surfaces, which may be considered more physiologically relevant.  
 
In summary, I have revealed a tissue-specific antiviral role for IL-22 during acute MCMV 
infection. Interestingly, via the observation that neutralisation of IL-22 was associated with 
a reduction in neutrophil numbers, I have also demonstrated that neutrophils can directly 
inhibit MCMV replication. A summary of these findings is shown in Fig. 5.28. These 
experiments not only uncover a novel role for IL-22 in host defence against viral 
pathogens, but also provide a new insight into the importance of neutrophils in limiting 
MCMV infection. These data therefore challenge the widely held view that comes from in 
vitro experiments which suggests that the only role for neutrophils in HCMV infection is to 
aid viral dissemination. 
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Figure 5.28. Summary of in vivo and in vitro findings on the role of IL-22 and 
neutrophils during acute MCMV infection 
In vivo experiments revealed a tissue-specific antiviral role for IL-22 during acute MCMV 
infection which was associated with a reduction in neutrophil accumulation. Neutrophil 
depletion experiments also revealed an antiviral role for neutrophils during acute MCMV 
infection and in vitro experiments demonstrated that neutrophils can directly inhibit MCMV 
replication 
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Chapter 6 - General discussion 
 
In this thesis, I set out to elucidate the role of mammalian IL-10 during acute MCMV 
infection, and also the role that the IL-10 family member IL-22 has during infection. These 
studies afforded novel insights into the in vivo functions of these cytokines. Firstly, a 
surprising antiviral role for IL-10 during acute MCMV infection was revealed, which was 
achieved via limitation of activation-induced death of NK cells, thus leading to a reduction 
in virus load. Secondly, a tissue-specific antiviral role for IL-22 during acute MCMV 
infection was also discovered; and further investigation into this led to the unpredicted 
finding that neutrophils play a protective role during infection by directly inhibiting MCMV 
replication. 
 
MCMV is the best-characterised and most widely used animal model for cytomegalovirus 
infection and is a powerful tool for defining the host immune response to infection due to 
the availability of extensive immunological reagents as well as transgenic mice with 
specific immune defects. In conjunction with the MCMV infection model, I utilised both 
blocking and neutralising antibodies to demonstrate previously unknown protective 
functions of the related cytokines IL-10 and IL-22 against acute herpesvirus infections in 
vivo. However, the ultimate reason for carrying out research in MCMV is to enhance our 
understanding of host-virus interactions which can be translated into the context of HCMV 
interactions with human hosts. From this research, we could potentially achieve better 
therapeutic strategies to treat HCMV infection or an HCMV vaccine to significantly reduce 
morbidity and mortality associated with HCMV infection and disease and consequently 
realise substantial savings in the health care costs associated with HCMV disease. 
Therefore I will discuss the findings made in this thesis in relation to this more extensive, 
long-term goal. 
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Firstly, I will address the question of whether IL-10 could be used as a therapeutic target 
for HCMV. Due to the broad anti-inflammatory effects of IL-10, a variety of clinical studies 
have been undertaken using systemic administration of recombinant IL-10 to treat 
patients with immune-mediated inflammatory diseases such as psoriasis, Crohn’s disease 
and rheumatoid arthritis. Early phase I and phase II studies showed promising results in 
psoriasis and Crohn’s disease, although results were less promising in rheumatoid 
arthritis patients. However, larger psoriasis studies showed only modest therapeutic 
benefits, whilst the most favourable clinical responses in Crohn’s disease patients were 
observed at an intermediate dose of IL-10 (reviewed in (265)).  
 
Experimental evidence suggests that exogenous IL-10 administration to HIV-infected 
monocyte-derived macrophages results in a dose-related inhibition of HIV reverse 
transcription activity and HIV proliferation. Furthermore, exogenous IL-10 may inhibit viral 
assembly in HIV-infected macrophages. Taken together, these findings strongly suggest 
that IL-10 administration to HIV-infected individuals may be beneficial (reviewed in (266)). 
To date, three phase I trials of treatment with recombinant human IL-10 in HIV infection 
have been reported. One study described a transient reduction in HIV replication; 
however the other two studies showed no significant reduction in HIV levels or changes in 
CD4+ T cell counts. Thus, IL-10 may be useful in arresting detrimental inflammatory 
responses caused by HIV, but may be ineffective when viral replication is ongoing 
(reviewed in (266)). Experiments using human PBMCs from individuals who were infected 
with a variety of pathogens demonstrated that immune responsiveness to these 
pathogens was improved in the presence of anti-IL-10 monoclonal antibodies. These 
specific pathogens included leishmaniasis, schistosomiasis, leprosy and tuberculosis 
(reviewed in (102, 265)).  
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Could administration of recombinant IL-10, or conversely treatment with anti-IL-10 
antibodies promote immune responses against HCMV infection? I demonstrated in 
chapter 3 of this thesis that IL-10 is expressed by numerous haematopoietic cells during 
acute MCMV infection and that virus-induced IL-10 promotes the accumulation of NK cells 
by limiting NK cell activation-induced death, which leads to enhanced viral clearance. 
Interestingly, an earlier study using an model of MCMV infection with uncontrolled virus 
replication in mice lacking perforin, demonstrated that NK cell-derived IL-10 suppressed 
pathogenic CD8+ T cell responses and limited MCMV replication (186). From the results 
of my investigations in conjunction with results from this study, it can be inferred that via 
its suppressive properties of limiting self-destructive immune responses, endogenous 
IL-10 functions to protect the host during acute herpesvirus infection. Therefore it could be 
suggested that increasing host IL-10 levels through the administration of recombinant 
IL-10 during primary infection may further enhance antiviral immunity against HCMV. 
However, it would be critical to ensure that the host immune response was not so 
severely suppressed by IL-10 that it could not mount any kind of attack against viral 
invasion, as the balance between pro-inflammatory and inhibitory signals during acute 
infection is an extremely important and finely tuned one, and if tipped too far in favour of 
immune inhibition, may lead to severe consequences. Furthermore, primary HCMV 
infection in immune-competent hosts is generally asymptomatic and therefore therapeutic 
treatment at this stage is very unlikely. Moreover, the predominant conclusion from the 
collective clinical studies described above was that therapeutic administration of IL-10 is 
unlikely to be beneficial in situations where pathogens have not yet been eradicated/are 
still undergoing replication.  
 
Additionally, the complex nature of herpesvirus infections makes potential treatment of 
HCMV infection with IL-10 even more problematic. After acute infection, herpesviruses 
establish persistency or latency within the host. It has been demonstrated in MCMV that 
during the chronic replicating or chronic latent stages of infection, endogenous IL-10 
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antagonizes antiviral immunity, thus contributing to viral dissemination and the 
development of latency within the host (167, 168).  Therefore, inhibiting the IL-10 
signalling pathway with anti-IL-10 antibodies to promote immune responses during these 
stages may be a more beneficial pathway to explore, as this could lead to a reduction in 
chronic HCMV infections, dissemination and reactivation, thus limiting the harmful 
consequences associated with this, such as congenital infections. Indeed, targeting the 
cmvIL-10 gene, UL111A, to improve immune responses to HCMV is a real possibility, as 
demonstrated by the work of Barry and colleagues showing rhcmvIL-10 to be a viable 
vaccine candidate because of its high immunogenicity during natural infection combined 
with the lack of cross-reactivity with rhesus cellular IL-10 (203, 204). Therefore I 
attempted to elucidate the functions of cmvIL-10 in a biologically relevant system by 
generating a cmvIL-10 deficient Merlin strain of HCMV. However, despite successfully 
creating this virus, the issue of low virus yields caused significant limitations to this 
research. Resolutions to this issue have nonetheless been discussed thoroughly in 
section 4.3. 
 
The second major discussion point that arises from the results of my thesis is whether 
IL-22 could be used as a therapeutic target for HCMV. Studies of mouse model systems 
and observations of human diseases including IBD, psoriasis, rheumatoid arthritis and 
cystic fibrosis where elevated levels of IL-22 are observed (reviewed in (135, 136)) 
indicate that targeting the IL-22-IL-22R pathway with functional agonists and antagonists 
such as recombinant cytokine or even via gene therapy delivery may provide new 
therapies for the treatment of infection, chronic inflammatory disorders and wound 
healing. However, the dual pro-inflammatory and anti-inflammatory functions of IL-22 are 
the biggest obstacle for developing therapeutics based on this cytokine.  
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The overriding message from previous studies investigating the role of IL-22 in viral 
infections was that the effects of this cytokine were pathogen-dependent. I demonstrated 
in chapter 5 that IL-22 is expressed by NK cells and CD4+, CD8+ and γδ T cells during 
acute MCMV infection, and that IL-22 provides tissue-specific protection by limiting 
MCMV replication. This is the first study to unequivocally demonstrate an antiviral role for 
IL-22 during herpesvirus infections. This would suggest that increasing IL-22 levels within 
the host during CMV infection could potentially enhance antiviral immunity. One 
advantage that administering IL-22 to HCMV infected individuals would have over that of 
IL-10 is that unlike the IL-10R1 which is expressed by most haematopoietic cells, the 
IL-22R1 is exclusively expressed on non-haematopoietic cells. The IL-22R1 is found 
extensively on epithelial cells, suggesting an important role in mucosal immunity, and is 
found on hepatocytes and has previously been shown to be important in limiting liver 
damage. My data showed that in the absence of IL-22 during acute MCMV infection, both 
the lung and liver had increased virus loads. Importantly, CMV remains the most 
important pathogen following lung transplantation (267) and is the most common cause of 
death after liver transplantation (268), thus enhancing IL-22 production after organ 
transplants may be beneficial by reducing virus load and subsequent CMV related 
disease of these organs. Furthermore, epithelial cells expressing the IL-22R are also 
found in the salivary gland. As one transmission route of HCMV is via saliva, treatment of 
IL-22 in HCMV infected individuals could potentially reduce levels of virus replication 
during the chronic replicating or chronic latent stages of infection or decrease the 
occurrences and severity of virus reactivation, thus reducing dissemination and spread of 
the virus. Therefore a major research focus of the laboratory is to establish a mucosal 
MCMV challenge model to enable the assessment of the role that IL-22 may play in 
infections via mucosal surface(s) using inoculum representative of “natural” infection. 
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Whilst investigating the effects of the cytokines IL-10 and IL-22 during acute MCMV 
infection, a somewhat unexpected finding was revealed. In chapter 5, I demonstrated that 
neutrophils have an antiviral role that had not been previously shown in relation to 
herpesvirus infections.  In vivo, neutrophils protect against virus-induced weight loss and 
contribute to controlling viral replication in a tissue-dependent manner and in vitro, I 
established that neutrophils could directly inhibit MCMV replication. This finding could 
potentially be of great importance if it is proved that neutrophils also promote antiviral 
immunity against HCMV infection. Not only would it challenge the broadly held view that 
neutrophils are only important for aiding viral dissemination during infection, but may also 
have consequences for HCMV treatment.  
 
HCMV infection is currently treated with a range of antiviral drugs including ganciclovir 
which is used in the treatment of CMV retinitis, CMV colitis and CMV disease in bone 
marrow and solid organ recipients; valganciclovir which is used in treatment of HIV 
patients and transplant recipients; foscarnet which is used against drug resistant CMV 
and for CMV retinitis; and cidofovir which is used to treat CMV retinitis in AIDS patients 
(269). However, one of the side effects of these antiviral drugs is that patients develop 
neutropenia. For example, both the pre-emptive treatment and the prophylactic treatment 
of CMV disease in haematopoietic cell transplant recipients with ganciclovir results in 
neutropenia (270). The treatment of congenital CMV infection in neonates results in 
transient neutropenia and post-natal treatment can result in absolute neutropenia (271). 
Neutropenia is also associated with cidofovir treatment of CMV retinitis (269). Currently, 
foscarnet is the preferred drug for patients who cannot be treated with ganciclovir due to 
dose-limiting neutropenia (272), although it is still considered only a second-line choice of 
therapy. If the finding in the mouse model of CMV infection that neutrophils actually 
protect against CMV infection holds true in human infection, then using drugs that cause 
neutropenia would be detrimental in fighting CMV disease. Thus, in the absence of 
neutropenia with foscarnet treatment, research into how this could be used more 
 206 
 
extensively in the treatment of CMV disease would be beneficial. Given the associated 
toxicity of this (and other) antiviral treatments, these data clearly highlight a critical need 
for new refined antiviral treatment approaches. 
 
The results from my investigations suggest three obvious routes of further exploration. 
Firstly, as discussed above, more research needs to be done in order to elucidate the 
mechanism for how neutrophils directly inhibit MCMV replication, and more importantly, 
ascertain if this is relevant to HCMV. Secondly, my results on the antiviral activity of IL-22 
in chapter 5 open up a second avenue of further investigation which includes 1) 
deciphering the additional mechanisms for how IL-22 provides antiviral protection against 
acute MCMV infection from as early as 2 days p.i; 2) set up a mucosal MCMV challenge 
model to enable the assessment of the role that IL-22 may play in infections via mucosal 
surfaces; 3) establishing if this cytokine also has antiviral properties during the chronic 
replicating and chronic latent phases of infection, especially as T cells play an important 
role in controlling infection during these phases, and therefore if it is possible to induce 
expression of IL-22 by T cells under the right polarizing conditions, this method could be 
exploited to enhance IL-22 expression to provide antiviral protection; and 4) determining if 
IL-22 enhances immunity against HCMV infection.  
 
Finally, a more generalised question could be asked, based on what has been revealed in 
this thesis about the roles of both IL-10 and IL-22 during acute MCMV infection: do other 
cytokines of the IL-10 family provide antiviral protection against herpesvirus infections? 
IL-22 belongs to the IL-20 subfamily whose roles to date include protecting against 
extracellular pathogens. Could IL-19, IL-20, IL-24 or IL-26 also provide protection from 
viral pathogens? The third subfamily of IL-10 family members are the type III IFNs; 
IL-28A, IL-28B and IL-29. These are expressed in response to most viruses and 
interestingly, administration of type III IFNs during a murine model of HSV-2 led to a 
reduction in hepatic viral titres and furthermore, in a localised model of HSV-2 infection, 
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type III IFN treatment totally prevented development of disease (273). If investigation into 
administration of these cytokines during MCMV infection also yields promising antiviral 
results, these could potentially be other targets for effective therapeutic treatment against 
HCMV infections.  
 
6.1 Conclusion 
I have shown that two members of the IL-10 family of cytokines, IL-10 and IL-22, provide 
antiviral protection against acute MCMV infection. IL-10 achieves this by sustaining the 
balance between pro-inflammatory and inhibitory signals received by NK cells to guard 
from activation-induced cell death. The mechanisms through which IL-22 exerts its 
antiviral functions are still to be fully elucidated; however, one way in which it 
accomplishes this is through enhancing neutrophil accumulation into specific tissues, 
wherein the neutrophils inhibit virus replication. These novel findings have enhanced our 
understanding of cytokine biology in the context of viral infections in vivo and highlight 
important considerations for future research into herpesvirus infections. 
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